

CUMULATIVE  
SUPPLEMENT 7  
JULY 2004



APPROVED  
DRUG PRODUCTS

WITH  
THERAPEUTIC EQUIVALENCE EVALUATIONS

24<sup>th</sup> EDITION

Department of Health and Human Services

Food and Drug Administration  
Center for Drug Evaluation and Research  
Office of Generic Drugs

RM  
301.45  
.A66  
2004  
v.24  
suppl.7

Prepared By  
Office of Generic Drugs  
Center for Drug Evaluation and Research  
Food and Drug Administration

**APPROVED DRUG PRODUCTS  
with  
THERAPEUTIC EQUIVALENCE EVALUATIONS**

**24<sup>th</sup> EDITION**

Cumulative Supplement 7

July 2004

**Library Use Only**

**CONTENTS**

	<b>PAGE</b>
1.0 INTRODUCTION .....	iii
1.1 How to Use the Cumulative Supplement .....	iii
1.2 Applicant Name Changes.....	iv
1.3 Ribavirin 200mg Oral Capsule.....	v
1.4 Levothyroxine Sodium.....	v
1.5 Availability of the Edition.....	vi
1.6 Report of Counts for the Prescription Drug Product List.....	vii
1.7 Cumulative Supplement Change Legend .....	viii
 <b>DRUG PRODUCT LISTS</b>	
Prescription Drug Product List.....	1-1
OTC Drug Product List.....	2-1
Drug Products with Approval under Section 505 of the Act	
Administered by the Center for Biologics Evaluation and Research List.....	3-1
Orphan Product Designations and Approvals List .....	4-1
Drug Products Which Must Demonstrate <i>in vivo</i> Bioavailability	
Only if Product Fails to Achieve Adequate Dissolution .....	5-1
 <b>PATENT AND EXCLUSIVITY INFORMATION ADDENDUM</b>	
A. Patent and Exclusivity Lists .....	A-1
B. Patent and Exclusivity Terms.....	B-1

Please Note:

The 24<sup>th</sup> Edition of the Orange Book will be the last paper version. All the components of the paper Orange Book are and have been available on the Internet since 1997. Refer to the Introduction 1.3, Availability of the Edition, for specific locations. Additional details will be made available in future Cumulative Supplement publications.

**APPROVED DRUG PRODUCTS  
with  
THERAPEUTIC EQUIVALENCE EVALUATIONS**

**24<sup>th</sup> EDITION**

**CUMULATIVE SUPPLEMENT 7  
July 2004**

**1.0 INTRODUCTION**

**1.1 HOW TO USE THE CUMULATIVE SUPPLEMENT**

This Cumulative Supplement is one of a series of monthly updates to the Approved Drug Products with Therapeutic Equivalence Evaluations, 24th Edition (the List). The List is composed of four parts: approved prescription drug products with therapeutic equivalence evaluations, over-the-counter (OTC) drug products that require approved applications as a condition of marketing, drug products with approval under Section 505 of the Act administered by the Center for Biologics Evaluation and Research and products that have never been marketed, are for exportation, have been discontinued from marketing or that have had their approvals withdrawn for other than safety or efficacy reasons.

The Cumulative Supplement provides, among other things, information on newly approved drugs and, if necessary, revised therapeutic equivalence evaluations and updated patent and exclusivity data. The Addendum contains appropriate drug patent and exclusivity information required of the Agency by the "Drug Price Competition and Patent Term Restoration Act of 1984" for the Prescription, OTC, and Drug Products with Approval under Section 505 of the Act Administered by the Center for Biologics Evaluation and Research Lists.

Because all parts of the publication are subject to changes, additions, or deletions, the List must be used in conjunction with the most current Cumulative Supplement. Users may wish to mark to the left of the ingredient(s) in the List to indicate that changes to that entry appear in the Cumulative Supplement. Drug product information is provided in each Cumulative Supplement for completeness to assist in locating the proper place in the List for the revision.

The presence of any therapeutic equivalence code indicates that the drug product is multisource; the deletion of a therapeutic equivalence code indicates that the drug product has become single source. (An infrequent exception exists when a therapeutic equivalence code is revised. In that case the deletion of the therapeutic equivalence code is followed immediately by the addition of the revised one.)

Products that have never been marketed, are for exportation, are for military use, or have been discontinued from marketing or that have had their approvals withdrawn for other than safety or efficacy reasons, will be flagged in this Cumulative Supplement with the "@" symbol to designate their non-marketed status. All products having a "@" symbol in the 12th Cumulative Supplement of the 23rd Edition List will then be added to the "Discontinued Drug Product List" appearing in the 24th Edition. The current edition Section 2. How To Use The Drug Product Lists describes the layout and usage of the List.

The Patent and Exclusivity Lists are arranged in alphabetical order by active ingredient name. For those products with multiple active ingredients, only the first active ingredient (in alphabetical sort) will appear. In addition, the trade name will be displayed to the right of the active ingredient name for each product. Also shown is the application number and product number (FDA's internal file number) for reference purposes. All patents with their expiration dates are displayed for each application number. Use patents are indicated with the symbol "U" followed by a number representing a specific use. Exclusivity information for a specific drug is indicated by an abbreviation followed by the date upon which the exclusivity expires. Refer to the Exclusivity Terms, Section A, in the Patent and Exclusivity Information Addendum for an explanation of all codes and abbreviations.

New additions to the Prescription Drug Product List and OTC Drug Product List are indicated by the symbol >A>. The Patent and Exclusivity Data are indicated by the symbol >ADD> to the left of the line on which new information exists. The >ADD> symbol is then dropped in subsequent Cumulative Supplements for that item.

New deletions to the Prescription Drug Product List and OTC Drug Product List are indicated by the symbol >D> (DELETE) to the left of the line. The information line with the >D> symbol is dropped in subsequent Cumulative Supplements for that item.

## 1.2 APPLICANT NAME CHANGES

It is not practical to identify in the Cumulative Supplement each and every product involved when an applicant transfers its entire line of approved drug products to another applicant, or when an applicant changes its name. Therefore, the cumulation of these transfers and name changes will be identified in this section only. Where only partial lines of approved products are transferred between applicants, each approved product involved will appear as an applicant name change entry in the Cumulative Supplement.

It is also not practical to identify each and every product involved when an applicant name is changed to meet internal publication standards (e.g., MSD or Zenith [Former Abbreviated Names] are changed, respectively, to Merck Sharp Dohme or Zenith Labs [New Abbreviated Names]). When this occurs, each product involved (either currently in the Cumulative Supplement or in the following year's edition) will reflect the new abbreviated name. Consequently, it will not appear as an applicant name change entry in the Cumulative Supplement nor will the cumulation of these name changes appear in this section.

### APPLICANT NAME CHANGES

#### FORMER APPLICANT NAME (FORMER ABBREVIATED NAME)

BERLEX  
(BERLEX)  
BERLEX LABORATORIES INC  
(BERLEX LABS)  
BERLEX LABORATORIES INC SUB SCHERING AG  
(BERLEX)  
AMERSHAM HEALTH  
(AMERSHAM)

#### NEW APPLICANT NAME (NEW ABBREVIATED NAME)

BERLEX INC  
(BERLEX INC)  
BERLEX INC  
(BERLEX INC)  
BERLEX INC  
(BERLEX INC)  
GE HEALTHCARE  
(GE HEALTHCARE)

### 1.3 RIBAVIRIN 200MG ORAL CAPSULE

The footnote for Ribavirin 200MG capsule product 001 was inadvertently omitted from the 24<sup>th</sup> Edition. The footnote: Indicated for use and comarketed with interferon alfa-2b, recombinant (Intron A), as Rebetron Combination Therapy.

### 1.4 LEVOTHYROXINE SODIUM

Because there are multiple reference listed drugs of levothyroxine sodium tablets and some reference listed drugs' sponsors have conducted studies to establish their drugs' therapeutic equivalence to other reference listed drugs, FDA has determined that its usual practice of assigning two or three character TE codes may be potentially confusing and inadequate for these drug products. Accordingly, FDA provides the following explanation and chart of therapeutic equivalence evaluations for levothyroxine sodium drug products.

Levothyroxine Sodium (Mylan ANDA 76187) tablets have been determined to be therapeutically equivalent to corresponding strengths of Unithroid (Jerome Stevens NDA 021210) tablets.

Levo-T (Alara NDA 021342) and Levothyroxine Sodium (Mylan ANDA 76187) tablets have been determined to be therapeutically equivalent to corresponding strengths of Synthroid (Abbott NDA 021402) tablets.

Levo-T (Alara NDA 021342), Unithroid (Jerome Stevens NDA 021210) and Levothyroxine Sodium (Mylan ANDA 076187) tablets have been determined to be therapeutically equivalent to corresponding strengths of Levoxyl (King/Jones Pharma NDA 021301) tablets.

Novothyrox (Genpharm NDA 021292) requires further investigation and review to establish therapeutic equivalence to corresponding strengths of any other levothyroxine sodium drug products and is rated BX.

Thyro-Tabs (Lloyd NDA 021116) requires further investigation and review to establish therapeutic equivalence to corresponding strengths of any other levothyroxine sodium drug products and is rated BX.

Levolet (Vintage NDA 021137) requires further investigation and review to establish therapeutic equivalence to corresponding strengths of any other levothyroxine sodium drug products and is rated BX.

The chart outlines TE codes for all 0.025mg products with other products being similar. Therapeutic equivalence has been established between products that have the same AB+number TE code. More than one TE code may apply to some products. One common TE code indicates therapeutic equivalence between products.

Trade Name	Applicant	Potency	TE Code	Appl No	Product No
UNITHROID	STEVENS J	0.025MG	AB1	21210	001
LEVOTHYROXINE SODIUM	MYLAN	0.025MG	AB1	76187	001
LEVOXYL	JONES PHARMA	0.025MG	AB1	21301	001
SYNTHROID	ABBOTT	0.025MG	AB2	21402	001
LEVOTHYROXINE SODIUM	MYLAN	0.025MG	AB2	76187	001
LEVO-T	ALARA PHARM	0.025MG	AB2	21342	001

Trade Name	Applicant	Potency	DE Code	Approval Date	Product Type
LEVOXYL	JONES PHARMA	0.025MG	AB3	21301	001
LEVO-T	ALARA PHARM	0.025MG	AB3	21342	001
UNITHROID	STEVENS J	0.025MG	AB3	21210	001
LEVOTHYROXINE SODIUM	MYLAN	0.025MG	AB3	76187	001
NOVOTHYROX	GENPHARM	0.025MG	BX	21292	001
THYRO-TABS	LLOYD	0.025MG	BX	21116	001
LEVOLET	VINTAGE PHARMS	0.025MG	BX	21137	001

## 1.5 AVAILABILITY OF THE EDITION

The 24th Edition of the Orange Book and its monthly cumulative supplements are available by subscription from the Government Printing Office:

Superintendent of Documents  
Government Printing Office  
P.O. Box 371954  
Pittsburgh, PA 15250-7954

The telephone number to charge your subscription is 202-512-1800 or toll free 866-512-1800. The cost is \$110.00 annually. A GPO Orange Book Subscription form is provided at the end of each cumulative supplement.

The Approved Drug Products with Therapeutic Equivalence Evaluation (Orange Book) and related drug information is also available on the Internet at the Food and Drug Administration, Center for Drug Evaluation and Research, Drug Info page.

The Electronic Orange Book Query (EOB) is at <http://www.fda.gov/cder/ob>. The Query provides searching of the approved drug list by active ingredient, proprietary name, applicant holder or applicant number. Product search categories are: prescription, over-the-counter, discontinued drugs. There are links to patent and exclusivity information that may be applicable to each product. The data is updated concurrently with the publication of the monthly cumulative supplements.

The Internet version of the Orange Book annual edition is at  
<http://www.fda.gov/cder/orange/adp.htm>.

The Internet version of the monthly supplement is at  
<http://www.fda.gov/cder/orange/supplement/cspreface.htm>.

There are ASCII text files of the Orange Book drug product, patent, and exclusivity data at <http://www.fda.gov/cder/orange/obreadme.htm>. The drug product text files are zipped into zipobtxt.exe. The files are updated concurrently with the publication of the monthly cumulative supplements. Appendix A and Appendix B text files of the paper annual Orange Book are updated quarterly.

The 24th annual edition of the 2003 Orange Book Patent and Exclusivity List is at  
vi

<http://www.fda.gov/cder/orange/24bookpub.pdf>

The current year Patent and Exclusivity cumulative supplement list that denotes the current month additions is at <http://www.fda.gov/cder/orange/supplement/patents.pdf>.

The Patent Term Extension and new Patents, Docket Number \*95S-0117, is at <http://www.fda.gov/cder/orange/docket.pdf>. It is updated approximately weekly.

Effective August 18, 2003, patent submissions for publication in the Orange Book and Docket \*95S-0117 need to be submitted on form FDA-3542 which may be downloaded from Program Support Center Forms Download Website,  
<http://forms.psc.gov/forms/FDA/fda.html>

The current listing of the Orphan Product Designations and Approvals is available at <http://www.fda.gov/orphan/designat/list.htm>.

## 1.6 REPORT OF COUNTS FOR THE PRESCRIPTION DRUG PRODUCT LIST

### DESCRIPTION OF REPORT

This report provides summary counts derived from the product information in the Prescription Drug Product List and the current Cumulative Supplement. Products included in the counts are domestically marketed drug products approved for both safety and effectiveness under section 505 of the Federal Food, Drug, and Cosmetic Act. Excluded are approved drug products marketed by distributors; those marketed solely abroad; and those now regarded as medical devices, biologics or foods.

The baseline column (Dec 2003) refers to the products in the Prescription Drug Product List. For each three-month period, a column of quarterly data is added which incorporates counts of product activity from the previous quarter(s) with those in the baseline count.

### DEFINITIONS

#### Drug Product

For this report, a drug product is the representation in the Prescription Drug Product List of an active moiety (molecular entity and its salts, esters and derivatives) either as a single ingredient or as a combination product provided in a specific dosage form and strength for a given route of administration with approval for marketing by a firm under a particular generic or trade name.

#### New Molecular Entity

A new molecular entity is considered an active moiety that has not previously been approved (either as the parent compound or as a salt, ester or derivative of the parent compound) in the United States for use in a drug product either as a single ingredient or as part of a combination.

REPORT OF COUNTS FOR THE PRESCRIPTION DRUG PRODUCT LIST

COUNTS CUMULATIVE BY QUARTER

<u>CATEGORIES COUNTED</u>	<u>DEC 2003</u>	<u>MAR 2004</u>	<u>JUN 2004</u>	<u>SEP 2004</u>
DRUG PRODUCTS LISTED	10665	10668	10702	
SINGLE SOURCE	2423 (22.7%)	2404 (22.5%)	2385 (22.3%)	
MULTISOURCE	8134 (76.3%)	8156 (76.5%)	8209 (76.7%)	
THERAPEUTICALLY EQUIVALENT	7856 (73.7%)	7885 (73.9%)	7995 (74.7%)	
NOT THERAPEUTICALLY EQUIVALENT	278 (2.6%)	271 (2.5%)	214 (2.0%)	
EXCEPTIONS <sup>1</sup>	108 (1.0%)	108 (1.0%)	108 (1.0%)	
NEW MOLECULAR ENTITIES	6	3	1	
APPROVED NUMBER OF APPLICANTS	601	586	602	

<sup>1</sup>Amino acid-containing products of varying composition (see Introduction, page xx of the List).

### 1.7 CUMULATIVE SUPPLEMENT LEGEND

The List is sorted by Ingredient(s) and, within each grouping, by the Dosage Form; Route and then by trade name.

The individual product record contains the Therapeutic Equivalence Code, Reference Listed Drug symbol, applicant holder, strength(s), New Drug Approval number, product number, and approval date. The last two columns describe the action. The Action Month is the CS month the action occurred. The OB Action is the type of change that has occurred.

New ingredient(s), new dosage form; route(s), new trade names, and new product additions are preceded by >A> during the action month. The change month is the current CS month; the change code for new approvals is NEWA. Following months will display the same information without the >A>.

Changes to currently listed products will list two records. The deleted product record will be proceeded by >D>. The product record change addition being made will be preceded by >A>. Following months will display only the >A> record without the >A>. All changes that occur to the product through the Annual year will be listed. The change month and change code will document the change.

The change code and description:

NEWA	New drug product approval usually in the supplement month.
CAHN	Applicant holder firm name has changed.
CAIN	Change. There has been a change in the Ingredient(s) name. All products will be deleted under the old name and all products will be added under the changed ingredient(s) name.
CDFR	Change. Dosage Form; Route of Administration.
CFTG	Change. A first time generic for the innovator product. A TE Code is added.
CMFD	Change. The product is moved from the Discontinued Section due to a change in marketing status.
CMS1	Change. Miscellaneous addition to list.
CMS2	Change. Miscellaneous deletion from list.
CPOT	Change. Potency amount/unit.
CRLD	Change. Reference Listed Drug.
CTEC	Change. Therapeutic Equivalence Code.
CTNA	Change. Trade Name.

DISC	Discontinued. The Rx or OTC listed product is not being marketed and will be moved to the discontinued section in the next edition.
WDAG	Withdrawn. The applicant holder has notified the FDA in writing that the product is no longer being marketed resulting in the product approval being withdrawn by mutual agreement. The product will be listed in the Discontinued Section.
WDRP	Withdrawn. The application approval has been withdrawn for failure to provide Annual Reports. The product will be moved to the Discontinued Section in the next edition.

PRESCRIPTION DRUG PRODUCT LIST - 24TH EDITION  
RX DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 7 - July 2004

1-1

>A>	<u>ACAMPROSATE CALCIUM</u>	
>A>	TABLET, DELAYED RELEASE; ORAL	
>A>	CAMPRAL	
>A>	+ LIPHA	333MG
	N21431 001 Jul 29, 2004 Jul NEWA	
<u>ACETAMINOPHEN; BUTALBITAL; CAFFEINE; CODEINE PHOSPHATE</u>		
	CAPSULE; ORAL	
	BUTALBITAL, ACETAMINOPHEN, CAFFEINE AND CODEINE PHOSPHATE	
AB	ANABOLIC LABS	325MG;50MG;40MG;30MG
	N76560 001 Jun 10, 2004 Jun NEWA	
<u>ACETAMINOPHEN; CODEINE PHOSPHATE</u>		
	SUSPENSION; ORAL	
	ACETAMINOPHEN AND CODEINE PHOSPHATE	
AA	+ AMARIN PHARMS	120MG/5ML;12MG/5ML
	N86024 001 Apr CRLD	
<u>ACETAMINOPHEN; HYDROCODONE BITARTRATE</u>		
	TABLET; ORAL	
	HYDROCODONE BITARTRATE AND ACETAMINOPHEN	
	+ MIKART	300MG;10MG
	N40556 001 Jun 23, 2004 Jun NEWA	
<u>ACETAMINOPHEN; OXYCODONE HYDROCHLORIDE</u>		
	TABLET; ORAL	
	OXYCODONE AND ACETAMINOPHEN	
AA	MALLINCKRODT	325MG;7.5MG
AA		325MG;10MG
AA		500MG;7.5MG
AA		650MG;10MG
	N40545 001 Jun 30, 2004 Jun NEWA	
	N40545 002 Jun 30, 2004 Jun NEWA	
	N40550 001 Jun 30, 2004 Jun NEWA	
	N40550 002 Jun 30, 2004 Jun NEWA	
<u>ACETAMINOPHEN; PROPOXYPHENE NAPSYLATE</u>		
	TABLET; ORAL	
	DARVOCET A500	
	AAIPHARMA	500MG;100MG
AB		500MG;100MG
	N76429 001 Sep 10, 2003 May CRLD	
	N76429 001 Sep 10, 2003 Jun CFTG	
	PROPOXYPHENE NAPSYLATE AND ACETAMINOPHEN	
	VINTAGE PHARMS	325MG;100MG
AB		500MG;100MG
	N76743 001 May 07, 2004 May NEWA	
	N76750 001 Jun 28, 2004 Jun NEWA	
<u>ACETAZOLAMIDE SODIUM</u>		
	INJECTABLE; INJECTION	
	ACETAZOLAMIDE SODIUM	
AP	HOSPIRA	EQ 500MG BASE/VIAL
	N40108 001 Oct 30, 1995 May CAHN	
<u>ACETIC ACID, GLACIAL</u>		
	SOLUTION; IRRIGATION, URETHRAL	
	ACETIC ACID 0.25% IN PLASTIC CONTAINER	
AT	HOSPIRA	250MG/100ML
	N17656 001 May CAHN	
<u>ACETYLCYSTEINE</u>		
	INJECTABLE; INTRAVENOUS	
	ACETADOTE	
	+ CUMBERLAND PHARMS	6GM /30ML(200MG/ML)
	N21539 001 Jan 23, 2004 Jan NEWA	

SOLUTION; INHALATION, ORAL  
ACETYLCYSTEINE

AN	HOSPIRA	10%	N73664 001 Aug 30, 1994 May CAHN
AN		20%	N74037 001 Aug 30, 1994 May CAHN

ACITRETIN

CAPSULE; ORAL SORIATANE CONNEXICS	10MG	N19821 001 Oct 28, 1996 Mar CAHN
+	25MG	N19821 002 Oct 28, 1996 Mar CAHN

ACYCLOVIR SODIUM

INJECTABLE; INJECTION ACYCLOVIR SODIUM		
AP HOSPIRA	EQ 500MG BASE/VIAL	N74663 001 Apr 22, 1997 May CAHN
AP	EQ 500MG BASE/VIAL	N74758 001 Apr 22, 1997 May CAHN
AP	EQ 1GM BASE/VIAL	N74663 002 Apr 22, 1997 May CAHN
AP	EQ 1GM BASE/VIAL	N74758 002 Apr 22, 1997 May CAHN
AP MAYNE PHARMA USA	EQ 50MG BASE/ML	N75065 001 Feb 25, 1999 Apr CAHN

ADENOSINE

INJECTABLE; INJECTION ADENOCARD		
AP + FUJISAWA HLTHCARE	3MG/ML	N19937 002 Oct 30, 1989 Jun CFTG
ADENOSINE		
AP BAXTER HLTHCARE	3MG/ML	N76500 001 Jun 16, 2004 Jun NEWA
AP	3MG/ML	N76501 001 Jun 16, 2004 Jun NEWA
AP BEDFORD	3MG/ML	N76404 001 Jun 16, 2004 Jun NEWA
AP SICOR PHARMS	3MG/ML	N76564 001 Jun 16, 2004 Jun NEWA

ALATROFLOXACIN MESYLATE

INJECTABLE; INJECTION TROVAN PRESERVATIVE FREE		
@ PFIZER	EQ 200MG BASE/VIAL	N20760 001 Dec 18, 1997 Jun DISC
@	EQ 300MG BASE/VIAL	N20760 002 Dec 18, 1997 Jun DISC

ALBUMIN IODINATED I-125 SERUM

INJECTABLE; INJECTION JEANATOPE		
ISO TEX	100UCI/10ML(10UCI/ML)	N17836 003 Jun 08, 2004 Jun NEWA
+ +	500uCi/0.5ML	N17836 001 Jun CMFD
	1,000uCi/ML	N17836 002 Jun CMFD
RADIOIODINATED SERUM ALBUMIN (HUMAN) IHSA I 125		
@ MALLINCKRODT	10uCi/ML	N17844 001 Jun DISC

ALBUTEROL SULFATE

SOLUTION; INHALATION ACCUNEB		
AN + DEY	EQ 0.042% BASE	N20949 001 Apr 30, 2001 Jun CFTG
ALBUTEROL SULFATE		
AN + BAUSCH AND LOMB	EQ 0.083% BASE	N75358 001 Mar 29, 2000 Jun CRLD
AN +	EQ 0.5% BASE	N75050 001 Jun 18, 1998 Jun CRLD
AN NEPHRON	EQ 0.042% BASE	N76355 001 Jun 28, 2004 Jun NEWA
PROVENTIL		
@ SCHERING	EQ 0.083% BASE	N19243 002 Jan 14, 1987 Jun DISC
@	EQ 0.5% BASE	N19243 001 Jan 14, 1987 Jun DISC

TABLET, EXTENDED RELEASE; ORAL  
ALBUTEROL SULFATE

+ PLIVA	EQ 4MG BASE	N76130 002 Sep 26, 2002 Jan CRLD
+ VOLMAX	EQ 8MG BASE	N76130 003 Sep 26, 2002 Jan CRLD
@ MURO	EQ 4MG BASE	N19604 002 Dec 23, 1992 Jan DISC
@	EQ 8MG BASE	N19604 001 Dec 23, 1992 Jan DISC

ALCLOMETASONE DIPROPIONATE

OINTMENT; TOPICAL  
ACLOVATE

>D>	+ GLAXOSMITHKLINE	0.05%	N18702 001 Dec 14, 1982 Jul CFTG
>A>	AB +	0.05%	N18702 001 Dec 14, 1982 Jul CFTG
>A>	ALCLOMETASONE DIPROPIONATE		
>A>	AB TARO	0.05%	N76730 001 Jul 29, 2004 Jul NEWA

ALCOHOL; DEXTROSE

INJECTABLE; INJECTION  
ALCOHOL 5% IN D5-W

AP	HOSPIRA	5ML/100ML;5GM/100ML	N83263 001 May CAHN
----	---------	---------------------	---------------------

ALFENTANIL HYDROCHLORIDE

INJECTABLE; INJECTION  
ALFENTANIL

AP	HOSPIRA	EQ 0.5MG BASE/ML	N75221 001 Oct 28, 1999 May CAHN
----	---------	------------------	----------------------------------

ALLOPURINOL SODIUM

INJECTABLE; INJECTION  
ALOPRIM

+ NABI	EQ 500MG BASE/VIAL	N20298 001 May 17, 1996 Jun CAHN
--------	--------------------	----------------------------------

ALMOTRIPTAN MALATE

TABLET; ORAL  
AXERT

>D>	JANSSEN ORTHO	EQ 6.25MG BASE	N21001 001 May 07, 2001 Jul CAHN
>D>	+	EQ 12.5MG BASE	N21001 002 May 07, 2001 Jul CAHN
>A>	ORTHO MCNEIL PHARM	EQ 6.25MG BASE	N21001 001 May 07, 2001 Jul CAHN
>A>	+	EQ 12.5MG BASE	N21001 002 May 07, 2001 Jul CAHN

AMIKACIN SULFATE

INJECTABLE; INJECTION  
AMIKACIN SULFATE

AP	HOSPIRA	EQ 50MG BASE/ML	N63263 001 Nov 30, 1994 May CAHN
		EQ 62.5MG BASE/ML	N63283 001 Oct 31, 1994 May CAHN

AP		EQ 250MG BASE/ML	N63264 001 Nov 30, 1994 May CAHN
AP		EQ 250MG BASE/ML	N64098 001 Jun 26, 1995 May CAHN

@		EQ 250MG BASE/ML	N64099 001 Jun 20, 1995 May CAHN
---	--	------------------	----------------------------------

## AMIKACIN SULFATE IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER

HOSPIRA	EQ 500MG BASE/100ML	N64146 001 Apr 02, 1997 May CAHN
---------	---------------------	----------------------------------

AMINO ACIDS

## INJECTABLE; INJECTION

## AMINOSYN 10%

HOSPIRA	10% (10GM/100ML)	N17673 003 May CAHN
---------	------------------	---------------------

## AMINOSYN 10% (PH6)

HOSPIRA	10% (10GM/100ML)	N17673 008 Nov 18, 1985 May CAHN
---------	------------------	----------------------------------

INJECTABLE; INJECTION

AMINOSYN 3.5%			
HOSPIRA	3.5% (3.5GM/100ML)	N17789 004	May CAHN
AMINOSYN 5%			
HOSPIRA	5% (5GM/100ML)	N17673 001	May CAHN
AMINOSYN 7%			
@ HOSPIRA	7% (7GM/100ML)	N17673 002	May CAHN
AMINOSYN 7% (PH6)			
HOSPIRA	7% (7GM/100ML)	N17673 006 Nov 18, 1985	May CAHN
AMINOSYN 8.5%			
@ HOSPIRA	8.5% (8.5GM/100ML)	N17673 004	May CAHN
AMINOSYN 8.5% (PH6)			
HOSPIRA	8.5% (8.5GM/100ML)	N17673 007 Nov 18, 1985	May CAHN
AMINOSYN II 10%			
HOSPIRA	10% (10GM/100ML)	N19438 005 Apr 03, 1986	May CAHN
AMINOSYN II 10% IN PLASTIC CONTAINER			
HOSPIRA	10% (10GM/100ML)	N20015 001 Dec 19, 1991	May CAHN
AMINOSYN II 15% IN PLASTIC CONTAINER			
HOSPIRA	15% (15GM/100ML)	N20041 001 Dec 19, 1991	May CAHN
AMINOSYN II 3.5%			
@ HOSPIRA	3.5% (3.5GM/100ML)	N19438 001 Apr 03, 1986	May CAHN
AMINOSYN II 5%			
@ HOSPIRA	5% (5GM/100ML)	N19438 002 Apr 03, 1986	May CAHN
AMINOSYN II 7%			
HOSPIRA	7% (7GM/100ML)	N19438 003 Apr 03, 1986	May CAHN
AMINOSYN II 8.5%			
HOSPIRA	8.5% (8.5GM/100ML)	N19438 004 Apr 03, 1986	May CAHN
AMINOSYN-HBC 7%			
HOSPIRA	7% (7GM/100ML)	N19374 001 Jul 12, 1985	May CAHN
AMINOSYN-HF 8%			
HOSPIRA	8% (8GM/100ML)	N20345 001 Apr 04, 1996	May CAHN
AMINOSYN-PF 10%			
HOSPIRA	10% (10GM/100ML)	N19492 002 Oct 17, 1986	May CAHN
AMINOSYN-PF 7%			
HOSPIRA	7% (7GM/100ML)	N19398 001 Sep 06, 1985	May CAHN
AMINOSYN-RF 5.2%			
HOSPIRA	5.2% (5.2GM/100ML)	N18429 001	May CAHN

AMINO ACIDS; CALCIUM CHLORIDE; DEXTROSE; MAGNESIUM CHLORIDE; POTASSIUM CHLORIDE; POTASSIUM PHOSPHATE, DIBASIC; SODIUM CHLORIDEINJECTABLE; INJECTION

AMINOSYN II 3.5% W/ ELECTROLYTES IN DEXTROSE 25% W/ CALCIUM IN PLASTIC CONTAINER			
HOSPIRA	3.5%;36.8MG/100ML;25GM/100ML;51MG /100ML;22.4MG/100ML;261MG/100ML;205MG/100ML	N19683 001 Nov 07, 1988	May CAHN
AMINOSYN II 4.25% W/ ELECTROLYTES IN DEXTROSE 20% W/ CALCIUM IN PLASTIC CONTAINER			
HOSPIRA	4.25%;36.8MG/100ML;20GM/100ML;51M G/100ML;22.4MG/100ML;261MG/100ML;205MG/100ML	N19683 002 Nov 07, 1988	May CAHN
AMINOSYN II 4.25% W/ ELECTROLYTES IN DEXTROSE 25% W/ CALCIUM IN PLASTIC CONTAINER			
HOSPIRA	4.25%;36.8MG/100ML;25GM/100ML;51M G/100ML;22.4MG/100ML;261MG/100ML;205MG/100ML	N19683 003 Nov 07, 1988	May CAHN
AMINOSYN II 5% W/ ELECTROLYTES IN DEXTROSE 25% W/ CALCIUM IN PLASTIC CONTAINER			
@ HOSPIRA	5%;36.8MG/100ML;25GM/100ML;51MG/100ML;22.4MG/100ML;261MG/100ML;205MG/100ML	N19683 004 Nov 07, 1988	May CAHN

AMINO ACIDS; DEXTROSE

## INJECTABLE; INJECTION

AMINOSYN II 3.5% IN DEXTROSE 25% IN PLASTIC CONTAINER

HOSPIRA 3.5%;25GM/100ML

N19681 001 Nov 01, 1988 May CAHN

AMINOSYN II 3.5% IN DEXTROSE 5% IN PLASTIC CONTAINER

HOSPIRA 3.5%;5GM/100ML

N19681 002 Nov 01, 1988 May CAHN

AMINOSYN II 4.25% IN DEXTROSE 10% IN PLASTIC CONTAINER

HOSPIRA 4.25%;10GM/100ML

N19681 004 Nov 01, 1988 May CAHN

AMINOSYN II 4.25% IN DEXTROSE 20% IN PLASTIC CONTAINER

HOSPIRA 4.25%;20GM/100ML

N19681 005 Nov 01, 1988 May CAHN

AMINOSYN II 4.25% IN DEXTROSE 25% IN PLASTIC CONTAINER

HOSPIRA 4.25%;25GM/100ML

N19681 003 Nov 01, 1988 May CAHN

AMINOSYN II 5% IN DEXTROSE 25% IN PLASTIC CONTAINER

HOSPIRA 5%;25GM/100ML

N19681 006 Nov 01, 1988 May CAHN

AMINO ACIDS; DEXTROSE; MAGNESIUM CHLORIDE; POTASSIUM ACETATE; POTASSIUM CHLORIDE; POTASSIUM PHOSPHATE, DIBASIC; SODIUM CHLORIDE

## INJECTABLE; INJECTION

AMINOSYN II 4.25% W/ ELECT AND ADJUSTED PHOSPHATE IN DEXTROSE 10% IN PLASTIC CONTAINER

@ HOSPIRA 4.25%;10GM/100ML;51MG/100ML;176.5 MG/100ML;22.4MG/100ML;104.5MG/100 ML;205MG/100ML

AMINO ACIDS; DEXTROSE; MAGNESIUM CHLORIDE; POTASSIUM CHLORIDE; SODIUM CHLORIDE; SODIUM PHOSPHATE, DIBASIC, HEPTAHYDRATE

## INJECTABLE; INJECTION

AMINOSYN II 3.5% M IN DEXTROSE 5% IN PLASTIC CONTAINER

HOSPIRA 3.5%;5GM/100ML;30MG/100ML;97MG/10 OML;120MG/100ML;49.3MG/100ML

N19682 001 Nov 01, 1988 May CAHN

AMINOSYN II 4.25% M IN DEXTROSE 10% IN PLASTIC CONTAINER

HOSPIRA 4.25%;5GM/100ML;30MG/100ML;97MG/100ML;120MG/100ML;49.3MG/100ML

N19682 002 Nov 01, 1988 May CAHN

AMINO ACIDS; MAGNESIUM ACETATE; PHOSPHORIC ACID; POTASSIUM ACETATE; SODIUM CHLORIDE

## INJECTABLE; INJECTION

AMINOSYN 3.5% M

HOSPIRA 3.5%;21MG/100ML;40MG/100ML;128MG/100ML;234MG/100ML

May CAHN

AMINO ACIDS; MAGNESIUM ACETATE; POTASSIUM ACETATE; SODIUM CHLORIDE

## INJECTABLE; INJECTION

AMINOSYN 3.5% M

@ HOSPIRA 3.5%;21MG/100ML;128MG/100ML;234MG/100ML

May CAHN

AMINO ACIDS; MAGNESIUM CHLORIDE; POTASSIUM CHLORIDE; POTASSIUM PHOSPHATE, DIBASIC; SODIUM CHLORIDE

## INJECTABLE; INJECTION

AMINOSYN II 10% W/ ELECTROLYTES

HOSPIRA 10%;102MG/100ML;45MG/100ML;522MG/100ML;410MG/100ML

N19437 004 Apr 03, 1986 May CAHN

AMINOSYN II 7% W/ ELECTROLYTES

@ HOSPIRA 7%;102MG/100ML;45MG/100ML;522MG/100ML;410MG/100ML

N19437 006 Apr 03, 1986 May CAHN

AMINOSYN II 8.5% W/ ELECTROLYTES

HOSPIRA 8.5%;102MG/100ML;45MG/100ML;522MG/100ML;410MG/100ML

N19437 005 Apr 03, 1986 May CAHN

AMINO ACIDS; MAGNESIUM CHLORIDE; POTASSIUM CHLORIDE; SODIUM CHLORIDE; SODIUM PHOSPHATE, DIBASIC, HEPTAHYDRATE

INJECTABLE; INJECTION

AMINOSYN II 3.5% M

@ HOSPIRA 3.5%;30MG/100ML;97MG/100ML;120MG/ N19437 007 Apr 03, 1986 May CAHN  
100ML;49MG/100MLAMINO ACIDS; MAGNESIUM CHLORIDE; POTASSIUM PHOSPHATE, DIBASIC; SODIUM CHLORIDE

INJECTABLE; INJECTION

AMINOSYN 7% W/ ELECTROLYTES

HOSPIRA 7%;102MG/100ML;522MG/100ML;410MG/ N17789 002 May CAHN  
100ML

AMINOSYN 8.5% W/ ELECTROLYTES

HOSPIRA 8.5%;102MG/100ML;522MG/100ML;410M N17673 005 May CAHN  
G/100MLAMINOCAPROIC ACID

INJECTABLE; INJECTION

AMINOCAPROIC ACID

AP HOSPIRA 250MG/ML N70888 001 Jun 16, 1988 May CAHN

AMINOCAPROIC ACID IN PLASTIC CONTAINER

AP HOSPIRA 250MG/ML N70010 001 Mar 09, 1987 May CAHN

AMINOPHYLLINE

INJECTABLE; INJECTION

AMINOPHYLLINE

AP HOSPIRA 25MG/ML N87242 001 Oct 26, 1983 May CAHN

AP + 25MG/ML N87601 001 Jul 23, 1982 May CAHN

AMINOPHYLLINE IN SODIUM CHLORIDE 0.45%

+ HOSPIRA 100MG/100ML N88147 002 May 03, 1983 May CAHN

+ 200MG/100ML N88147 003 May 03, 1983 May CAHN

AMINOPHYLLINE IN SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER

@ HOSPIRA 100MG/100ML N18924 001 Dec 12, 1984 May CAHN

@ 200MG/100ML N18924 002 Dec 12, 1984 May CAHN

@ 400MG/100ML N18924 003 Dec 12, 1984 May CAHN

@ 500MG/100ML N18924 004 Dec 12, 1984 May CAHN

AMIODARONE HYDROCHLORIDE

INJECTABLE; INJECTION

AMIODARONE HCL

AP HOSPIRA 50MG/ML N75955 001 Oct 18, 2002 May CAHN

AMIODARONE HYDROCHLORIDE

AP INTL MEDICATION SYS 50MG/ML N21594 001 Feb 04, 2004 Feb NEWA

TABLET; ORAL

AMIODARONE HCL

&gt;D&gt; AB + TARO 400MG N76362 001 Nov 29, 2002 Jul DISC

&gt;A&gt; @ 400MG N76362 001 Nov 29, 2002 Jul DISC

AMITRIPTYLINE HYDROCHLORIDE

TABLET; ORAL

ELAVIL

&gt;D&gt; AB ASTRAZENECA 10MG N12703 001 Jul DISC

&gt;A&gt; @ 10MG N12703 001 Jul DISC

&gt;D&gt; AB + 25MG N12703 003 Jul DISC

&gt;A&gt; @ 25MG N12703 003 Jul DISC

&gt;D&gt; AB 50MG N12703 004 Jul DISC

&gt;A&gt; @ 50MG N12703 004 Jul DISC

TABLET; ORAL

>D>	ELAVIL				
>D>	AB	ASTRAZENECA	75MG	N12703 005	Jul DISC
>A>	@		75MG	N12703 005	Jul DISC
>D>	AB		100MG	N12703 006	Jul DISC
>A>	@		100MG	N12703 006	Jul DISC
>D>	AB		150MG	N12703 007	Jul DISC
>A>	@		150MG	N12703 007	Jul DISC

AMLODIPINE BESYLATE; ATORVASTATIN CALCIUMTABLET; ORALCADUETPFIZER

EQ 5MG BASE;EQ 10MG BASE	N21540 001	Jan 30, 2004	Jan	NEWA
EQ 5MG BASE;EQ 20MG BASE	N21540 002	Jan 30, 2004	Jan	NEWA
EQ 5MG BASE;EQ 40MG BASE	N21540 003	Jan 30, 2004	Jan	NEWA
EQ 5MG BASE;EQ 80MG BASE	N21540 004	Jan 30, 2004	Jan	NEWA
EQ 10MG BASE;EQ 10MG BASE	N21540 005	Jan 30, 2004	Jan	NEWA
EQ 10MG BASE;EQ 20MG BASE	N21540 006	Jan 30, 2004	Jan	NEWA
EQ 10MG BASE;EQ 40MG BASE	N21540 007	Jan 30, 2004	Jan	NEWA
EQ 10MG BASE;EQ 80MG BASE	N21540 008	Jan 30, 2004	Jan	NEWA

+

AMLODIPINE MALEATETABLET; ORALAMVAZ

@ DR REDDYS LABS INC	2.5MG	N21435 001	Oct 31, 2003	Mar	DISC
@	5MG	N21435 002	Oct 31, 2003	Mar	DISC
@	10MG	N21435 003	Oct 31, 2003	Mar	DISC

AMMONIUM CHLORIDEINJECTABLE; INJECTIONAMMONIUM CHLORIDE IN PLASTIC CONTAINER

+ HOSPIRA	5MEQ/ML	N88366 001	Jun 13, 1984	May	CAHN
-----------	---------	------------	--------------	-----	------

AMMONIUM LACTATELOTION; TOPICALAMMONIUM LACTATE

AB CLAY PARK	EQ 12% BASE	N75570 001	Jun 23, 2004	Jun	NEWA
AB TARO	EQ 12% BASE	N76216 001	May 28, 2004	May	NEWA

AMOXICILLIN; CLAVULANATE POTASSIUMFOR SUSPENSION; ORALAMOXICILLIN AND CLAVULANATE POTASSIUM

AB TEVA	200MG/5ML;EQ 28.5MG BASE/5ML	N65089 001	May 25, 2004	May	NEWA
AB	400MG/5ML;EQ 57MG BASE/5ML	N65089 002	May 25, 2004	May	NEWA
AB	600MG/5ML;EQ 42.9MG BASE/5ML	N65162 001	Mar 12, 2004	Mar	NEWA
AUGMENTIN ES-600					
AB + GLAXOSMITHKLINE	600MG/5ML;EQ 42.9MG BASE/5ML	N50755 001	Jun 22, 2001	Mar	CFTG

AMPICILLIN SODIUMINJECTABLE; INJECTIONAMPICILLIN SODIUM

AP + SANDOZ	EQ 125MG BASE/VIAL	N61395 001	Jun	CAHN
AP +	EQ 250MG BASE/VIAL	N61395 002	Jun	CAHN
AP +	EQ 500MG BASE/VIAL	N61395 003	Jun	CAHN
AP +	EQ 1GM BASE/VIAL	N61395 004	Jun	CAHN
AP +	EQ 2GM BASE/VIAL	N61395 005	Jun	CAHN

INJECTABLE; INJECTION  
AMPICILLIN SODIUM

AP + SANDOZ EQ 10GM BASE/VIAL N61395 006 Jun CAHN

APOMORPHINE HYDROCHLORIDE

INJECTABLE; SUBCUTANEOUS

APOKYN  
BERTEK 20MG/2ML (10MG/ML) N21264 001 Apr 20, 2004 Apr NEWA  
+ 30MG/3ML (10MG/ML) N21264 002 Apr 20, 2004 Apr NEWA

ASCORBIC ACID; BIOTIN; CHOLECALCIFEROL; CYANOCOBALAMIN; DEXPANTHENOL; FOLIC ACID;  
NIACINAMIDE; PYRIDOXINE; RIBOFLAVIN; THIAMINE; TOCOPHEROL ACETATE; VITAMIN A; VITAMIN K

INJECTABLE; IV (INFUSION)

INFUVITE PEDIATRIC (PHARMACY BULK PACKAGE)

+ SABEX 2002 80MG/VIAL;0.02MG/VIAL;400 IU/VIAL;0.001MG/VIAL;5MG/VIAL;0.1 4MG/VIAL;17MG/VIAL;1MG/VIAL;1.4MG /VIAL;1.2MG/VIAL;7 IU/VIAL;2,300 IU/VIAL;0.2MG/VIAL N21646 001 Jan 29, 2004 Jan NEWA

ASCORBIC ACID; BIOTIN; CYANOCOBALAMIN; DEXPANTHENOL; ERGOCALCIFEROL; FOLIC ACID;  
NIACINAMIDE; PHYTONADIONE; PYRIDOXINE HYDROCHLORIDE; RIBOFLAVIN PHOSPHATE SODIUM; THIAMINE  
HYDROCHLORIDE; VITAMIN A; VITAMIN E

FOR SOLUTION; IV (INFUSION)

M.V.I. PEDIATRIC

+ MAYNE PHARMA USA 80MG/VIAL;0.02MG/VIAL;0.001MG/VIA L;5MG/VIAL;0.01MG/VIAL;0.14MG/VIA L;17MG/VIAL;0.2MG/VIAL;1MG/VIAL;1 .4MG/VIAL;EQ 1.2MG BASE/VIAL;0.7MG/VIAL;7MG/VIAL N18920 001 Sep 21, 2000 Apr CAHN

ASCORBIC ACID; BIOTIN; CYANOCOBALAMIN; DEXPANTHENOL; ERGOCALCIFEROL; FOLIC ACID;  
NIACINAMIDE; PYRIDOXINE HYDROCHLORIDE; RIBOFLAVIN PHOSPHATE SODIUM; THIAMINE HYDROCHLORIDE;  
VITAMIN A; VITAMIN E

INJECTABLE; INJECTION

M.V.I.-12

+ MAYNE PHARMA USA 10MG/ML;0.006MG/ML;0.5UGM/ML;1.5M G/ML;20 IU/ML;0.04MG/ML;4MG/ML;0.4MG/ML;0 .36MG/ML;0.3MG/ML;330 UNITS/ML;1 IU/ML N08809 004 Aug 08, 1985 Apr CAHN

ASCORBIC ACID; BIOTIN; CYANOCOBALAMIN; DEXPANTHENOL; ERGOCALCIFEROL; FOLIC ACID;  
NIACINAMIDE; PYRIDOXINE HYDROCHLORIDE; RIBOFLAVIN PHOSPHATE SODIUM; THIAMINE HYDROCHLORIDE;  
VITAMIN A; VITAMIN E; VITAMIN K

INJECTABLE; IV (INFUSION)

M.V.I. ADULT

+ AAIPHARMA LLC 200MG/VIAL;0.06MG/VIAL;0.005MG/VI AL;15MG/VIAL;0.005MG/VIAL;0.6MG/V IAL;40MG/VIAL;6MG/VIAL;3.6MG/VIAL ;6MG/VIAL;1IMG/VIAL;10MG/VIAL;0.15 MG/VIAL N21625 001 Jan 30, 2004 Jan NEWA

+ MAYNE PHARMA USA 200MG/VIAL;0.06MG/VIAL;0.005MG/VI AL;15MG/VIAL;0.005MG/VIAL;0.6MG/V IAL;40MG/VIAL;6MG/VIAL;3.6MG/VIAL ;6MG/VIAL;1IMG/VIAL;10MG/VIAL;0.15 MG/VIAL N21625 001 Jan 30, 2004 Apr CAHN

M.V.I. ADULT (PHARMACY BULK PACKAGE)

+ AAIPHARMA LLC 200MG/5ML;0.06MG/5ML;0.005MG/5ML; 15MG/5ML;0.005MG/5ML;0.6MG/5ML;40 MG/5ML;6MG/5ML;3.6MG/5ML;6MG/5ML; 1IMG/5ML;10MG/5ML;0.15MG/5ML N21643 001 Feb 18, 2004 Feb NEWA

+ MAYNE PHARMA USA 200MG/5ML;0.06MG/5ML;0.005MG/5ML; 15MG/5ML;0.005MG/5ML;0.6MG/5ML;40 MG/5ML;6MG/5ML;3.6MG/5ML;6MG/5ML; 1IMG/5ML;10MG/5ML;0.15MG/5ML N21643 001 Feb 18, 2004 Apr CAHN

ASCORBIC ACID; BIOTIN; CYANOCOBALAMIN; DEXPANTHENOL; ERGOCALCIFEROL; FOLIC ACID; NIACINAMIDE; PYRIDOXINE HYDROCHLORIDE; RIBOFLAVIN; THIAMINE HYDROCHLORIDE; VITAMIN A; VITAMIN E

INJECTABLE; INJECTION

M.V.I.-12

+ MAYNE PHARMA USA 20MG/ML;0.006MG/ML;0.5UGM/ML;1.5M G/ML;20 IU/ML;0.6MG/ML;4MG/ML;0.4MG/ML;0.36MG/ML;0.6MG/ML;330 UNITS/ML;1 IU/ML

ASPIRIN; CAFFEINE; PROPOXYPHENE HYDROCHLORIDE

CAPSULE; ORAL

DARVON COMPOUND

@ AAIPHARMA LLC

389MG;32.4MG;32MG

N10996 006 Mar 08, 1983 Jun DISC

ATENOLOL

TABLET; ORAL

ATENOLOL

>A>	AB	ABLE	25MG	N76907 001 Jul 30, 2004 Jul NEWA
>A>	AB		50MG	N76907 002 Jul 30, 2004 Jul NEWA
>A>	AB		100MG	N76907 003 Jul 30, 2004 Jul NEWA
>A>	AB	TEVA	25MG	N74056 003 Jul 19, 2004 Jul NEWA

ATRACURIUM BESYLATE

INJECTABLE; INJECTION

ATRACURIUM BESYLATE

AP	HOSPIRA	10MG/ML	N74632 001 Dec 23, 1996 May CAHN
AP	ATRACURIUM BESYLATE PRESERVATIVE FREE		N74633 001 Dec 23, 1996 May CAHN
AP	HOSPIRA	10MG/ML	N74639 001 Mar 25, 1997 May CAHN
AP		10MG/ML	
AP	TRACRIUM		
AP	+ HOSPIRA	10MG/ML	N18831 002 Jun 20, 1985 May CAHN
AP	TRACRIUM PRESERVATIVE FREE		
AP	+ HOSPIRA	10MG/ML	N18831 001 Nov 23, 1983 May CAHN

ATROPINE SULFATE

INJECTABLE; IM-IV-SC

ATROPINE SULFATE ANSRY PLASTIC SYRINGE

HOSPIRA 0.05MG/ML

+ 0.1MG/ML N21146 002 Jul 09, 2001 May CAHN

N21146 001 Jul 09, 2001 May CAHN

ATROPINE SULFATE; DIFENOXIN HYDROCHLORIDE

TABLET; ORAL

MOTOFEN

+ VALEANT	0.025MG;1MG	N17744 002	May CAHN
MOTOFEN HALF-STRENGTH			
@ VALEANT	0.025MG;0.5MG	N17744 001	May CAHN

AZACITIDINE

INJECTABLE; SUBCUTANEOUS

VIDAZA

+ PHARMION 100MG/VIAL N50794 001 May 19, 2004 May NEWA

AZATADINE MALEATE

TABLET; ORAL  
OPTIMINE  
@ SCHERING 1MG N17601 001 May DISC

AZATADINE MALEATE; PSEUDOEPHEDRINE SULFATE

TABLET, EXTENDED RELEASE; ORAL  
TRINALIN  
@ SCHERING 1MG;120MG N18506 001 Mar 23, 1982 May DISC

AZATHIOPRINE SODIUM

INJECTABLE; INJECTION  
AZATHIOPRINE SODIUM  
+ BEDFORD EQ 100MG BASE/VIAL N74419 001 Mar 31, 1995 May CRLD  
IMURAN  
@ PROMETHEUS LABS EQ 100MG BASE/VIAL N17391 001 May DISC

AZITHROMYCIN

CAPSULE; ORAL  
ZITHROMAX  
@ PFIZER EQ 250MG BASE N50670 001 Nov 01, 1991 Mar DISC

AZTREONAM

INJECTABLE; INJECTION  
AZACTAM  
>D> @ BRISTOL MYERS SQUIBB 500MG/VIAL N50580 001 Dec 31, 1986 Jul CMFD  
>A> + 500MG/VIAL N50580 001 Dec 31, 1986 Jul CMFD  
>D> @ 1GM/VIAL N50580 002 Dec 31, 1986 Jul CMFD  
>A> + 1GM/VIAL N50580 002 Dec 31, 1986 Jul CMFD  
>D> @ 2GM/VIAL N50580 003 Dec 31, 1986 Jul CMFD  
>A> + 2GM/VIAL N50580 003 Dec 31, 1986 Jul CMFD

BACITRACIN ZINC; HYDROCORTISONE; NEOMYCIN SULFATE; POLYMYXIN B SULFATE

OINTMENT; OPHTHALMIC  
CORTISPORIN  
AT MONARCH PHARMS 400 UNITS/GM;1%;EQ 3.5MG N50416 002 Mar CRLD  
NEOMYCIN AND POLYMYXIN B SULFATES, BACITRACIN ZINC AND HYDROCORTISONE  
AT + BAUSCH AND LOMB 400 UNITS/GM;1%;EQ 3.5MG N64068 001 Oct 30, 1995 Mar CRLD  
BASE/GM;10,000 UNITS/GM

BACITRACIN ZINC; NEOMYCIN SULFATE; POLYMYXIN B SULFATE

OINTMENT; OPHTHALMIC  
NEOMYCIN AND POLYMYXIN B SULFATE AND BACITRACIN ZINC  
AT AKORN 400 UNITS/GM;EQ 3.5MG N65088 001 Feb 06, 2004 Feb NEWA  
BASE/GM;10,000 UNITS/GM  
NEOMYCIN AND POLYMYXIN B SULFATES AND BACITRACIN ZINC  
AT + BAUSCH AND LOMB 400 UNITS/GM;EQ 3.5MG N64064 001 Oct 30, 1995 Mar CRLD  
BASE/GM;10,000 UNITS/GM  
NEOSPORIN  
AT MONARCH PHARMS 400 UNITS/GM;EQ 3.5MG N50417 001 Mar CRLD  
BASE/GM;10,000 UNITS/GM

BACITRACIN ZINC; POLYMYXIN B SULFATE

OINTMENT; OPHTHALMIC  
BACITRACIN ZINC AND POLYMYXIN B SULFATE  
AT + BAUSCH AND LOMB 500 UNITS/GM;10,000 UNITS/GM N64046 001 Jan 26, 1995 Mar CRLD

## OINTMENT; OPHTHALMIC

POLYSPORIN

AT MONARCH PHARMS 500 UNITS/GM;10,000 UNITS/GM N61229 001 Mar CRLD

DISC

BECLOMETHASONE DIPROPIONATE

AEROSOL, METERED; INHALATION

VANCERIL

+ SCHERING 0.042MG/INH N17573 001 Jun CTEC

DISC

VANCERIL DOUBLE STRENGTH

@ SCHERING 0.084MG/INH N20486 001 Dec 24, 1996 Jun DISC

BECLOMETHASONE DIPROPIONATE MONOHYDRATE

SPRAY, METERED; NASAL

BECONASE AQ

+ GLAXOSMITHKLINE EQ 0.042MG DIPROP/SPRAY N19389 001 Jul 27, 1987 Jun CTEC

CRLD

VANCENASE AQ

@ SCHERING EQ 0.042MG DIPROP/SPRAY N19589 001 Dec 23, 1987 Jun DISC

DISC

BENAZEPRIL HYDROCHLORIDE

TABLET; ORAL

BENAZEPRIL HCL

DISC

AB ANDRX PHARMS 5MG N76267 001 Feb 11, 2004 Feb NEWA  
AB 10MG N76267 002 Feb 11, 2004 Feb NEWA  
AB 20MG N76267 003 Feb 11, 2004 Feb NEWA  
AB 40MG N76267 004 Feb 11, 2004 Feb NEWA  
AB EON 5MG N76402 001 Feb 11, 2004 Feb NEWA  
CMFD AB 10MG N76402 002 Feb 11, 2004 Feb NEWA  
CMFD AB 20MG N76402 003 Feb 11, 2004 Feb NEWA  
CMFD AB 40MG N76402 004 Feb 11, 2004 Feb NEWA

CMFD

AB GENPHARM 5MG N76476 001 Feb 11, 2004 Feb NEWA  
CMFD AB 10MG N76476 002 Feb 11, 2004 Feb NEWA  
CMFD AB 20MG N76476 003 Feb 11, 2004 Feb NEWA  
AB 40MG N76476 004 Feb 11, 2004 Feb NEWA  
AB IVAX PHARMS 5MG N76333 001 Feb 11, 2004 Feb NEWA  
AB 10MG N76333 002 Feb 11, 2004 Feb NEWA  
AB 20MG N76333 003 Feb 11, 2004 Feb NEWA

CMFD

AB 40MG N76333 004 Feb 11, 2004 Feb NEWA  
AB KV PHARM 5MG N76118 001 Feb 11, 2004 Feb NEWA  
AB 10MG N76118 002 Feb 11, 2004 Feb NEWA

CMFD

AB 20MG N76118 003 Feb 11, 2004 Feb NEWA  
AB 40MG N76118 004 Feb 11, 2004 Feb NEWA  
AB MYLAN 5MG N76430 001 Feb 11, 2004 Feb NEWA  
AB 10MG N76430 002 Feb 11, 2004 Feb NEWA

CMFD

AB 20MG N76430 003 Feb 11, 2004 Feb NEWA  
AB 40MG N76430 004 Feb 11, 2004 Feb NEWA  
AB RANBAXY 5MG N76344 001 Feb 11, 2004 Feb NEWA  
AB 10MG N76344 002 Feb 11, 2004 Feb NEWA

CMFD

AB 20MG N76344 003 Feb 11, 2004 Feb NEWA  
AB 40MG N76344 004 Feb 11, 2004 Feb NEWA  
AB TEVA 5MG N76211 001 Feb 11, 2004 Feb NEWA  
AB 10MG N76211 002 Feb 11, 2004 Feb NEWA

CMFD

AB 20MG N76211 003 Feb 11, 2004 Feb NEWA  
AB 40MG N76211 004 Feb 11, 2004 Feb NEWA  
AB LOTENSIN 5MG N19851 001 Jun 25, 1991 Feb CFTG  
AB NOVARTIS 10MG N19851 002 Jun 25, 1991 Feb CFTG

CMFD

## TABLET; ORAL

## LOTENSIN

AB	NOVARTIS	20MG	N19851 003	Jun 25, 1991	Feb	CFTG
AB	+	40MG	N19851 004	Jun 25, 1991	Feb	CFTG

BENAZEPRIL HYDROCHLORIDE; HYDROCHLOROTHIAZIDE

## TABLET; ORAL

## BENAZEPRIL HCL AND HYDROCHLOROTHIAZIDE

AB	ANDRX PHARMS	5MG;6.25MG	N76342 001	Feb 11, 2004	Feb	NEWA
AB		10MG;12.5MG	N76342 002	Feb 11, 2004	Feb	NEWA
AB		20MG;12.5MG	N76342 003	Feb 11, 2004	Feb	NEWA
AB		20MG;25MG	N76342 004	Feb 11, 2004	Feb	NEWA
AB	EON	5MG;6.25MG	N76631 001	Feb 11, 2004	Feb	NEWA
AB		10MG;12.5MG	N76631 002	Feb 11, 2004	Feb	NEWA
AB		20MG;12.5MG	N76631 003	Feb 11, 2004	Feb	NEWA
AB		20MG;25MG	N76631 004	Feb 11, 2004	Feb	NEWA
AB	GENPHARM	5MG;6.25MG	N76612 001	Feb 11, 2004	Feb	NEWA
AB		10MG;12.5MG	N76612 002	Feb 11, 2004	Feb	NEWA
AB		20MG;12.5MG	N76612 003	Feb 11, 2004	Feb	NEWA
AB		20MG;25MG	N76612 004	Feb 11, 2004	Feb	NEWA
AB	IVAX PHARMS	5MG;6.25MG	N76348 001	Feb 11, 2004	Feb	NEWA
AB		10MG;12.5MG	N76348 002	Feb 11, 2004	Feb	NEWA
AB		20MG;12.5MG	N76348 003	Feb 11, 2004	Feb	NEWA
AB		20MG;25MG	N76348 004	Feb 11, 2004	Feb	NEWA
AB	MYLAN	5MG;6.25MG	N76688 001	Feb 11, 2004	Feb	NEWA
AB		10MG;12.5MG	N76688 002	Feb 11, 2004	Feb	NEWA
AB		20MG;12.5MG	N76688 003	Feb 11, 2004	Feb	NEWA
AB		20MG;25MG	N76688 004	Feb 11, 2004	Feb	NEWA
	LOTENSIN HCT					
AB	NOVARTIS	5MG;6.25MG	N20033 001	May 19, 1992	Feb	CFTG
AB		10MG;12.5MG	N20033 002	May 19, 1992	Feb	CFTG
AB		20MG;12.5MG	N20033 004	May 19, 1992	Feb	CFTG
AB	+	20MG;25MG	N20033 003	May 19, 1992	Feb	CFTG

BENZOYL PEROXIDE; ERYTHROMYCIN

## GEL; TOPICAL

## BENZAMYCIN

AB	+	DERMIK LABS	5%;3%	N50557 001	Oct 26, 1984	Mar	CFTG
		ERYTHROMYCIN AND BENZOYL PEROXIDE					
AB		ATRIX	5%;3%	N65112 001	Mar 29, 2004	Mar	NEWA

BETAMETHASONE DIPROPIONATE

## CREAM, AUGMENTED; TOPICAL

## BETAMETHASONE DIPROPIONATE

AB		ATRIX	EQ 0.05% BASE	N76603 001	Jan 23, 2004	Jan	NEWA
----	--	-------	---------------	------------	--------------	-----	------

BETAMETHASONE DIPROPIONATE; CLOTRIMAZOLE

## LOTION; TOPICAL

>A> CLOTRIMAZOLE AND BETAMETHASONE DIPROPIONATE

>A> AB	TARO	EQ 0.05% BASE;1%	N76493 001	Jul 28, 2004	Jul	NEWA
--------	------	------------------	------------	--------------	-----	------

## LOTRISONE

>D>	+	SCHERING PLOUGH RES	EQ 0.05% BASE;1%	N20010 001	Dec 08, 2000	Jul	CFTG
-----	---	---------------------	------------------	------------	--------------	-----	------

>A> AB	+		EQ 0.05% BASE;1%	N20010 001	Dec 08, 2000	Jul	CFTG
--------	---	--	------------------	------------	--------------	-----	------

BETAMETHASONE SODIUM PHOSPHATE

CFTG INJECTABLE; INJECTION

CFTG BETAMETHASONE SODIUM PHOSPHATE

CFTG @ STERIS EQ 3MG BASE/ML N85738 001 Feb DISC

CELESTONE

@ SCHERING EQ 3MG BASE/ML N17561 001 Feb DISC

BETHANECHOL CHLORIDE

NEWA INJECTABLE; INJECTION

NEWA URECHOLINE

NEWA @ ODYSSEY PHARMS 5MG/ML N06536 001 Jun CAHN

NEWA TABLET; ORAL

NEWA BETHANECHOL CHLORIDE

>A>	AA	ABLE	5MG	N40492 001	Jul 27, 2004	Jul	NEWA
>A>	AA		10MG	N40483 001	Jul 27, 2004	Jul	NEWA
>A>	AA		25MG	N40485 001	Jul 27, 2004	Jul	NEWA
>A>	AA		50MG	N40509 001	Jul 27, 2004	Jul	NEWA

NEWA DUVOID

>D>		@ WELLSPRING PHARM	10MG	N86262 001	Jul	CMFD
>A>	AA		10MG	N86262 001	Jul	CMFD
>D>		@	25MG	N86263 001	Jul	CMFD
>A>	AA		25MG	N86263 001	Jul	CMFD

NEWA URECHOLINE

		@ ODYSSEY PHARMS	5MG	N06536 003	Jun	CAHN
		@	10MG	N06536 002	Jun	CAHN
		@	25MG	N06536 004	Jun	CAHN
		@	50MG	N06536 005	Jun	CAHN

BISACODYL; POLYETHYLENE GLYCOL; POTASSIUM CHLORIDE; SODIUM BICARBONATE; SODIUM CHLORIDE

CFTG FOR SOLUTION; TABLET, DELAYED RELEASE; ORAL

CFTG HALFLYTLY

CFTG + BRAINTREE 5MG;210GM;0.74GM;2.86GM;5.6GM N21551 001 May 10, 2004 May NEWA

BRETYLIUM TOSYLATE

CFTG INJECTABLE; INJECTION

CFTG BRETYLIUM TOSYLATE

AP	+	HOSPIRA	50MG/ML	N19033 001	Apr 29, 1986	May	CAHN
		@	50MG/ML	N19033 001	Apr 29, 1986	Jun	DISC
AP	+	INTL MEDICATION	50MG/ML	N70119 001	Apr 29, 1986	Jun	CRLD
BRETYLIUM TOSYLATE IN DEXTROSE 5% IN PLASTIC CONTAINER							
AP	+	HOSPIRA	200MG/100ML	N19008 002	Apr 29, 1986	May	CAHN
AP	+		400MG/100ML	N19008 003	Apr 29, 1986	May	CAHN
		@	800MG/100ML	N19008 001	Apr 29, 1986	May	CAHN
BRETYLIUM TOSYLATE IN PLASTIC CONTAINER							
AP	+	HOSPIRA	50MG/ML	N19030 001	Apr 29, 1986	May	CAHN

BUMETANIDE

NEWA INJECTABLE; INJECTION

NEWA BUMETANIDE

AP		HOSPIRA	0.25MG/ML	N74160 001	Oct 30, 1997	May	CAHN
AP			0.25MG/ML	N74332 001	Oct 31, 1994	May	CAHN

BUPIVACAINE HYDROCHLORIDE

INJECTABLE; INJECTION  
BUPIVACAINE HCL

AP	HOSPIRA	0.25%	N18053 002	May	CAHN	
AP		0.25%	N70583 001	Feb 17, 1987	May	CAHN
AP		0.25%	N70586 001	Mar 03, 1987	May	CAHN
AP		0.25%	N70590 001	Feb 17, 1987	May	CAHN
AP		0.5%	N18053 001		May	CAHN
AP		0.5%	N70584 001	Feb 17, 1986	May	CAHN
AP		0.5%	N70597 001	Mar 03, 1987	May	CAHN
AP		0.5%	N70609 001	Mar 03, 1987	May	CAHN
AP		0.75%	N18053 003		May	CAHN
AP		0.75%	N70585 001	Mar 03, 1987	May	CAHN
AP		0.75%	N70587 001	Mar 03, 1987	May	CAHN
BUPIVACAINE HCL KIT						
	@ HOSPIRA	0.075%	N19978 001	Sep 03, 1992	May	CAHN
	@	0.114%	N19978 002	Sep 03, 1992	May	CAHN
	@	0.23%	N19978 003	Sep 03, 1992	May	CAHN
MARCAINE HCL						
AP	+ HOSPIRA	0.25%	N16964 001		May	CAHN
AP	+	0.5%	N16964 006		May	CAHN
MARCAINE HCL PRESERVATIVE FREE						
AP	+ HOSPIRA	0.25%	N16964 012		May	CAHN
AP	+	0.5%	N16964 005		May	CAHN
AP	+	0.75%	N16964 009		May	CAHN
INJECTABLE; SPINAL						
BUPIVACAINE						
AP	HOSPIRA	0.75%	N71810 001	Dec 11, 1987	May	CAHN
MARCAINE						
AP	+ HOSPIRA	0.75%	N18692 001	May 04, 1984	May	CAHN

BUPIVACAINE HYDROCHLORIDE; EPINEPHRINE

INJECTABLE; INJECTION  
BUPIVACAINE HCL AND EPINEPHRINE

+	HOSPIRA	0.25%;0.005MG/ML	N71165 001	Jun 16, 1988	May	CAHN
		0.25%;0.005MG/ML	N71166 001	Jun 16, 1988	May	CAHN
		0.25%;0.005MG/ML	N71167 001	Jun 16, 1988	May	CAHN
+		0.5%;0.005MG/ML	N71168 001	Jun 16, 1988	May	CAHN
		0.5%;0.005MG/ML	N71169 001	Jun 16, 1988	May	CAHN
		0.5%;0.005MG/ML	N71170 001	Jun 16, 1988	May	CAHN
+		0.75%;0.005MG/ML	N71171 001	Jun 16, 1988	May	CAHN

BUPIVACAINE HYDROCHLORIDE; EPINEPHRINE BITARTRATE

INJECTABLE; INJECTION  
MARCAINE HCL W/ EPINEPHRINE

AP	+ HOSPIRA	0.25%;0.0091MG/ML	N16964 004		May	CAHN
AP	+	0.5%;0.0091MG/ML	N16964 008		May	CAHN
MARCAINE HCL W/ EPINEPHRINE PRESERVATIVE FREE						
AP	+ HOSPIRA	0.25%;0.0091MG/ML	N16964 013		May	CAHN
AP	+	0.5%;0.0091MG/ML	N16964 007		May	CAHN
AP	+	0.75%;0.0091MG/ML	N16964 010		May	CAHN

BUPRENORPHINE HYDROCHLORIDE

INJECTABLE; INJECTION

BUPRENORPHINE HCL

AP HOSPIRA EQ 0.3MG BASE/ML

N74137 001 Jun 03, 1996 May CAHN

BUPROPION HYDROCHLORIDE

TABLET, EXTENDED RELEASE; ORAL

BUPROPION HCL

AB1	EON	100MG	N75932 001 Nov 25, 2003 May CFTG
AB		150MG	N75932 002 Mar 22, 2004 Mar NEWA
AB1		150MG	N75932 002 Mar 22, 2004 May CTEC
AB	IMPAX LABS	100MG	N75913 001 Jan 28, 2004 Jan NEWA
AB1		100MG	N75913 001 Jan 28, 2004 May CTEC
AB		150MG	N75913 002 Mar 22, 2004 Mar NEWA
AB1		150MG	N75913 002 Mar 22, 2004 May CTEC
AB2		150MG	N75914 001 May 27, 2004 May NEWA
WELLBUTRIN SR			
AB1	GLAXOSMITHKLINE	100MG	N20358 002 Oct 04, 1996 May CTEC
AB	+	150MG	N20358 003 Oct 04, 1996 Mar CFTG
AB1	+	150MG	N20358 003 Oct 04, 1996 Jun CTEC
AB	+	150MG	N20358 003 Oct 04, 1996 May CTEC
ZYBAN			
AB2	+	150MG	N20711 003 May 14, 1997 Jun CTEC
AB	+	150MG	N20711 003 May 14, 1997 May CFTG

BUSPIRONE HYDROCHLORIDE

TABLET; ORAL

BUSPIRONE HCL

AB TEVA 30MG N75022 004 Mar 25, 2004 Mar NEWA

BUTORPHANOL TARTRATE

INJECTABLE; INJECTION

BUTORPHANOL TARTRATE

AP	HOSPIRA	1MG/ML	N75559 001 Mar 20, 2000 May CAHN
AP		2MG/ML	N75559 002 Mar 20, 2000 May CAHN
BUTORPHANOL TARTRATE PRESERVATIVE FREE			
AP	HOSPIRA	1MG/ML	N74620 001 Jan 22, 1997 May CAHN
AP		1MG/ML	N74626 001 Jan 23, 1997 May CAHN
AP		2MG/ML	N74620 002 Jan 22, 1997 May CAHN
AP		2MG/ML	N74626 002 Jan 23, 1997 May CAHN

CALCITRIOL

INJECTABLE; INJECTION

CALCITRIOL

AP MAYNE PHARMA USA 0.001MG/ML N75816 001 Jan 16, 2004 Jan NEWA  
AP 0.002MG/ML N75816 002 Jan 16, 2004 Jan NEWACALCIUM CHLORIDE

INJECTABLE; INJECTION

CALCIUM CHLORIDE 10% IN PLASTIC CONTAINER

+ HOSPIRA 100MG/ML N21117 001 Jan 28, 2000 May CAHN

CALCIUM CHLORIDE; DEXTROSE; POTASSIUM CHLORIDE; SODIUM CHLORIDE

## INJECTABLE; INJECTION

DEXTROSE 5% AND RINGER'S IN PLASTIC CONTAINER

AP HOSPIRA 33MG/100ML;5GM/100ML;30MG/100ML;8 N18254 001 May CAHN  
60MG/100ML

CALCIUM CHLORIDE; DEXTROSE; POTASSIUM CHLORIDE; SODIUM CHLORIDE; SODIUM LACTATE

## INJECTABLE; INJECTION

DEXTROSE 5% AND LACTATED RINGER'S IN PLASTIC CONTAINER

AP HOSPIRA 20MG/100ML;5GM/100ML;30MG/100ML;6 N17608 001 May CAHN  
00MG/100ML;310MG/100ML

POTASSIUM CHLORIDE 10MEQ IN DEXTROSE 5% AND LACTATED RINGER'S IN PLASTIC CONTAINER

@ HOSPIRA 20MG/100ML;5GM/100ML;104MG/100ML; N19685 005 Oct 17, 1988 May CAHN  
600MG/100ML;310MG/100ML  
@ 20MG/100ML;5GM/100ML;179MG/100ML; N19685 006 Oct 17, 1988 May CAHN  
600MG/100ML;310MG/100ML

POTASSIUM CHLORIDE 15MEQ IN DEXTROSE 5% AND LACTATED RINGER'S IN PLASTIC CONTAINER

@ HOSPIRA 20MG/100ML;5GM/100ML;254MG/100ML; N19685 007 Oct 17, 1988 May CAHN  
600MG/100ML;310MG/100ML

POTASSIUM CHLORIDE 20MEQ IN DEXTROSE 5% AND LACTATED RINGER'S IN PLASTIC CONTAINER

AP HOSPIRA 20MG/100ML;5GM/100ML;179MG/100ML; N19685 002 Oct 17, 1988 May CAHN  
600MG/100ML;310MG/100ML

AP HOSPIRA 20MG/100ML;5GM/100ML;328MG/100ML; N19685 008 Oct 17, 1988 May CAHN  
600MG/100ML;310MG/100ML

POTASSIUM CHLORIDE 30MEQ IN DEXTROSE 5% AND LACTATED RINGER'S IN PLASTIC CONTAINER

@ HOSPIRA 20MG/100ML;5GM/100ML;254MG/100ML; N19685 003 Oct 17, 1988 May CAHN  
600MG/100ML;310MG/100ML

POTASSIUM CHLORIDE 40MEQ IN DEXTROSE 5% AND LACTATED RINGER'S IN PLASTIC CONTAINER

AP HOSPIRA 20MG/100ML;5GM/100ML;328MG/100ML; N19685 004 Oct 17, 1988 May CAHN  
600MG/100ML;310MG/100ML

POTASSIUM CHLORIDE 5MEQ IN DEXTROSE 5% AND LACTATED RINGER'S IN PLASTIC CONTAINER

@ HOSPIRA 20MG/100ML;5GM/100ML;104MG/100ML; N19685 001 Oct 17, 1988 May CAHN  
600MG/100ML;310MG/100ML

CALCIUM CHLORIDE; MAGNESIUM CHLORIDE; POTASSIUM CHLORIDE; SODIUM ACETATE; SODIUM CHLORIDE

## INJECTABLE; INJECTION

TPN ELECTROLYTES IN PLASTIC CONTAINER

HOSPIRA 16.5MG/ML;25.4MG/ML;74.6MG/ML;121 N18895 001 Jul 20, 1984 May CAHN  
MG/ML;16.1MG/ML

CALCIUM CHLORIDE; MAGNESIUM CHLORIDE; POTASSIUM CHLORIDE; SODIUM CHLORIDE

## SOLUTION; PERfusion, CARDIAC

PLEGISOL IN PLASTIC CONTAINER

AT + HOSPIRA 17.6MG/100ML;325.3MG/100ML;119.3M N18608 001 Feb 26, 1982 May CAHN  
G/100ML;643MG/100ML

CALCIUM CHLORIDE; POTASSIUM CHLORIDE; SODIUM CHLORIDE

## INJECTABLE; INJECTION

RINGER'S IN PLASTIC CONTAINER

AP HOSPIRA 33MG/100ML;30MG/100ML;860MG/100ML N18251 001 May CAHN

## SOLUTION; IRRIGATION

RINGER'S IN PLASTIC CONTAINER

AT HOSPIRA 33MG/100ML;30MG/100ML;860MG/100ML N17635 001 May CAHN

CALCIUM CHLORIDE; POTASSIUM CHLORIDE; SODIUM CHLORIDE; SODIUM LACTATE

## INJECTABLE; INJECTION

LACTATED RINGER'S IN PLASTIC CONTAINER

AP HOSPIRA 20MG/100ML;30MG/100ML;600MG/100ML N17641 001 May CAHN  
;310MG/100ML

SOLUTION; IRRIGATION  
 LACTATED RINGER'S IN PLASTIC CONTAINER  
 AT HOSPIRA 20MG/100ML;30MG/100ML;600MG/100ML N19416 001 Jan 17, 1986 May CAHN  
 ;310MG/100ML

CAPTOPRIL

TABLET; ORAL  
 CAPTOPRIL  
 AB DURAMED PHARMS BARR 12.5MG N74477 001 Feb 13, 1996 May CAHN  
 25MG N74477 002 Feb 13, 1996 May CAHN  
 AB 50MG N74477 003 Feb 13, 1996 May CAHN  
 AB 100MG N74477 004 Feb 13, 1996 May CAHN

CARBAMAZEPINE

CAPSULE, EXTENDED RELEASE; ORAL  
 CARBATROL  
 SHIRE PHARM 100MG N20712 003 Sep 30, 1997 Mar CRLD  
 200MG N20712 001 Sep 30, 1997 Mar CRLD

CARBIDOPA; LEVODOPA

TABLET, EXTENDED RELEASE; ORAL  
 CARBIDOPA AND LEVODOPA  
 AB IMPAX LABS 25MG;100MG N76521 001 May 14, 2004 May NEWA  
 AB 50MG;200MG N76521 002 May 14, 2004 May NEWA  
 AB KV PHARM 50MG;200MG N76663 001 Jun 24, 2004 Jun NEWA  
 AB TORPHARM 25MG;100MG N76212 001 Jun 16, 2004 Jun NEWA  
 AB 50MG;200MG N76212 002 Jun 16, 2004 Jun NEWA

CARBOPLATIN

INJECTABLE; IV (INFUSION)  
 PARAPLATIN  
 + BRISTOL MYERS SQUIBB EQ 600MG /60ML(10MG/ML) N20452 004 Jan 15, 2004 Jan NEWA

CARTEOLOL HYDROCHLORIDE

TABLET; ORAL  
 CARTROL  
 @ ABBOTT 2.5MG N19204 001 Dec 28, 1988 Jun DISC  
 @ 5MG N19204 002 Dec 28, 1988 Jun DISC

CEFACLOR

CAPSULE; ORAL  
 CEFACLOR  
 AB CARLSBAD EQ 250MG BASE N65146 001 Jan 22, 2004 Jan NEWA  
 AB EQ 500MG BASE N65146 002 Jan 22, 2004 Jan NEWA  
 FOR SUSPENSION; ORAL  
 CECLOR  
 AB CEPH INTL EQ 125MG BASE/5ML N62206 001 May CAHN  
 AB EQ 187MG BASE/5ML N62206 003 Apr 20, 1988 May CAHN  
 AB EQ 250MG BASE/5ML N62206 002 May CAHN  
 AB + EQ 375MG BASE/5ML N62206 004 Apr 20, 1988 May CAHN  
 TABLET, EXTENDED RELEASE; ORAL  
 CECLOR CD  
 @ LILLY EQ 500MG BASE N50673 002 Jun 28, 1996 Jun DISC  
 CEFACLOR  
 AB + IVAX PHARMS EQ 500MG BASE N65057 001 Jan 05, 2001 Jun CRLD

CEFAMANDOLE NAFATE

>D>	INJECTABLE; INJECTION				
>D>	MANDOL				
>D>	+ LILLY	EQ 1GM BASE/VIAL	N50504 002	Jul	DISC
>A>	@	EQ 1GM BASE/VIAL	N50504 002	Jul	DISC
>D>	+	EQ 2GM BASE/VIAL	N50504 003	Jul	DISC
>A>	@	EQ 2GM BASE/VIAL	N50504 003	Jul	DISC

CEFAZOLIN SODIUM

INJECTABLE; INJECTION					
CEFAZOLIN SODIUM					
@ MARSAM PHARMS LLC	EQ 250MG BASE/VIAL	N62988 001	Dec 29, 1989	Jun	DISC
@	EQ 500MG BASE/VIAL	N62988 002	Dec 29, 1989	Jun	DISC
@	EQ 1GM BASE/VIAL	N62988 003	Dec 29, 1989	Jun	DISC
@	EQ 5GM BASE/VIAL	N62989 001	Dec 29, 1989	Jun	DISC
@	EQ 10GM BASE/VIAL	N62989 002	Dec 29, 1989	Jun	DISC
@	EQ 20GM BASE/VIAL	N62989 003	Dec 29, 1989	Jun	DISC
KEFZOL					
@ LILLY	EQ 250MG BASE/VIAL	N61773 001		Jun	DISC
@	EQ 500MG BASE/VIAL	N61773 002		Jun	DISC
@	EQ 1GM BASE/VIAL	N61773 003		Jun	DISC
@	EQ 10GM BASE/VIAL	N61773 004		Jun	DISC
@	EQ 20GM BASE/VIAL	N61773 005	Sep 08, 1987	Jun	DISC

CEFDINIR

FOR SUSPENSION; ORAL					
OMNICEF					
>D>	+ ABBOTT	125MG/5ML	N50749 001	Dec 04, 1997	Jul CRLD
>A>		125MG/5ML	N50749 001	Dec 04, 1997	Jul CRLD
>A>	+	250MG/5ML	N50749 002	Jul 29, 2004	Jul NEWA

CEFIXIME

SUSPENSION; ORAL					
SUPRAX					
+ LUPIN	100MG/5ML	N65129 001	Feb 23, 2004	Feb	NEWA
TABLET; ORAL					
SUPRAX					
+ LUPIN	400MG	N65130 001	Feb 12, 2004	Feb	NEWA

CEFOTAXIME SODIUM

INJECTABLE; INJECTION					
CEFOTAXIME AND DEXTROSE 2.4% IN PLASTIC CONTAINER					
>A>	+ B BRAUN	EQ 2GM BASE	N50792 001	Jul 29, 2004	Jul NEWA
>A>	CEFOTAXIME AND DEXTROSE 3.9% IN PLASTIC CONTAINER				
>A>	+ B BRAUN	EQ 1GM BASE	N50792 002	Jul 29, 2004	Jul NEWA

CEFTAZIDIME

INJECTABLE; INJECTION					
CEFTAZIDIME					
AP	ACS DOBFAR	500MG/VIAL	N62640 001	Nov 20, 1985	Apr CTNA
AP		1GM/VIAL	N62640 002	Nov 20, 1985	Apr CTNA
AP		2GM/VIAL	N62640 003	Nov 20, 1985	Apr CTNA
TAZICEF					
AP	HOSPIRA	500MG/VIAL	N62662 001	Mar 06, 1986	May CAHN
AP		1GM/VIAL	N62662 002	Mar 06, 1986	May CAHN

INJECTABLE; INJECTION

TAZICEF						
AP HOSPIRA	1GM/VIAL	N64032	001	Oct 31, 1993	May	CAHN
	2GM/VIAL	N62662	003	Mar 06, 1986	May	CAHN
AP	2GM/VIAL	N64032	002	Oct 31, 1993	May	CAHN
AP	6GM/VIAL	N62662	004	Mar 06, 1986	May	CAHN
TAZIDIME						
@ LILLY	1GM/VIAL	N62655	001	Nov 20, 1985	Apr	DISC
@	2GM/VIAL	N62655	002	Nov 20, 1985	Apr	DISC

CEFUROXIME SODIUM

INJECTABLE; IM-IV						
CEFUROXIME						
AB HIKMA FARMACEUTICA	EQ 750MG BASE/VIAL	N65048	001	Jan 09, 2004	Jan	NEWA
KEFUROX						
@ LILLY	EQ 750MG BASE/VIAL	N62591	001	Jan 10, 1986	Jun	DISC
INJECTABLE; INJECTION						
CEFUROXIME						
AP HIKMA FARMACEUTICA	EQ 1.5GM BASE/VIAL	N65048	002	Jan 09, 2004	Jan	NEWA
AP	EQ 7.5GM BASE/VIAL	N65046	001	Jan 09, 2004	Jan	NEWA
KEFUROX						
@ LILLY	EQ 1.5GM BASE/VIAL	N62591	002	Jan 10, 1986	Jun	DISC
@	EQ 1.5GM BASE/VIAL	N62592	002	Jan 10, 1986	Jun	DISC
@	EQ 7.5GM BASE/VIAL	N62591	003	Dec 17, 1987	Jun	DISC
INJECTABLE; INTRAVENOUS						
KEFUROX						
@ LILLY	EQ 750MG BASE/VIAL	N62592	001	Jan 10, 1986	Jun	DISC

CEPHALEXIN

CAPSULE; ORAL						
KEFLEX						
AB ADVANCIS PHARM	EQ 250MG BASE	N50405	002		Jun	CAHN
AB +	EQ 500MG BASE	N50405	003		Jun	CAHN
FOR SUSPENSION; ORAL						
KEFLEX						
@ ADVANCIS PHARM	EQ 100MG BASE/ML	N50406	003		Jun	CAHN
@	EQ 125MG BASE/5ML	N50406	001		Jun	CAHN
@	EQ 250MG BASE/5ML	N50406	002		Jun	CAHN
TABLET; ORAL						
KEFLET						
@ LILLY	EQ 250MG BASE	N50440	003	Feb 26, 1987	Jun	DISC

>D> CEPHALEXIN HYDROCHLORIDE

>D> TABLET; ORAL						
>D> KEFTAB						
>D> + LILLY	EQ 500MG BASE	N50614	002	Oct 29, 1987	Jul	DISC
>A> @	EQ 500MG BASE	N50614	002	Oct 29, 1987	Jul	DISC

CETIRIZINE HYDROCHLORIDE

TABLET, CHEWABLE; ORAL						
ZYRTEC						
Pfizer	5MG	N21621	001	Mar 16, 2004	Mar	NEWA
+	10MG	N21621	002	Mar 16, 2004	Mar	NEWA

CEVIMELINE HYDROCHLORIDE

CAPSULE; ORAL EVOXAC + DAIICHI	EQ 30MG BASE	N20989 002 Jan 11, 2000 Jun CAHN
--------------------------------------	--------------	----------------------------------

CHLORDIAZEPOXIDE HYDROCHLORIDE

INJECTABLE; INJECTION LIBRIUM @ VALEANT PHARM INTL	100MG/AMP	N12301 001 Jun DISC
--	-----------	---------------------

CHLORHEXIDINE GLUCONATE

SOLUTION; DENTAL CHLORHEXIDINE GLUCONATE AT MORTON GROVE	0.12%	N75006 001 Mar 03, 2004 Mar NEWA
--	-------	----------------------------------

CHLOROPROCAINE HYDROCHLORIDE

INJECTABLE; INJECTION CHLOROPROCAINE HCL AP HOSPIRA AP NESACAIN AP ASTRAZENECA	2% 3% 2%	N87447 001 Apr 16, 1982 May CAHN N87446 001 Apr 16, 1982 May CAHN N09435 002 Jun CTEC
--	----------------	---

CHLORPHENIRAMINE POLISTIREX; CODEINE POLISTIREX

SUSPENSION, EXTENDED RELEASE; ORAL CODEPREX + CELLTECH PHARMS	EQ 4MG MALEATE/5ML; EQ 20MG BASE/5ML	N21369 001 Jun 21, 2004 Jun NEWA
---	---	----------------------------------

CHORIOGONADOTROPIN ALFA

INJECTABLE; INJECTION OVIDREL @ SERONO INC	0.25MG/VIAL	N21149 001 Sep 20, 2000 May DISC
INJECTABLE; SUBCUTANEOUS OVIDREL + SERONO INC	EQ 0.25MG /0.5ML	N21149 002 Oct 06, 2003 Apr CPOT

CHROMIC CHLORIDE

INJECTABLE; INJECTION CHROMIC CHLORIDE IN PLASTIC CONTAINER + HOSPIRA	EQ 0.004MG CHROMIUM/ML	N18961 001 Jun 26, 1986 May CAHN
---	------------------------	----------------------------------

CIMETIDINE HYDROCHLORIDE

INJECTABLE; INJECTION CIMETIDINE HCL AP HOSPIRA	EQ 300MG BASE/2ML	N74296 001 Mar 28, 1997 May CAHN
AP	EQ 300MG BASE/2ML	N74344 001 Jan 31, 1995 May CAHN
AP	EQ 300MG BASE/2ML	N74345 001 Jan 31, 1995 May CAHN
AP	EQ 300MG BASE/2ML	N74412 001 Mar 28, 1997 May CAHN
AP	EQ 300MG BASE/2ML	N74422 001 Jan 31, 1995 May CAHN
CIMETIDINE HCL IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER		
AP HOSPIRA	EQ 6MG BASE/ML	N74269 001 Dec 27, 1994 May CAHN
+	EQ 90MG BASE/100ML	N74468 005 Dec 29, 1994 May CAHN
+	EQ 120MG BASE/100ML	N74468 006 Dec 29, 1994 May CAHN
+	EQ 180MG BASE/100ML	N74468 003 Dec 29, 1994 May CAHN
+	EQ 240MG BASE/100ML	N74468 004 Dec 29, 1994 May CAHN

## INJECTABLE; INJECTION

CIMETIDINE HCL IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER

+ HOSPIRA	EQ 360MG BASE/100ML	N74468 001 Dec 29, 1994 May CAHN
+	EQ 480MG BASE/100ML	N74468 002 Dec 29, 1994 May CAHN

CINACALCET HYDROCHLORIDE

## TABLET; ORAL

## SENSIPAR

AMGEN	EQ 30MG BASE	N21688 001 Mar 08, 2004 Mar NEWA
	EQ 60MG BASE	N21688 002 Mar 08, 2004 Mar NEWA
+	EQ 90MG BASE	N21688 003 Mar 08, 2004 Mar NEWA

CIPROFLOXACIN HYDROCHLORIDE

## SOLUTION/DROPS; OPHTHALMIC

## CIPROFLOXACIN

AT BAUSCH AND LOMB	EQ 0.3% BASE	N76754 001 Jun 09, 2004 Jun NEWA
AT NOVEX	EQ 0.3% BASE	N75928 001 Jun 09, 2004 Jun NEWA

## TABLET; ORAL

## CIPRO

AB BAYER PHARMS	EQ 100MG BASE	N19537 001 Apr 08, 1996 Jun CFTG
AB	EQ 250MG BASE	N19537 002 Oct 22, 1987 Jun CFTG
AB	EQ 500MG BASE	N19537 003 Oct 22, 1987 Jun CFTG
AB +	EQ 750MG BASE	N19537 004 Oct 22, 1987 Jun CFTG

## CIPROFLOXACIN

AB BARR	EQ 250MG BASE	N74124 001 Jun 09, 2004 Jun NEWA
AB	EQ 500MG BASE	N74124 002 Jun 09, 2004 Jun NEWA
AB	EQ 750MG BASE	N74124 003 Jun 09, 2004 Jun NEWA
AB COBALT	EQ 250MG BASE	N76794 002 Jun 09, 2004 Jun NEWA
AB	EQ 500MG BASE	N76794 003 Jun 09, 2004 Jun NEWA
AB	EQ 750MG BASE	N76794 004 Jun 09, 2004 Jun NEWA
AB DR REDDYS LABS LTD	EQ 100MG BASE	N75593 002 Jun 09, 2004 Jun NEWA
AB	EQ 250MG BASE	N75593 003 Jun 09, 2004 Jun NEWA
AB	EQ 500MG BASE	N75593 004 Jun 09, 2004 Jun NEWA
AB	EQ 750MG BASE	N75593 001 Jun 09, 2004 Jun NEWA
AB EON	EQ 250MG BASE	N76593 002 Jun 09, 2004 Jun NEWA
AB	EQ 500MG BASE	N76593 003 Jun 09, 2004 Jun NEWA
AB	EQ 750MG BASE	N76593 004 Jun 09, 2004 Jun NEWA
AB GENPHARM	EQ 250MG BASE	N75817 002 Jun 09, 2004 Jun NEWA
AB	EQ 500MG BASE	N75817 003 Jun 09, 2004 Jun NEWA
AB	EQ 750MG BASE	N75817 004 Jun 09, 2004 Jun NEWA
AB HIKMA	EQ 250MG BASE	N76558 002 Jun 09, 2004 Jun NEWA
AB	EQ 500MG BASE	N76558 003 Jun 09, 2004 Jun NEWA
AB	EQ 750MG BASE	N76558 004 Jun 09, 2004 Jun NEWA
AB IVAX PHARMS	EQ 250MG BASE	N76089 002 Jun 09, 2004 Jun NEWA
AB	EQ 500MG BASE	N76089 003 Jun 09, 2004 Jun NEWA
AB	EQ 750MG BASE	N76089 004 Jun 09, 2004 Jun NEWA
AB MARTEC	EQ 250MG BASE	N76138 001 Jun 09, 2004 Jun NEWA
AB	EQ 500MG BASE	N76138 002 Jun 09, 2004 Jun NEWA
AB	EQ 750MG BASE	N76138 003 Jun 09, 2004 Jun NEWA
AB MYLAN	EQ 250MG BASE	N75685 002 Jun 09, 2004 Jun NEWA
AB	EQ 500MG BASE	N75685 003 Jun 09, 2004 Jun NEWA
AB	EQ 750MG BASE	N75685 001 Jun 09, 2004 Jun NEWA
AB RANBAXY	EQ 250MG BASE	N75747 001 Jun 09, 2004 Jun NEWA
AB	EQ 500MG BASE	N75747 002 Jun 09, 2004 Jun NEWA
AB	EQ 750MG BASE	N75747 003 Jun 09, 2004 Jun NEWA
AB SANDOZ	EQ 250MG BASE	N75939 002 Jun 09, 2004 Jun NEWA
AB	EQ 500MG BASE	N75939 003 Jun 09, 2004 Jun NEWA

## TABLET; ORAL

## CIPROFLOXACIN

AB	SANDOZ	EQ 750MG BASE	N75939 004 Jun 09, 2004 Jun NEWA
AB	TEVA	EQ 250MG BASE	N76136 001 Jun 09, 2004 Jun NEWA
AB		EQ 500MG BASE	N76136 002 Jun 09, 2004 Jun NEWA
AB		EQ 750MG BASE	N76136 003 Jun 09, 2004 Jun NEWA

CIPROFLOXACIN; CIPROFLOXACIN HYDROCHLORIDE

## TABLET, EXTENDED RELEASE; ORAL

## CIPRO XR

+ BAYER PHARMS	425.2MG; EQ 574.9MG BASE	N21473 002 Aug 28, 2003 Feb CDER
----------------	--------------------------	----------------------------------

CITRIC ACID; MAGNESIUM OXIDE; SODIUM CARBONATE

## SOLUTION; IRRIGATION

## UROLOGIC G IN PLASTIC CONTAINER

AT	HOSPIRA	3.24GM/100ML; 380MG/100ML; 430MG/10 OML	N18904 001 May 27, 1983 May CAHN
----	---------	---	----------------------------------

CLADRBINE

## INJECTABLE; INJECTION

## CLADRBINE

AP	AM PHARM	1MG/ML	N76571 001 Apr 22, 2004 Apr NEWA
----	----------	--------	----------------------------------

CLARITHROMYCIN

## TABLET, EXTENDED RELEASE; ORAL

## BIAxin XL

AB	+ ABBOTT	500MG	N50775 001 Mar 03, 2000 Jun CFTG
----	----------	-------	----------------------------------

AB	ANDRX PHARMS	500MG	N65145 001 Jun 24, 2004 Jun NEWA
----	--------------	-------	----------------------------------

## TABLET; ORAL

## BIAxin

AB	+ ABBOTT	250MG	N50662 001 Oct 31, 1991 May CFTG
----	----------	-------	----------------------------------

AB	+ NOVARTIS	500MG	N50662 002 Oct 31, 1991 May CFTG
----	------------	-------	----------------------------------

## CLARITHROMYCIN

AB	ROXANE	250MG	N65178 002 May 25, 2004 May NEWA
----	--------	-------	----------------------------------

AB		500MG	N65178 001 May 25, 2004 May NEWA
----	--	-------	----------------------------------

CLEMASTINE FUMARATE

## TABLET; ORAL

## CLEMASTINE FUMARATE

AB	+ TEVA	2.68MG	N73283 001 Jan 31, 1992 Mar CRLD
----	--------	--------	----------------------------------

## TAVIST

@ NOVARTIS	2.68MG	N17661 001 Mar DISC
------------	--------	---------------------

CLINDAMYCIN HYDROCHLORIDE

## CAPSULE; ORAL

## CLINDAMYCIN HCL

AB	COREPHARMA	EQ 150MG BASE	N65194 001 Mar 22, 2004 Mar NEWA
----	------------	---------------	----------------------------------

AB		EQ 300MG BASE	N65194 002 Mar 22, 2004 Mar NEWA
----	--	---------------	----------------------------------

CLINDAMYCIN PALMITATE HYDROCHLORIDE

## FOR SOLUTION; ORAL

## CLEOCIN

+ PHARMACIA AND UPJOHN	EQ 75MG BASE/5ML	N62644 001 Apr 07, 1986 May CRLD
------------------------	------------------	----------------------------------

CLINDAMYCIN PHOSPHATE

INJECTABLE; INJECTION

CLINDAMYCIN PHOSPHATE

AP	HOSPIRA	EQ 150MG BASE/ML	N62800	001	Jul 24, 1987	May	CAHN
AP		EQ 150MG BASE/ML	N62801	001	Jul 24, 1987	May	CAHN
	@	EQ 150MG BASE/ML	N62943	001	Sep 29, 1988	May	CAHN

SOLUTION; TOPICAL

CLINDAMYCIN PHOSPHATE

AT	TARO PHARM IND	EQ 1% BASE	N65184	001	Mar 31, 2004	Mar	NEWA
----	----------------	------------	--------	-----	--------------	-----	------

CLOBETASOL PROPIONATE

SHAMPOO; TOPICAL

CLOBEX

+	GALDERMA LABS	0.05%	N21644	001	Feb 05, 2004	Feb	NEWA
---	---------------	-------	--------	-----	--------------	-----	------

CLONIDINE HYDROCHLORIDE

INJECTABLE; INJECTION

DURA CLON

	AAIPHARMA	0.1MG/ML	N20615	001	Oct 02, 1996	Jun	CRLD
+		0.5MG/ML	N20615	002	Apr 27, 1999	Jun	NEWA

CLOTTRIMAZOLE

TROCHE/LOZENGE; ORAL

CLOTTRIMAZOLE

>A>	AB	ROXANE	10MG	N76387	001	Jul 29, 2004	Jul	NEWA
		MYCELEX						
>D>	+	BAYER PHARMS	10MG	N18713	001	Jun 17, 1983	Jul	CFTG
>A>	AB	+	10MG	N18713	001	Jun 17, 1983	Jul	CFTG

CLOZAPINE

TABLET, ORALLY DISINTEGRATING; ORAL

FAZACLO

>D>		ALAMO PHARMS	25MG	N21590	001	Feb 10, 2004	Jul	CTNA
			25MG	N21590	001	Feb 10, 2004	Feb	NEWA
>D>	+		100MG	N21590	002	Feb 10, 2004	Jul	CTNA
	+		100MG	N21590	002	Feb 10, 2004	Feb	NEWA
>A>		FAZACLO ODT						
>A>		ALAMO PHARMS	25MG	N21590	001	Feb 10, 2004	Jul	CTNA
>A>	+		100MG	N21590	002	Feb 10, 2004	Jul	CTNA

COLISTIMETHATE SODIUM

INJECTABLE; INJECTION

COLISTIMETHATE

AP	PADDOCK	EQ 150MG BASE/VIAL	N65177	001	Mar 19, 2004	Mar	NEWA
----	---------	--------------------	--------	-----	--------------	-----	------

CROMOLYN SODIUM

AEROSOL, METERED; INHALATION

INTAL

+	KING PHARMS	0.8MG/INH	N18887	001	Dec 05, 1985	Jan	CAHN
---	-------------	-----------	--------	-----	--------------	-----	------

SOLUTION; INHALATION

INTAL

AN	+	KING PHARMS	10MG/ML	N18596	001	May 28, 1982	Jan	CAHN
----	---	-------------	---------	--------	-----	--------------	-----	------

CUPRIC CHLORIDE

INJECTABLE; INJECTION

CUPRIC CHLORIDE IN PLASTIC CONTAINER

+ HOSPIRA EQ 0.4MG COPPER/ML

N18960 001 Jun 26, 1986 May CAHN

CYANOCOBALAMIN

INJECTABLE; INJECTION

CYANOCOBALAMIN

AP BIONICHE ANIM HLTH 1MG/ML

N40451 001 Sep 23, 2003 Apr CAHN

CYTARABINE

INJECTABLE; INJECTION

CYTARABINE

AP AM PHARM 100MG/ML

N76512 001 Jan 15, 2004 Jan NEWA

AP + MAYNE PHARMA USA 100MG/ML

N75383 001 Nov 22, 1999 Jan CFTG

DAUNORUBICIN HYDROCHLORIDE

INJECTABLE; INJECTION

DAUNORUBICIN HCL

&gt;D&gt; AP BIGMAR EQ 20MG BASE/VIAL

N65000 001 May 25, 1999 Jul CAHN

&gt;A&gt; AP BIGMAR BIOPEN PHARMS EQ 20MG BASE/VIAL

N65000 001 May 25, 1999 Jul CAHN

DEFEROXAMINE MESYLATE

INJECTABLE; INJECTION

DEFEROXAMINE MESYLATE

AP ABBOTT 500MG/VIAL

N76019 001 Mar 17, 2004 Mar NEWA

AP 2GM/VIAL

N76019 002 Mar 17, 2004 Mar NEWA

AP HOSPIRA 500MG/VIAL

N76019 001 Mar 17, 2004 May CAHN

AP 2GM/VIAL

N76019 002 Mar 17, 2004 May CAHN

DESFERAL

AP + NOVARTIS 500MG/VIAL

N16267 001 Mar CFTG

AP + 2GM/VIAL

N16267 002 May 25, 2000 Mar CFTG

DEMECLOCYCLINE HYDROCHLORIDE

TABLET; ORAL

DECLOMYCIN

AB ESP PHARMA 150MG

N50261 002 Mar CFTG

AB + 300MG

N50261 003 Mar CFTG

DEMECLOCYCLINE HCL

AB IMPAX LABS 150MG

N65094 001 Mar 22, 2004 Mar NEWA

AB 300MG

N65094 002 Mar 22, 2004 Mar NEWA

DESERPIDINE; METHYCLOTHIAZIDE

TABLET; ORAL

ENDURONYL

@ ABBOTT 0.25MG;5MG

N12775 001 Jun DISC

ENDURONYL FORTE

@ ABBOTT 0.5MG;5MG

N12775 002 Jun DISC

DESIRUDIN

INJECTABLE; SUBCUTANEOUS

IPRIVASK

+ CANYON 15MG/VIAL

N21271 001 Apr 04, 2003 Apr CAHN

DESMOPRESSIN ACETATE

INJECTABLE; INJECTION  
DESMOPRESSIN ACETATE  
AP HOSPIRA 0.004MG/ML N75220 001 Aug 28, 2000 May CAHN

DESOGESTREL; ETHINYL ESTRADIOL

TABLET; ORAL-28  
CYCLESSA  
AB + ORGANON USA INC 0.1MG, 0.125MG, 0.15MG; 0.025MG, 0.02 5MG, 0.025MG N21090 001 Dec 20, 2000 Feb CFTG  
VELIVET  
AB DURAMED PHARMS BARR 0.1MG, 0.125MG, 0.15MG; 0.025MG, 0.02 5MG, 0.025MG N76455 001 Feb 24, 2004 Feb NEWA

DESOXIMETASONE

CREAM; TOPICAL  
TOPICORT  
AB + TARO PHARMS NORTH 0.25% N17856 001 Jun CAHN  
TOPICORT LP  
AB + TARO PHARMS NORTH 0.05% N18309 001 Jun CAHN  
GEL; TOPICAL  
TOPICORT  
AB + TARO PHARMS NORTH 0.05% N18586 001 Mar 29, 1982 Jun CAHN  
OINTMENT; TOPICAL  
TOPICORT  
@ TARO PHARMS NORTH 0.05% N18594 001 Jan 17, 1985 Jun CAHN  
AB + 0.25% N18763 001 Sep 30, 1983 Jun CAHN

DEXAMETHASONE; NEOMYCIN SULFATE; POLYMYXIN B SULFATE

SUSPENSION/DROPS; OPHTHALMIC  
DEXACIDIN  
@ NOVARTIS 0.1%; EQ 3.5MG BASE/ML; 10,000 UNITS/ML N62544 001 Oct 29, 1984 Apr DISC

DEXMEDETOMIDINE

INJECTABLE; INJECTION  
PRECEDEX  
+ HOSPIRA EQ 100UGM BASE/ML N21038 001 Dec 17, 1999 May CAHN

DEXTROSE

INJECTABLE; INJECTION  
DEXTROSE 10% IN PLASTIC CONTAINER  
AP HOSPIRA 10GM/100ML N18080 001 May CAHN  
DEXTROSE 2.5% IN PLASTIC CONTAINER  
@ B BRAUN 2.5GM/100ML N18358 001 May DISC  
DEXTROSE 20% IN PLASTIC CONTAINER  
AP HOSPIRA 20GM/100ML N18564 001 Mar 23, 1982 May CAHN  
DEXTROSE 25%  
HOSPIRA 250MG/ML N19445 002 Nov 23, 1998 May CAHN  
DEXTROSE 30% IN PLASTIC CONTAINER  
AP HOSPIRA 30GM/100ML N19345 001 Jan 26, 1985 May CAHN  
DEXTROSE 40% IN PLASTIC CONTAINER  
AP HOSPIRA 40GM/100ML N18562 001 Mar 23, 1982 May CAHN  
DEXTROSE 5% IN PLASTIC CONTAINER  
AP HOSPIRA 50MG/ML N16367 002 May CAHN  
AP 50MG/ML N19222 001 Jul 13, 1984 May CAHN  
AP 5GM/100ML N19466 001 Jul 15, 1985 May CAHN

INJECTABLE; INJECTION  
 DEXTROSE 5% IN PLASTIC CONTAINER  
 AP HOSPIRA 5GM/100ML N19479 001 Sep 17, 1985 May CAHN  
 DEXTROSE 50% IN PLASTIC CONTAINER  
 @ HOSPIRA 500MG/ML N19445 001 Jun 03, 1986 May CAHN  
 AP 50GM/100ML N18563 001 Mar 23, 1982 May CAHN  
 AP 50GM/100ML N19894 001 Dec 26, 1989 May CAHN  
 DEXTROSE 60% IN PLASTIC CONTAINER  
 AP HOSPIRA 60GM/100ML N19346 001 Jan 25, 1985 May CAHN  
 DEXTROSE 70% IN PLASTIC CONTAINER  
 AP HOSPIRA 70GM/100ML N18561 001 Mar 23, 1982 May CAHN  
 AP 70GM/100ML N19893 001 Dec 26, 1989 May CAHN

DEXTROSE; MAGNESIUM ACETATE; POTASSIUM ACETATE; SODIUM CHLORIDE

INJECTABLE; INJECTION  
 NORMOSOL-M AND DEXTROSE 5% IN PLASTIC CONTAINER  
 HOSPIRA 5GM/100ML;21MG/100ML;128MG/100ML; 234MG/100ML N17610 001 May CAHN

DEXTROSE; MAGNESIUM CHLORIDE; POTASSIUM CHLORIDE; POTASSIUM PHOSPHATE, DIBASIC; SODIUM ACETATE

INJECTABLE; INJECTION  
 ISOLYTE P W/ DEXTROSE 5% IN PLASTIC CONTAINER  
 @ B BRAUN 5GM/100ML;31MG/100ML;130MG/100ML; 26MG/100ML;320MG/100ML N19025 001 Dec 27, 1984 May DISC

DEXTROSE; MAGNESIUM CHLORIDE; POTASSIUM CHLORIDE; POTASSIUM PHOSPHATE, DIBASIC; SODIUM CHLORIDE; SODIUM LACTATE; SODIUM PHOSPHATE, MONOBASIC, ANHYDROUS

INJECTABLE; INJECTION  
 IONOSOL B AND DEXTROSE 5% IN PLASTIC CONTAINER  
 HOSPIRA 5GM/100ML;53MG/100ML;100MG/100ML; 100MG/100ML;180MG/100ML;280MG/100ML;16MG/100ML N19515 001 May 08, 1986 May CAHN

DEXTROSE; MAGNESIUM CHLORIDE; POTASSIUM CHLORIDE; POTASSIUM PHOSPHATE, MONOBASIC; SODIUM LACTATE; SODIUM PHOSPHATE, MONOBASIC, ANHYDROUS

INJECTABLE; INJECTION  
 IONOSOL MB AND DEXTROSE 5% IN PLASTIC CONTAINER  
 HOSPIRA 5GM/100ML;30MG/100ML;141MG/100ML; 15MG/100ML;260MG/100ML;25MG/100ML N19513 001 May 08, 1986 May CAHN

DEXTROSE; MAGNESIUM CHLORIDE; POTASSIUM CHLORIDE; SODIUM ACETATE; SODIUM CHLORIDE

INJECTABLE; INJECTION  
 ISOLYTE H W/ DEXTROSE 5% IN PLASTIC CONTAINER  
 @ B BRAUN 5GM/100ML;30MG/100ML;97MG/100ML;2 20MG/100ML;140MG/100ML N18273 001 May DISC

DEXTROSE; MAGNESIUM CHLORIDE; POTASSIUM CHLORIDE; SODIUM ACETATE; SODIUM CHLORIDE; SODIUM GLUCONATE

INJECTABLE; INJECTION  
 NORMOSOL-R AND DEXTROSE 5% IN PLASTIC CONTAINER  
 HOSPIRA 5GM/100ML;30MG/100ML;37MG/100ML;2 22MG/100ML;526MG/100ML;502MG/100ML N17609 001 May CAHN

DEXTROSE; POTASSIUM CHLORIDE

INJECTABLE; INJECTION  
 POTASSIUM CHLORIDE 20MEQ IN DEXTROSE 5% IN PLASTIC CONTAINER  
 HOSPIRA 5GM/100ML;149MG/100ML N18371 001 May CAHN  
 POTASSIUM CHLORIDE 30MEQ IN DEXTROSE 5% IN PLASTIC CONTAINER  
 AP HOSPIRA 5GM/100ML;224MG/100ML N18371 003 May CAHN

INJECTABLE; INJECTION

POTASSIUM CHLORIDE 40MEQ IN DEXTROSE 5% IN PLASTIC CONTAINER

HOSPIRA

5GM/100ML;298MG/100ML

N18371 002

May CAHN

DEXTROSE; POTASSIUM CHLORIDE; POTASSIUM LACTATE; SODIUM CHLORIDE; SODIUM PHOSPHATE,  
MONOBASIC, ANHYDROUSINJECTABLE; INJECTION

IONOSOL T AND DEXTROSE 5% IN PLASTIC CONTAINER

HOSPIRA

5GM/100ML;111MG/100ML;256MG/100ML  
;146MG/100ML;207MG/100ML

N19514 001 May 08, 1986 May CAHN

DEXTROSE; POTASSIUM CHLORIDE; POTASSIUM PHOSPHATE, DIBASIC; SODIUM ACETATE; SODIUM CHLORIDEINJECTABLE; INJECTION

ISOLYTE M W/ DEXTROSE 5% IN PLASTIC CONTAINER

@ B BRAUN

5GM/100ML;150MG/100ML;130MG/100ML  
;280MG/100ML;91MG/100ML

N18270 001

May DISC

DEXTROSE; POTASSIUM CHLORIDE; SODIUM CHLORIDEINJECTABLE; INJECTION

POTASSIUM CHLORIDE 10MEQ IN DEXTROSE 5% AND SODIUM CHLORIDE 0.225% IN PLASTIC CONTAINER

HOSPIRA 5GM/100ML;74.5MG/100ML;225MG/100M N18365 002 Jul 05, 1983 May CAHN  
L

5GM/100ML;149MG/100ML;225MG/100ML N18365 006 Mar 28, 1988 May CAHN

POTASSIUM CHLORIDE 10MEQ IN DEXTROSE 5% AND SODIUM CHLORIDE 0.3% IN PLASTIC CONTAINER

HOSPIRA 5GM/100ML;74.5MG/100ML;300MG/100M N18876 001 Jan 17, 1986 May CAHN  
L

5GM/100ML;149MG/100ML;300MG/100ML N18876 006 Mar 28, 1988 May CAHN

POTASSIUM CHLORIDE 10MEQ IN DEXTROSE 5% AND SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER

AP HOSPIRA 5GM/100ML;74.5MG/100ML;450MG/100M N18362 005 Mar 28, 1988 May CAHN  
L

5GM/100ML;74.5MG/100ML;450MG/100M N18362 009 Jul 05, 1983 May CAHN

POTASSIUM CHLORIDE 10MEQ IN DEXTROSE 5% AND SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER

AP HOSPIRA 5GM/100ML;74.5MG/100ML;900MG/100M N19691 002 Mar 24, 1988 May CAHN  
L

5GM/100ML;149MG/100ML;900MG/100ML N19691 004 Mar 24, 1988 May CAHN

POTASSIUM CHLORIDE 15MEQ IN DEXTROSE 5% AND SODIUM CHLORIDE 0.225% IN PLASTIC CONTAINER

HOSPIRA 5GM/100ML;224MG/100ML;225MG/100ML N18365 008 Mar 28, 1988 May CAHN

POTASSIUM CHLORIDE 15MEQ IN DEXTROSE 5% AND SODIUM CHLORIDE 0.3% IN PLASTIC CONTAINER

HOSPIRA 5GM/100ML;224MG/100ML;300MG/100ML N18876 007 Mar 28, 1988 May CAHN

POTASSIUM CHLORIDE 15MEQ IN DEXTROSE 5% AND SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER

AP HOSPIRA 5GM/100ML;224MG/100ML;450MG/100M N18362 006 Mar 28, 1988 May CAHN

POTASSIUM CHLORIDE 15MEQ IN DEXTROSE 5% AND SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER

AP HOSPIRA 5GM/100ML;224MG/100ML;900MG/100M N19691 006 Mar 24, 1988 May CAHN

POTASSIUM CHLORIDE 20MEQ IN DEXTROSE 5% AND SODIUM CHLORIDE 0.225% IN PLASTIC CONTAINER

HOSPIRA 5GM/100ML;149MG/100ML;225MG/100M N18365 001 May CAHN  
5GM/100ML;298MG/100ML;225MG/100ML N18365 009 Mar 28, 1988 May CAHN

POTASSIUM CHLORIDE 20MEQ IN DEXTROSE 5% AND SODIUM CHLORIDE 0.3% IN PLASTIC CONTAINER

HOSPIRA 5GM/100ML;298MG/100ML;300MG/100M N18876 008 Mar 28, 1988 May CAHN

POTASSIUM CHLORIDE 20MEQ IN DEXTROSE 5% AND SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER

AP HOSPIRA 5GM/100ML;149MG/100ML;450MG/100M N18362 010 Jul 05, 1983 May CAHN  
5GM/100ML;298MG/100ML;450MG/100ML N18362 007 Mar 28, 1988 May CAHN

POTASSIUM CHLORIDE 20MEQ IN DEXTROSE 5% AND SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER

AP HOSPIRA 5GM/100ML;149MG/100ML;900MG/100M N19691 005 Mar 24, 1988 May CAHN  
5GM/100ML;298MG/100ML;900MG/100M N19691 008 Mar 24, 1988 May CAHN

POTASSIUM CHLORIDE 20MEQ IN DEXTROSE 5% AND SODIUM CHLORIDE 0.3% IN PLASTIC CONTAINER

HOSPIRA 5GM/100ML;149MG/100ML;300MG/100M N18876 002 Jan 17, 1986 May CAHN

POTASSIUM CHLORIDE 30MEQ IN DEXTROSE 5% AND SODIUM CHLORIDE 0.225% IN PLASTIC CONTAINER

HOSPIRA 5GM/100ML;224MG/100ML;225MG/100M N18365 003 Jul 05, 1983 May CAHN

INJECTABLE; INJECTION

POTASSIUM CHLORIDE 30MEQ IN DEXTROSE 5% AND SODIUM CHLORIDE 0.3% IN PLASTIC CONTAINER  
 HOSPIRA 5GM/100ML;224MG/100ML;300MG/100ML N18876 003 Jan 17, 1986 May CAHN

POTASSIUM CHLORIDE 30MEQ IN DEXTROSE 5% AND SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER  
 AP HOSPIRA 5GM/100ML;224MG/100ML;450MG/100ML N18362 002 May CAHN

POTASSIUM CHLORIDE 30MEQ IN DEXTROSE 5% AND SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER  
 AP HOSPIRA 5GM/100ML;224MG/100ML;900MG/100ML N19691 007 Mar 24, 1988 May CAHN

POTASSIUM CHLORIDE 40MEQ IN DEXTROSE 5% AND SODIUM CHLORIDE 0.225% IN PLASTIC CONTAINER  
 HOSPIRA 5GM/100ML;298MG/100ML;225MG/100ML N18365 004 Jul 05, 1983 May CAHN

POTASSIUM CHLORIDE 40MEQ IN DEXTROSE 5% AND SODIUM CHLORIDE 0.3% IN PLASTIC CONTAINER  
 HOSPIRA 5GM/100ML;298MG/100ML;300MG/100ML N18876 004 Mar 28, 1988 May CAHN

POTASSIUM CHLORIDE 40MEQ IN DEXTROSE 5% AND SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER  
 AP HOSPIRA 5GM/100ML;298MG/100ML;450MG/100ML N18362 003 May CAHN

POTASSIUM CHLORIDE 40MEQ IN DEXTROSE 5% AND SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER  
 AP HOSPIRA 5GM/100ML;298MG/100ML;900MG/100ML N19691 009 Mar 24, 1988 May CAHN

POTASSIUM CHLORIDE 5MEQ IN DEXTROSE 5% AND SODIUM CHLORIDE 0.225% IN PLASTIC CONTAINER  
 HOSPIRA 5GM/100ML;74.5MG/100ML;225MG/100M N18365 005 Mar 28, 1988 May CAHN  
 L  
 5GM/100ML;149MG/100ML;225MG/100ML N18365 007 Mar 28, 1988 May CAHN

POTASSIUM CHLORIDE 5MEQ IN DEXTROSE 5% AND SODIUM CHLORIDE 0.3% IN PLASTIC CONTAINER  
 HOSPIRA 5GM/100ML;74.5MG/100ML;300MG/100M N18876 005 Mar 28, 1988 May CAHN  
 L  
 5GM/100ML;149MG/100ML;300MG/100ML N18876 009 Mar 28, 1988 May CAHN

POTASSIUM CHLORIDE 5MEQ IN DEXTROSE 5% AND SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER  
 AP HOSPIRA 5GM/100ML;74.5MG/100ML;450MG/100M N18362 008 Mar 28, 1988 May CAHN  
 L  
 5GM/100ML;149MG/100ML;450MG/100ML N18362 004 Mar 28, 1988 May CAHN

POTASSIUM CHLORIDE 5MEQ IN DEXTROSE 5% AND SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER  
 AP HOSPIRA 5GM/100ML;74.5MG/100ML;900MG/100M N19691 001 Mar 24, 1988 May CAHN  
 L  
 5GM/100ML;149MG/100ML;900MG/100ML N19691 003 Mar 24, 1988 May CAHN

DEXTROSE; SODIUM CHLORIDE

INJECTABLE; INJECTION

DEXTROSE 2.5% AND SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER  
 AP HOSPIRA 2.5GM/100ML;450MG/100ML N18096 001 May CAHN

DEXTROSE 5% AND SODIUM CHLORIDE 0.225% IN PLASTIC CONTAINER  
 HOSPIRA 5GM/100ML;225MG/100ML N17606 001 May CAHN

DEXTROSE 5% AND SODIUM CHLORIDE 0.3% IN PLASTIC CONTAINER  
 HOSPIRA 5GM/100ML;300MG/100ML N17799 001 May CAHN

DEXTROSE 5% AND SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER  
 AP HOSPIRA 5GM/100ML;450MG/100ML N17607 001 May CAHN

DEXTROSE 5% AND SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER  
 AP ABBOTT 5GM/100ML;900MG/100ML N17585 001 May CAHN

DIATRIZOATE MEGLUMINE

INJECTABLE; INJECTION

HYPaque  
 @ GE HEALTHCARE 30% N16403 002 May DISC

RENO-DIP  
 + BRACCO 30% N10040 012 May CRLD

DIATRIZOATE MEGLUMINE; DIATRIZOATE SODIUM

INJECTABLE; INJECTION

HYPaque-76  
 @ GE HEALTHCARE 66%;10% N86505 001 May DISC

DIAZEPAM

INJECTABLE; INJECTION

DIAZEPAM

AP	+	HOSPIRA	5MG/ML	N71583 001 Oct 13, 1987 May CAHN
AP			5MG/ML	N71584 001 Oct 13, 1987 May CAHN
AP			5MG/ML	N72079 001 Dec 20, 1988 May CAHN
AP		PARENTA PHARMS	5MG/ML	N76815 001 Apr 15, 2004 Apr NEWA

DICLOFENAC POTASSIUM

TABLET; ORAL

DICLOFENAC POTASSIUM

AB		TORPHARM	50MG	N76561 001 Mar 18, 2004 Mar NEWA
----	--	----------	------	----------------------------------

DICLOXACILLIN SODIUM

CAPSULE; ORAL

DICLOXACILLIN SODIUM

SANDOZ		EQ 125MG BASE	N61454 002	Mar CAHN
AB		EQ 250MG BASE	N61454 001	Mar CAHN
AB	+	EQ 500MG BASE	N61454 003	Mar CAHN

DIDANOSINE

FOR SOLUTION; ORAL

VIDEX

+ BRISTOL MYERS SQUIBB	10MG/ML	N20156 001 Oct 09, 1991 Jun CRLD
@	100MG/PACKET	N20155 003 Oct 09, 1991 Jun DISC
@	167MG/PACKET	N20155 004 Oct 09, 1991 Jun DISC
@	250MG/PACKET	N20155 005 Oct 09, 1991 Jun DISC

TABLET, CHEWABLE; ORAL

VIDEX

>D>	+ BRISTOL MYERS SQUIBB	25MG	N20154 002 Oct 09, 1991 Jul CRLD
>A>		25MG	N20154 002 Oct 09, 1991 Jul CRLD
>D>		200MG	N20154 006 Oct 28, 1999 Jul CRLD
>A>	+	200MG	N20154 006 Oct 28, 1999 Jul CRLD

DIENESTROL

CREAM; VAGINAL

DIENESTROL

>D>	@ ORTHO MCNEIL	0.01%	N06110 005	Jul CAHN
>A>	@ ORTHO MCNEIL PHARM	0.01%	N06110 005	Jul CAHN

DIGOXIN

INJECTABLE; INJECTION

DIGOXIN

AP	HOSPIRA	0.25MG/ML	N40093 001 May 16, 1996 May CAHN
AP		0.25MG/ML	N40206 001 Aug 28, 1998 May CAHN
AP	DIGOXIN PEDIATRIC		
AP	HOSPIRA	0.1MG/ML	N40092 001 Apr 25, 1996 May CAHN

DILTIAZEM HYDROCHLORIDE

CAPSULE, EXTENDED RELEASE; ORAL

CARDIZEM SR

@ AVENTIS PHARMS	60MG	N19471 001 Jan 23, 1989 Jun DISC
@	90MG	N19471 002 Jan 23, 1989 Jun DISC
@	120MG	N19471 003 Jan 23, 1989 Jun DISC

## CAPSULE, EXTENDED RELEASE; ORAL

	DILT-CD				
AB3	TORPHARM	120MG	N76151 001	May 20, 2004	May NEWA
AB3		180MG	N76151 002	May 20, 2004	May NEWA
AB3		240MG	N76151 003	May 20, 2004	May NEWA
AB3		300MG	N76151 004	May 20, 2004	May NEWA
	DILTIAZEM HCL				
	@ BIOVAIL	60MG	N74845 001	Sep 15, 1999	Jun DISC
	@	90MG	N74845 002	Sep 15, 1999	Jun DISC
	@	120MG	N74845 003	Sep 15, 1999	Jun DISC
+	MYLAN	60MG	N74910 001	May 02, 1997	Jun CRLD
+		90MG	N74910 002	May 02, 1997	Jun CRLD
+		120MG	N74910 003	May 02, 1997	Jun CRLD
	@ TEVA	60MG	N74079 001	Nov 30, 1993	Jun DISC
	@	90MG	N74079 002	Nov 30, 1993	Jun DISC
	@	120MG	N74079 003	Nov 30, 1993	Jun DISC

## INJECTABLE; INJECTION

	DILTIAZEM HCL				
AP	HOSPIRA	5MG/ML	N74941 001	Apr 15, 1998	May CAHN
AP		5MG/ML	N75004 001	Feb 16, 2000	May CAHN
AP		100MG/VIAL	N75853 001	Dec 17, 2002	May CAHN

## TABLET, EXTENDED RELEASE; ORAL

	CARDIZEM LA				
	BIOVAIL	120MG	N21392 001	Feb 06, 2003	Jan CRLD
		180MG	N21392 002	Feb 06, 2003	Jan CRLD
		240MG	N21392 003	Feb 06, 2003	Jan CRLD
		300MG	N21392 004	Feb 06, 2003	Jan CRLD
		360MG	N21392 005	Feb 06, 2003	Jan CRLD

DIMENHYDRINATE

	INJECTABLE; INJECTION				
	DIMENHYDRINATE				
AP	AM PHARM	50MG/ML	N40519 001	Jun 23, 2004	Jun NEWA
AP	STERIS	50MG/ML	N80615 001		Jun CFTG

DIMYRISTOYL LECITHIN; PERFLUXANE

	INJECTABLE; INTRAVENOUS				
	IMAGENT				
+	IMCOR PH	0.92MG/VIAL; 0.092MG/VIAL	N21191 001	May 31, 2002	Feb CAHN

DIPHENHYDRAMINE HYDROCHLORIDE

	INJECTABLE; INJECTION				
	DIPHENHYDRAMINE HCL				
AP	HOSPIRA	50MG/ML	N40140 001	Nov 20, 1998	May CAHN

DIPYRIDAMOLE

	INJECTABLE; INJECTION				
	DIPYRIDAMOLE				
AP	HOSPIRA	5MG/ML	N74601 001	Dec 19, 1997	May CAHN

>D> DIRITHROMYCIN

>D>	TABLET, DELAYED RELEASE; ORAL				
>D>	DYNABAC				
>D>	+ LILLY RES LABS	250MG	N50678 001	Jun 19, 1995	Jul DISC
>A>	@	250MG	N50678 001	Jun 19, 1995	Jul DISC

DISULFIRAM

TABLET; ORAL			
ANTABUSE			
@ ODYSSEY PHARMS	250MG	N07883 003	Jun CAHN
@	500MG	N07883 002	Jun CAHN

DIVALPROEX SODIUM

TABLET, DELAYED RELEASE; ORAL			
DEPAKOTE			
ABBOTT	EQ 125MG VALPROIC ACID	N18723 003 Oct 26, 1984 Jan CRLD	
	EQ 250MG VALPROIC ACID	N18723 001 Mar 10, 1983 Jan CRLD	

DOBUTAMINE HYDROCHLORIDE

## INJECTABLE; INJECTION

## DOBUTAMINE HCL

AP	HOSPIRA	EQ 12.5MG BASE/ML	N74086 001 Nov 29, 1993 May CAHN
AP		EQ 12.5MG BASE/ML	N74292 001 Feb 16, 1995 May CAHN
AP		EQ 1.25GM BASE/100ML	N74634 001 Sep 27, 1996 May CAHN
AP	DOBUTAMINE HCL IN DEXTROSE 5%		
AP	+ HOSPIRA	EQ 50MG BASE/100ML	N20269 001 Oct 19, 1993 May CAHN
AP	+	EQ 100MG BASE/100ML	N20269 002 Oct 19, 1993 May CAHN
AP	+	EQ 200MG BASE/100ML	N20269 003 Oct 19, 1993 May CAHN
AP	DOBUTAMINE HCL IN DEXTROSE 5% IN PLASTIC CONTAINER		
AP	+ HOSPIRA	EQ 50MG BASE/100ML	N20201 003 Oct 19, 1993 May CAHN
AP	+	EQ 100MG BASE/100ML	N20201 002 Oct 19, 1993 May CAHN
AP	+	EQ 200MG BASE/100ML	N20201 001 Oct 19, 1993 May CAHN
AP	+	EQ 400MG BASE/100ML	N20201 006 Jul 07, 1994 May CAHN
	DOBUTREX		
@ LILLY		EQ 12.5MG BASE/ML	N17820 002 Jun DISC

DOPAMINE HYDROCHLORIDE

## INJECTABLE; INJECTION

## DOPAMINE HCL

AP	+ HOSPIRA	40MG/ML	N18132 001 May CAHN
AP		40MG/ML	N74403 001 May 23, 1996 May CAHN
AP	+	80MG/100ML	N18132 002 Feb 04, 1982 May CAHN
AP	+	80MG/ML	N18132 004 Jul 09, 1982 May CAHN
AP	+	160MG/100ML	N18132 003 Feb 04, 1982 May CAHN
AP	DOBAMINE HCL IN DEXTROSE 5%		
AP	+ HOSPIRA	1.6MG/ML	N20542 001 Aug 30, 1995 May CAHN
	@	1.6MG/ML	N20542 001 Aug 30, 1995 Jun DISC
AP	DOBAMINE HCL IN DEXTROSE 5% IN PLASTIC CONTAINER		
AP	+ HOSPIRA	80MG/100ML	N18826 001 Sep 30, 1983 May CAHN
AP	+	160MG/100ML	N18826 002 Sep 30, 1983 May CAHN
AP	+	320MG/100ML	N18826 003 Sep 30, 1983 May CAHN

DOXAZOSIN MESYLATE

## TABLET; ORAL

AB	DOXAZOSIN MESYLATE		
AB	CLONMEL HLTHCARE	EQ 1MG BASE	N76161 001 Jun 10, 2004 Jun NEWA
AB		EQ 2MG BASE	N76161 002 Jun 10, 2004 Jun NEWA
AB		EQ 4MG BASE	N76161 003 Jun 10, 2004 Jun NEWA
AB		EQ 8MG BASE	N76161 004 Jun 10, 2004 Jun NEWA

DOXEPEPIN HYDROCHLORIDE

CONCENTRATE; ORAL

DOXEPEPIN HCL

AA PHARM ASSOC EQ 10MG BASE/ML

N75924 001 Jan 15, 2004 Jan NEWA

DOXERCALCIFEROL

CAPSULE; ORAL

HECTOROL

BONE CARE 0.5UGM

N20862 002 Apr 23, 2004 Apr NEWA

DOXORUBICIN HYDROCHLORIDE

INJECTABLE; INJECTION

ADRIAMYCIN RDF

@ PHARMACIA AND UPJOHN 10MG/VIAL

N50467 001 Jun DISC

@ 20MG/VIAL

N50467 003 May 20, 1985 Jun DISC

@ 50MG/VIAL

N50467 002 Jun DISC

DOXYCYCLINE

CAPSULE; ORAL

DOXYCYCLINE

AB WATSON LABS EQ 50MG BASE  
AB EQ 100MG BASEN65041 001 Apr 28, 2000 Apr CAHN  
N65041 002 Apr 28, 2000 Apr CAHNDOXYCYCLINE HYCLATE

CAPSULE, COATED PELLETS; ORAL

DORYX

>A> FH FAULDING CO LTD EQ 75MG BASE  
>A> AB + EQ 100MG BASE  
>D> MAYNE PHARMA USA EQ 75MG BASE  
>D> AB + EQ 100MG BASEN50582 002 Aug 13, 2001 Jul CAHN  
N50582 001 Jul 22, 1985 Jul CAHN  
N50582 002 Aug 13, 2001 Jul CAHN  
N50582 001 Jul 22, 1985 Jul CAHNCAPSULE; ORAL  
DOXYCYCLINE HYCLATEAB WATSON LABS EQ 50MG BASE  
AB EQ 100MG BASEN61717 001 Apr CAHN  
N61717 002 Apr CAHNDROPERIDOL

INJECTABLE; INJECTION

DROPERIDOL

AP HOSPIRA 2.5MG/ML  
AP 2.5MG/MLN71981 001 Feb 29, 1988 May CAHN  
N72272 001 Aug 31, 1995 May CAHNDROPERIDOL; FENTANYL CITRATE

INJECTABLE; INJECTION

FENTANYL CITRATE AND DROPERIDOL

+ HOSPIRA 2.5MG/ML; EQ 0.05MG BASE/ML

N71982 001 May 04, 1988 May CAHN

ECONAZOLE NITRATE

CREAM; TOPICAL

ECONAZOLE NITRATE

AB CLAY PARK 1%

N76479 001 Jun 23, 2004 Jun NEWA

EDETADE DISODIUM

INJECTABLE; INJECTION

ENDRATE

AP + HOSPIRA 150MG/ML

N11355 001 May CAHN

EDROPHONIUM CHLORIDE

INJECTABLE; INJECTION  
 EDROPHONIUM CHLORIDE  
 AP HOSPIRA 10MG/ML N40131 001 Feb 24, 1998 May CAHN

EFAVIRENZ

TABLET; ORAL  
 SUSTIVA  
 @ BRISTOL MYERS SQUIBB 300MG N21360 001 Feb 01, 2002 Jun DISC

EFLORNITHINE HYDROCHLORIDE

CREAM; TOPICAL  
 VANIQA  
 >A> + SKINMEDICA 13.9% N21145 001 Jul 27, 2000 Jul CAHN  
 >D> + WOMEN FIRST HLTHCARE 13.9% N21145 001 Jul 27, 2000 Jul CAHN

ENALAPRILAT

INJECTABLE; INJECTION  
 ENALAPRILAT  
 AP HOSPIRA 1.25MG/ML N75456 001 Aug 22, 2000 May CAHN  
 AP 1.25MG/ML N75458 001 Aug 22, 2000 May CAHN

EPINEPHRINE

INJECTABLE; INTRAMUSCULAR, SUBCUTANEOUS  
 EPINEPHRINE  
 + HOLLISTER STIER LABS EQ 0.15MG /DELIVERY N20800 002 May 28, 2004 May NEWA

EPINEPHRINE; LIDOCAINE HYDROCHLORIDE

INJECTABLE; INJECTION  
 LIDOCAINE HCL AND EPINEPHRINE  
 AP HOSPIRA 0.005MG/ML;0.5% N89635 001 Jun 21, 1988 May CAHN  
 AP 0.005MG/ML;1% N89649 001 Jun 21, 1988 May CAHN  
 AP 0.005MG/ML;1.5% N88571 001 Sep 13, 1985 May CAHN  
 AP 0.005MG/ML;1.5% N89645 001 Jun 21, 1988 May CAHN  
 AP 0.005MG/ML;1.5% N89650 001 Jun 21, 1988 May CAHN  
 AP 0.005MG/ML;2% N89651 001 Jun 21, 1988 May CAHN  
 AP 0.01MG/ML;1% N89644 001 Jun 21, 1988 May CAHN  
 AP 0.01MG/ML;2% N89646 001 Jun 21, 1988 May CAHN

PATCH; IONTOPHORESIS  
 LIDOSITE TOPICAL SYSTEM KIT  
 + VYTERIS 1.05MG/PATCH;100MG/PATCH N21504 001 May 06, 2004 May NEWA

SOLUTION; IONTOPHORESIS  
 IONTOCAINE  
 + IOMED 0.01MG/ML;2% N20530 001 Dec 21, 1995 May MAGC

ERYTHROMYCIN

CAPSULE, DELAYED REL PELLETS; ORAL  
 ERYC  
 AB WARNER CHILCOTT 250MG N62338 001 Jan CMFD  
 GEL; TOPICAL  
 ERYGEL  
 >D> AT + ALLERGAN HERBERT 2% N50617 001 Oct 21, 1987 Jul CAHN  
 >A> AT + MERZ PHARMS 2% N50617 001 Oct 21, 1987 Jul CAHN

OINTMENT; OPHTHALMIC			
	ERYTHROMYCIN	0.5%	N62447 001 Sep 26, 1983 Jul CRLD
>D>	AT FOUGERA	0.5%	N62447 001 Sep 26, 1983 Jul CRLD
>A>	AT +		
>D>	ILOTYCIN		N50368 001 Jul DISC
>D>	AT + DISTA	0.5%	N50368 001 Jul DISC
>A>	@	0.5%	
SOLUTION; TOPICAL			
	C-SOLVE-2		N62468 001 Jul 03, 1985 Jun DISC
	@ BIOGLAN PHARMA	2%	
<u>ERYTHROMYCIN ESTOLATE</u>			
SUSPENSION; ORAL			
	ERYTHROMYCIN ESTOLATE		N62353 001 Nov 18, 1982 Jan CTEC
	ALPHARMA	EQ 125MG BASE/5ML	N62409 001 Dec 16, 1982 Jan CRLD
	+	EQ 250MG BASE/5ML	
	ILOSONE		N50010 001 Jan DISC
	@ LILLY	EQ 125MG BASE/5ML	N50010 002 Jan DISC
	@	EQ 250MG BASE/5ML	
<u>ERYTHROMYCIN LACTOBIONATE</u>			
INJECTABLE; INJECTION			
	ERYTHROCIN		N50182 002 May CAHN
AP	+ HOSPIRA	EQ 500MG BASE/VIAL	N50609 001 Sep 24, 1986 May CAHN
AP		EQ 500MG BASE/VIAL	N62638 001 Oct 31, 1986 May CAHN
AP		EQ 500MG BASE/VIAL	N50182 003 May CAHN
AP	+	EQ 1GM BASE/VIAL	N50609 002 Sep 24, 1986 May CAHN
AP		EQ 1GM BASE/VIAL	N62638 002 Oct 31, 1986 May CAHN
AP		EQ 1GM BASE/VIAL	
<u>ESCITALOPRAM OXALATE</u>			
TABLET; ORAL			
	LEXAPRO		N21323 001 Aug 14, 2002 Apr CMFD
	FOREST LABS	5MG	
<u>ESTRADIOL</u>			
FILM, EXTENDED RELEASE; TRANSDERMAL			
	MENOSTAR		N21674 001 Jun 08, 2004 Jun NEWA
	+	BERLEX LABS	0.014MG/24HR
	VIVELLE		N20323 005 Aug 16, 2000 Jul CTEC
>D>	+	NOVARTIS	0.025MG/24HR
>A>	AB1 +		N20323 005 Aug 16, 2000 Jul CTEC
>D>	AB1 +		N20323 001 Oct 28, 1994 Jul DISC
>A>	@		N20323 001 Oct 28, 1994 Jul DISC
>D>	AB1 +		N20323 003 Oct 28, 1994 Jul DISC
>A>	@		N20323 003 Oct 28, 1994 Jul DISC
	VIVELLE-DOT		N20538 009 May 03, 2002 Jul NEWA
>A>	AB1 NOVARTIS	0.025MG/24HR	N20538 005 Jan 08, 1999 Jul CTEC
>D>	AB1	0.0375MG/24HR	N20538 005 Jan 08, 1999 Jul CTEC
>A>	BX	0.0375MG/24HR	N20538 007 Jan 08, 1999 Jul CTEC
>D>	AB1	0.075MG/24HR	N20538 007 Jan 08, 1999 Jul CTEC
>A>	BX	0.075MG/24HR	
GEL, METERED; TOPICAL			
	ESTROGEL		N21166 002 Feb 09, 2004 Feb NEWA
	SOLVAY	0.06%	

GEL; TOPICAL

ESTROGEL	0.06%	N21166 001 Feb 09, 2004 Mar CRLD
+ SOLVAY	0.06%	N21166 001 Feb 09, 2004 Feb NEWA

ESTRADIOL ACETATE

INSERT, EXTENDED RELEASE; VAGINAL

FEMRING	EQ 0.05MG BASE/24HR	N21367 001 Mar 20, 2003 May CPOT
GALEN LTD	EQ 0.1MG BASE/24HR	N21367 002 Mar 20, 2003 May CPOT

ESTROGENS, CONJUGATED

TABLET; ORAL		
PREMARIN		
@ WYETH PHARMS INC	2.5MG	N04782 002 May DISC

ESTROGENS, CONJUGATED SYNTHETIC A

TABLET; ORAL		
CENESTIN		
DURAMED	0.45MG	N20992 005 Feb 05, 2004 Feb NEWA

ESTROGENS, CONJUGATED SYNTHETIC B

>D>	TABLET; ORAL		
>D>	ENJUVIA		
>D>	DURAMED	0.625MG	N21443 003 May 10, 2004 Jul DISC
>A>	@	0.625MG	N21443 003 May 10, 2004 Jul DISC
		0.625MG	N21443 003 May 10, 2004 May NEWA
>D>	+	1.25MG	N21443 004 May 10, 2004 Jul DISC
>A>	@	1.25MG	N21443 004 May 10, 2004 Jul DISC
	+	1.25MG	N21443 004 May 10, 2004 May NEWA

ETHAMBUTOL HYDROCHLORIDE

TABLET; ORAL			
MYAMBUTOL			
@ ELAN PHARMS	100MG	N16320 001 Feb CAHN	
@	200MG	N16320 002 Feb CAHN	
@	400MG	N16320 003 Feb CAHN	
@	500MG	N16320 004 Feb CAHN	
AB	STAT TRADE	100MG	N16320 001 May CMFD
	@	200MG	N16320 002 May CAHN
AB		400MG	N16320 003 May CMFD
	@	500MG	N16320 004 May CAHN

ETHINYL ESTRADIOL

TABLET; ORAL			
ESTINYL			
@ SCHERING	0.02MG	N05292 001 Apr DISC	
@	0.05MG	N05292 002 Apr DISC	
@	0.5MG	N05292 003 Apr DISC	

ETHINYL ESTRADIOL; LEVONORGESTREL

TABLET; ORAL			
PREVEN EMERGENCY CONTRACEPTIVE KIT			
+ DURAMED	0.05MG;0.25MG	N20946 001 Sep 01, 1998 Jul DISC	
@	0.05MG;0.25MG	N20946 001 Sep 01, 1998 Jul DISC	
+	0.05MG;0.25MG	N20946 001 Sep 01, 1998 Feb CAHN	

TABLET; ORAL-21

LEVLITE

AB2	+	BERLEX	0.02MG;0.1MG	N20860 001 Jul 13, 1998 May CTEC
		TABLET; ORAL-28		
		ALESSE		
>D>	AB1	WYETH PHARMS INC	0.02MG;0.1MG	N20683 002 Mar 27, 1997 Jul CRLD
>A>	AB1	+	0.02MG;0.1MG	N20683 002 Mar 27, 1997 Jul CRLD
		LESSINA-28		
AB2		BARR	0.02MG;0.1MG	N75803 002 Mar 20, 2002 May CTEC
		LEVLITE		
>D>	AB2	BERLEX	0.02MG;0.1MG	N20860 002 Jul 13, 1998 Jul CRLD
>A>	AB2	+	0.02MG;0.1MG	N20860 002 Jul 13, 1998 Jul CRLD
		AB2	0.02MG;0.1MG	N20860 002 Jul 13, 1998 May CTEC

ETHINYL ESTRADIOL; NORETHINDRONE

TABLET; ORAL-21

BALZIVA-21

AB		BARR	0.035MG;0.4MG	N76198 001 Apr 22, 2004 Apr NEWA
		OVCON-35		
AB	+	WARNER CHILCOTT	0.035MG;0.4MG	N18127 001 Apr CFTG
		TABLET; ORAL-28		
		BALZIVA-28		
AB		BARR	0.035MG;0.4MG	N76238 001 Apr 22, 2004 Apr NEWA
		ORTHO-NOVUM 1/35-28		
AB	+	ORTHO MCNEIL PHARM	0.035MG;1MG	N17919 002 Mar CRLD
		OVCON-35		
AB	+	WARNER CHILCOTT	0.035MG;0.4MG	N17716 001 Apr CFTG

ETHINYL ESTRADIOL; NORGESTIMATE

TABLET; ORAL-28

ORTHO TRI-CYCLEN LO

	+	ORTHO MCNEIL PHARM	0.025MG, 0.025MG, 0.25MG;0.18MG, 0.25MG, 0.215MG	N21241 001 Aug 22, 2002 Jun CAHN
		PREVIFEM		
AB		ANDRX PHARMS	0.035MG;0.25MG	N76334 001 Jan 09, 2004 Jan NEWA
		TRI-PREVIFEM		
AB		ANDRX PHARMS	0.035MG, 0.035MG, 0.035MG;0.18MG, 0.215MG, 0.25MG	N76335 001 Mar 26, 2004 Mar NEWA

ETIDRONATE DISODIUM

INJECTABLE; INJECTION

DIDRONEL

	@ MGI PHARMA INC	50MG/ML	N19545 001 Apr 20, 1987 Jun DISC
--	------------------	---------	----------------------------------

ETODOLAC

TABLET, EXTENDED RELEASE; ORAL

LODINE XL

AB		WYETH PHARMS INC	400MG	N20584 001 Oct 25, 1996 May CRLD
>D>	AB		500MG	N20584 003 Jan 20, 1998 Jul CRLD
>A>	AB	+	500MG	N20584 003 Jan 20, 1998 Jul CRLD
		AB	500MG	N20584 003 Jan 20, 1998 May CRLD
>D>	AB	+	600MG	N20584 002 Oct 25, 1996 Jul DISC
>A>		@	600MG	N20584 002 Oct 25, 1996 Jul DISC

ETOMIDATE

INJECTABLE; INJECTION

AMIDATE

AP + HOSPIRA 2MG/ML N18227 001 Sep 07, 1982 May CAHN

ETOPOSIDE

INJECTABLE; INJECTION

ETOPOSIDE

AP HOSPIRA 20MG/ML N74320 001 Aug 30, 1995 May CAHN  
AP 20MG/ML N74351 001 Aug 30, 1995 May CAHNEZETIMIBE; SIMVASTATIN

TABLET; ORAL

VYTORIN

>A> MSP SINGAPORE 10MG;10MG N21687 001 Jul 23, 2004 Jul NEWA  
>A> 10MG;20MG N21687 002 Jul 23, 2004 Jul NEWA  
>A> 10MG;40MG N21687 003 Jul 23, 2004 Jul NEWA  
>A> + 10MG;80MG N21687 004 Jul 23, 2004 Jul NEWAFAMOTIDINE

INJECTABLE; INJECTION

FAMOTIDINE

AP HOSPIRA 10MG/ML N75870 001 Nov 23, 2001 May CAHN  
AP 10MG/ML N75905 001 Nov 23, 2001 May CAHNFENOLDOPAM MESYLATE

INJECTABLE; INJECTION

CORLOPAM

AP + HOSPIRA EQ 10MG BASE/ML N19922 001 Sep 23, 1997 May CAHN

FENTANYL

FILM, EXTENDED RELEASE; TRANSDERMAL

DURAGESIC

>D> AB + ALZA 0.6MG/24HR N19813 004 Aug 07, 1990 Jul CTEC  
>A> + 0.6MG/24HR N19813 004 Aug 07, 1990 Jul CTEC  
>D> AB 1.2MG/24HR N19813 003 Aug 07, 1990 Jul CTEC  
>A> 1.2MG/24HR N19813 003 Aug 07, 1990 Jul CTEC  
>D> AB 1.8MG/24HR N19813 002 Aug 07, 1990 Jul CTEC  
>A> 1.8MG/24HR N19813 002 Aug 07, 1990 Jul CTEC  
>D> AB 2.4MG/24HR N19813 001 Aug 07, 1990 Jul CTEC  
>A> 2.4MG/24HR N19813 001 Aug 07, 1990 Jul CTECFENTANYL CITRATE

INJECTABLE; INJECTION

FENTANYL CITRATE

AP HOSPIRA EQ 0.05MG BASE/ML N19115 001 Jan 12, 1985 May CAHN

AP HOSPIRA FENTANYL CITRATE PRESERVATIVE FREE EQ 0.05MG BASE/ML N72786 001 Sep 24, 1991 May CAHN

TROCHE/LOZENGE; ORAL

ACTIQ

CEPHALON

EQ 0.2MG BASE N20747 001 Nov 04, 1998 Feb CAHN  
EQ 0.4MG BASE N20747 002 Nov 04, 1998 Feb CAHN  
EQ 0.6MG BASE N20747 003 Nov 04, 1998 Feb CAHN  
EQ 0.8MG BASE N20747 004 Nov 04, 1998 Feb CAHN  
EQ 1.2MG BASE N20747 005 Nov 04, 1998 Feb CAHN

## TROCHE/LOZENGE; ORAL

ACTIQ

+ CEPHALON

EQ 1.6MG BASE

N20747 006 Nov 04, 1998 Feb CAHN

FLUCONAZOLE

## FOR SUSPENSION; ORAL

## DIFLUCAN

>D>	PFIZER	50MG/5ML	N20090 001	Dec 23, 1993	Jul	CFTG
>A> AB		50MG/5ML	N20090 001	Dec 23, 1993	Jul	CFTG
>D>	+	200MG/5ML	N20090 002	Dec 23, 1993	Jul	CFTG
>A> AB	+	200MG/5ML	N20090 002	Dec 23, 1993	Jul	CFTG
>A>	FLUCONAZOLE					
>A> AB	RANBAXY	50MG/5ML	N76332 001	Jul 29, 2004	Jul	NEWA
>A> AB		200MG/5ML	N76332 002	Jul 29, 2004	Jul	NEWA
>A> AB	ROXANE	50MG/5ML	N76246 001	Jul 29, 2004	Jul	NEWA
>A> AB		200MG/5ML	N76246 002	Jul 29, 2004	Jul	NEWA

## INJECTABLE; INJECTION

## DIFLUCAN IN DEXTROSE 5% IN PLASTIC CONTAINER

>D>	+ PFIZER	200MG/100ML	N19950 003	Sep 29, 1992	Jul	CFTG
>A> AP	+	200MG/100ML	N19950 003	Sep 29, 1992	Jul	CFTG
	DIFLUCAN IN SODIUM CHLORIDE 0.9%					
>D>	+ PFIZER	200MG/100ML	N19950 001	Jan 29, 1990	Jul	CFTG
>A> AP	+	200MG/100ML	N19950 001	Jan 29, 1990	Jul	CFTG
	DIFLUCAN IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER					
>D>	+ PFIZER	200MG/100ML	N19950 002	Jan 29, 1990	Jul	CFTG
>A> AP	+	200MG/100ML	N19950 002	Jan 29, 1990	Jul	CFTG
	FLUCONAZOLE IN DEXTROSE 5% IN PLASTIC CONTAINER					
>A> AP	HOSPIRA	200MG/100ML	N76304 001	Jul 29, 2004	Jul	NEWA
	FLUCONAZOLE IN SODIUM CHLORIDE 0.9%					
>A> AP	AM PHARM PARTNERS	200MG/100ML	N76145 001	Jul 29, 2004	Jul	NEWA
>A> AP	BEDFORD	200MG/100ML	N76087 001	Jul 29, 2004	Jul	NEWA
>A> AP	SICOR PHARMS	200MG/100ML	N76653 001	Jul 29, 2004	Jul	NEWA
	FLUCONAZOLE IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER					
>A> AP	BAXTER HLTHCARE	200MG/100ML	N76766 001	Jul 29, 2004	Jul	NEWA
>A> AP	HOSPIRA	200MG/100ML	N76303 001	Jul 29, 2004	Jul	NEWA
>A> AP	+ MAYNE PHARMA USA	200MG/100ML	N76617 001	Jul 29, 2004	Jul	NEWA

## TABLET; ORAL

## DIFLUCAN

>D>	PFIZER	50MG	N19949 001	Jan 29, 1990	Jul	CFTG
>A> AB		50MG	N19949 001	Jan 29, 1990	Jul	CFTG
>D>		100MG	N19949 002	Jan 29, 1990	Jul	CFTG
>A> AB		100MG	N19949 002	Jan 29, 1990	Jul	CFTG
>D>		150MG	N19949 004	Jun 30, 1994	Jul	CFTG
>A> AB		150MG	N19949 004	Jun 30, 1994	Jul	CFTG
>D>	+	200MG	N19949 003	Jan 29, 1990	Jul	CFTG
>A> AB	+	200MG	N19949 003	Jan 29, 1990	Jul	CFTG
	FLUCONAZOLE					
>A> AB	DR REDDYS LABS INC	50MG	N76658 001	Jul 29, 2004	Jul	NEWA
>A> AB		100MG	N76658 002	Jul 29, 2004	Jul	NEWA
>A> AB		150MG	N76658 003	Jul 29, 2004	Jul	NEWA
>A> AB		200MG	N76658 004	Jul 29, 2004	Jul	NEWA
>A> AB	GEDEON RICHTER USA	50MG	N76432 001	Jul 29, 2004	Jul	NEWA
>A> AB		100MG	N76432 002	Jul 29, 2004	Jul	NEWA
>A> AB		150MG	N76432 003	Jul 29, 2004	Jul	NEWA
>A> AB		200MG	N76432 004	Jul 29, 2004	Jul	NEWA
>A> AB	GENPHARM	50MG	N76042 001	Jul 29, 2004	Jul	NEWA
>A> AB		100MG	N76042 002	Jul 29, 2004	Jul	NEWA

TABLET; ORAL

>A>	AB	FLUCONAZOLE GENPHARM	150MG	N76042 003 Jul 29, 2004 Jul NEWA
>A>	AB		200MG	N76042 004 Jul 29, 2004 Jul NEWA
>A>	AB	IVAX PHARMS	50MG	N76077 001 Jul 29, 2004 Jul NEWA
>A>	AB		100MG	N76077 002 Jul 29, 2004 Jul NEWA
>A>	AB		150MG	N76077 003 Jul 29, 2004 Jul NEWA
>A>	AB		200MG	N76077 004 Jul 29, 2004 Jul NEWA
>A>	AB	MYLAN	50MG	N76351 001 Jul 29, 2004 Jul NEWA
>A>	AB		100MG	N76351 002 Jul 29, 2004 Jul NEWA
>A>	AB		150MG	N76351 003 Jul 29, 2004 Jul NEWA
>A>	AB		200MG	N76351 004 Jul 29, 2004 Jul NEWA
>A>	AB	PLIVA	50MG	N76424 001 Jul 29, 2004 Jul NEWA
>A>	AB		100MG	N76424 002 Jul 29, 2004 Jul NEWA
>A>	AB		150MG	N76424 003 Jul 29, 2004 Jul NEWA
>A>	AB		200MG	N76424 004 Jul 29, 2004 Jul NEWA
>A>	AB	RANBAXY	50MG	N76386 001 Jul 29, 2004 Jul NEWA
>A>	AB		100MG	N76386 002 Jul 29, 2004 Jul NEWA
>A>	AB		150MG	N76386 003 Jul 29, 2004 Jul NEWA
>A>	AB		200MG	N76386 004 Jul 29, 2004 Jul NEWA
>A>	AB	ROXANE	50MG	N76213 001 Jul 29, 2004 Jul NEWA
>A>	AB		100MG	N76213 002 Jul 29, 2004 Jul NEWA
>A>	AB		150MG	N76213 003 Jul 29, 2004 Jul NEWA
>A>	AB		200MG	N76213 004 Jul 29, 2004 Jul NEWA
>A>	AB	SANDOZ	50MG	N76086 001 Jul 29, 2004 Jul NEWA
>A>	AB		100MG	N76086 002 Jul 29, 2004 Jul NEWA
>A>	AB		150MG	N76086 003 Jul 29, 2004 Jul NEWA
>A>	AB		200MG	N76086 004 Jul 29, 2004 Jul NEWA
>A>	AB	TARO	50MG	N76507 001 Jul 29, 2004 Jul NEWA
>A>	AB		100MG	N76507 002 Jul 29, 2004 Jul NEWA
>A>	AB		150MG	N76507 003 Jul 29, 2004 Jul NEWA
>A>	AB		200MG	N76507 004 Jul 29, 2004 Jul NEWA
>A>	AB	TEVA	50MG	N74681 001 Jul 29, 2004 Jul NEWA
>A>	AB		100MG	N74681 002 Jul 29, 2004 Jul NEWA
>A>	AB		150MG	N74681 003 Jul 29, 2004 Jul NEWA
>A>	AB		200MG	N74681 004 Jul 29, 2004 Jul NEWA
>A>	AB	TORPHARM	50MG	N76665 001 Jul 29, 2004 Jul NEWA
>A>	AB		100MG	N76665 002 Jul 29, 2004 Jul NEWA
>A>	AB		150MG	N76665 003 Jul 29, 2004 Jul NEWA
>A>	AB		200MG	N76665 004 Jul 29, 2004 Jul NEWA

FLUDARABINE PHOSPHATE

## INJECTABLE; INJECTION

## FLUDARABINE PHOSPHATE

+ GENSIA SICOR PHARMS

50MG/2ML (25MG/ML)

N76661 001 Apr 28, 2004 Apr NEWA

FLUDEOXYGLUCOSE, F-18

## INJECTABLE; INJECTION

## FLUDEOXYGLUCOSE F 18

@ DOWNSTATE CLINCL

4-90mCi/ML

N20306 002 Sep 25, 2001 May DISC

FLUNISOLIDE

## SPRAY, METERED; NASAL

## FLUNISOLIDE

+ BAUSCH AND LOMB

0.025MG/SPRAY

N74805 001 Feb 20, 2002 Jun CRLD

## SPRAY, METERED; NASAL

NASALIDE

@ IVAX RES

0.025MG/SPRAY

N18148 001

Jun DISC

FLUOCINONIDE

CREAM; TOPICAL

FLUOCINONIDE EMULSIFIED BASE

AB2 ALTANA 0.05%

N76586 001 Jun 23, 2004 Jun NEWA

FLUOROURACIL

INJECTABLE; INJECTION

FLUOROURACIL

&gt;D&gt; AP BIGMAR 50MG/ML

N40291 001 Mar 24, 1999 Jul CAHN

&gt;D&gt; AP 50MG/ML

N40379 001 Nov 15, 2000 Jul CAHN

&gt;A&gt; AP BIGMAR BIOREN PHARMS 50MG/ML

N40291 001 Mar 24, 1999 Jul CAHN

&gt;A&gt; AP 50MG/ML

N40379 001 Nov 15, 2000 Jul CAHN

FLUOXETINE HYDROCHLORIDE

SOLUTION; ORAL

FLUOXETINE HCL

AA PAR PHARM EQ 20MG BASE/5ML

N76458 001 May 14, 2004 May NEWA

FLUPHENAZINE DECANOATE

INJECTABLE; INJECTION

FLUPHENAZINE DECANOATE

@ MAYNE PHARMA USA 25MG/ML

N74966 001 Apr 16, 1998 Apr CAHN

FLUPHENAZINE HYDROCHLORIDE

CONCENTRATE; ORAL

PERMITIL

@ SCHERING 5MG/ML

N16008 001

Jun DISC

FLUTICASONE PROPIONATE

AEROSOL, METERED; INHALATION

FLOVENT HFA

GLAXOSMITHKLINE 0.044MG/INH

N21433 003 May 14, 2004 May NEWA

0.11MG/INH

N21433 002 May 14, 2004 May NEWA

+ 0.22MG/INH

N21433 001 May 14, 2004 May NEWA

CREAM; TOPICAL

CUTIVATE

AB + GLAXOSMITHKLINE 0.05%

N19958 001 Dec 18, 1990 May CFTG

FLUTICASONE PROPIONATE

AB ALTANA 0.05%

N76451 001 May 14, 2004 May NEWA

AB ATRIX 0.05%

N76633 001 May 14, 2004 May NEWA

AB CLAY PARK 0.05%

N76793 001 May 14, 2004 May NEWA

OINTMENT; TOPICAL

CUTIVATE

AB + GLAXOSMITHKLINE 0.005%

N19957 001 Dec 14, 1990 May CFTG

FLUTICASONE PROPIONATE

AB ALTANA 0.005%

N76300 001 May 14, 2004 May NEWA

AB CLAY PARK 0.005%

N76668 001 May 14, 2004 May NEWA

FOLLITROPIN ALFA/BETA

INJECTABLE; IM-SC

FOLLISTIM

BX ORGANON USA INC 75 IU/VIAL

N20582 001 Sep 29, 1997 Mar CDFR

	INJECTABLE; IM-SC						
	FOLLISTIM						
BX	+ ORGANON USA INC	75 IU/VIAL	N20582 001	Sep 29, 1997	Jun	CTEC	
		150 IU/VIAL	N20582 002	Sep 29, 1997	Mar	CDFR	
	+ +	150 IU/VIAL	N20582 002	Sep 29, 1997	Jun	CTEC	
	INJECTABLE; SUBCUTANEOUS						
	FOLLISTIM AQ						
	ORGANON USA INC	300 IU/0.525ML	N21211 001	Mar 23, 2004	Mar	NEWA	
	+ +	600 IU/0.885ML	N21211 002	Mar 23, 2004	Mar	NEWA	
	GONAL-F						
	SERONO INC	37.5 IU/VIAL	N21765 001	Mar 25, 2004	Mar	NEWA	
	@ @	37.5 IU/VIAL	N21765 001	Mar 25, 2004	May	DISC	
		75 IU/VIAL	N20378 001	Sep 29, 1997	Jun	DISC	
BX		75 IU/VIAL	N20378 001	Sep 29, 1997	Mar	CDFR	
	+ +	75 IU/VIAL	N21765 002	Mar 25, 2004	Jun	CRLD	
		75 IU/VIAL	N21765 002	Mar 25, 2004	Mar	NEWA	
	@ @	150 IU/VIAL	N20378 002	Sep 29, 1997	Jun	DISC	
BX		150 IU/VIAL	N20378 002	Sep 29, 1997	Mar	CDFR	
	+ +	150 IU/VIAL	N21765 003	Mar 25, 2004	Mar	NEWA	
	@ @	150 IU/VIAL	N21765 003	Mar 25, 2004	May	DISC	
		450 IU/VIAL	N20378 005	Mar 26, 2004	Mar	NEWA	
	+ +	1,200 IU/VIAL	N20378 004	Feb 28, 2001	Mar	CAIN	
		1,050 IU/VIAL	N20378 004	Feb 28, 2001	Apr	CPOT	
	GONAL-F RFF PEN						
	SERONO INC	300 IU/0.5ML	N21684 001	May 25, 2004	May	NEWA	
		450 IU/0.75ML	N21684 002	May 25, 2004	May	NEWA	
	+ +	900 IU/1.5ML	N21684 003	May 25, 2004	May	NEWA	

FOMIVIRSEN SODIUM

	INJECTABLE; INJECTION					
	VITRAVENE PRESERVATIVE FREE					
+ +	NOVARTIS	6.6MG/ML	N20961 001	Aug 26, 1998	Jan	CAHN

FONDAPARINUX SODIUM

	INJECTABLE; SUBCUTANEOUS					
	ARIIXTRA					
+ +	FONDA BV	5MG/0.4ML	N21345 002	May 28, 2004	May	NEWA
	+ +	7.5MG/0.6ML	N21345 003	May 28, 2004	May	NEWA
	+ +	10MG/0.8ML	N21345 004	May 28, 2004	May	NEWA

FOSINOPRIL SODIUM

	TABLET; ORAL					
	FOSINOPRIL SODIUM					
AB	EON	10MG	N76483 001	Apr 23, 2004	Apr	NEWA
AB		20MG	N76483 002	Apr 23, 2004	Apr	NEWA
AB		40MG	N76483 003	Apr 23, 2004	Apr	NEWA
AB	RANBAXY	10MG	N76580 001	Apr 23, 2004	Apr	NEWA
AB		20MG	N76580 002	Apr 23, 2004	Apr	NEWA
AB		40MG	N76580 003	Apr 23, 2004	Apr	NEWA

FROVATRIPTAN SUCCINATE

	TABLET; ORAL					
	FROVA					
+ +	VERNALIS	EQ 2.5MG BASE	N21006 001	Nov 08, 2001	May	CAHN

FUROSEMIDE

INJECTABLE; INJECTION

FUROSEMIDE

AP	HOSPIRA	10MG/ML	N18667 001	May 28, 1982	May	CAHN
AP		10MG/ML	N70578 001	Jul 08, 1987	May	CAHN
AP		10MG/ML	N72080 001	Aug 13, 1991	May	CAHN
AP		10MG/ML	N74337 001	Oct 31, 1994	May	CAHN
AP		10MG/ML	N75241 001	May 28, 1999	May	CAHN

TABLET; ORAL

FUROSEMIDE

AB	VINTAGE PHARMS	20MG	N76796 001	Mar 26, 2004	Mar	NEWA
AB		40MG	N76796 002	Mar 26, 2004	Mar	NEWA
AB		80MG	N76796 003	Mar 26, 2004	Mar	NEWA

GABAPENTIN

TABLET; ORAL

GABAPENTIN

IVAX PHARMS	100MG	N76017 001	Apr 28, 2004	Apr	NEWA
	300MG	N76017 002	Apr 28, 2004	Apr	NEWA
	400MG	N76017 003	Apr 28, 2004	Apr	NEWA

GANIRELIX ACETATE

INJECTABLE; INJECTION

GANIRELIX ACETATE INJECTION

+ ORGANON USA INC	EQ 250UGM BASE/0.5ML	N21057 001	Jul 29, 1999	Jun	CTNA
-------------------	----------------------	------------	--------------	-----	------

GEMIFLOXACIN MESYLATE

TABLET; ORAL

FACTIVE

+ OSCIENT	EQ 320MG BASE	N21158 001	Apr 04, 2003	Apr	CAHN
-----------	---------------	------------	--------------	-----	------

GENTAMICIN SULFATE

INJECTABLE; INJECTION

GENTAMICIN SULFATE

AP	HOSPIRA	EQ 10MG BASE/ML	N62420 001	Aug 15, 1983	May	CAHN
AP		EQ 10MG BASE/ML	N62612 004	Feb 20, 1986	May	CAHN
AP		EQ 40MG BASE/ML	N62420 002	Aug 15, 1983	May	CAHN
AP		GENTAMICIN SULFATE IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER				
AP	HOSPIRA	EQ 1.2MG BASE/ML	N62414 001	Aug 15, 1983	May	CAHN
	@	EQ 1.2MG BASE/ML	N62588 001	Jan 06, 1986	May	CAHN
AP		EQ 1.4MG BASE/ML	N62414 002	Aug 15, 1983	May	CAHN
	@	EQ 1.4MG BASE/ML	N62588 002	Jan 06, 1986	May	CAHN
AP		EQ 1.6MG BASE/ML	N62414 003	Aug 15, 1983	May	CAHN
	@	EQ 1.6MG BASE/ML	N62583 003	Jan 06, 1986	May	CAHN
AP		EQ 1.8MG BASE/ML	N62414 004	Aug 15, 1983	May	CAHN
	@	EQ 1.8MG BASE/ML	N62588 004	Jan 06, 1986	May	CAHN
AP		EQ 2MG BASE/ML	N62414 005	Aug 15, 1983	May	CAHN
	@	EQ 2MG BASE/ML	N62588 005	Jan 06, 1986	May	CAHN
AP		EQ 60MG BASE/100ML	N62414 006	Aug 15, 1983	May	CAHN
	@	EQ 60MG BASE/100ML	N62588 006	Jan 06, 1986	May	CAHN
AP		EQ 70MG BASE/100ML	N62414 007	Aug 15, 1983	May	CAHN
	@	EQ 70MG BASE/100ML	N62588 007	Jan 06, 1986	May	CAHN
AP		EQ 80MG BASE/100ML	N62414 008	Aug 15, 1983	May	CAHN
	@	EQ 80MG BASE/100ML	N62588 008	Jan 06, 1986	May	CAHN
AP		EQ 90MG BASE/100ML	N62414 009	Aug 15, 1983	May	CAHN

INJECTABLE; INJECTION

GENTAMICIN SULFATE IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER

AP	@ HOSPIRA	EQ 90MG BASE/100ML	N62588 009	Jan 06, 1986	May CAHN
		EQ 100MG BASE/100ML	N62414 010	Aug 15, 1983	May CAHN
	@	EQ 100MG BASE/100ML	N62588 010	Jan 06, 1986	May CAHN

ointment; opthalmic

GENTAMICIN SULFATE

>D>	+ AKORN	EQ 0.3% BASE	N64093 001	Aug 31, 1995	Jul CFTG
>A>	AT +	EQ 0.3% BASE	N64093 001	Aug 31, 1995	Jul CFTG
>A>	AT ALTANA	EQ 0.3% BASE	N65024 001	Jul 30, 2004	Jul NEWA

solution/drops; opthalmic

GARAMYCIN

AT	+ SCHERRING	EQ 0.3% BASE	N50039 002	Jan	CDFR
	GENTAMICIN SULFATE				
AT	ALTANA	EQ 3% BASE	N65121 001	Jan 30, 2004	Jan NEWA

GLUTAMINEFOR SOLUTION; ORAL

NUTRESTORE

>A>	+ NUTRITIONAL RESTART	5GM/PACKET	N21667 001	Jun 10, 2004	Jul CMS2
		5GM/PACKET	N21677 001	Jun	CMS2

GLYBURIDE; METFORMIN HYDROCHLORIDETABLET; ORAL

GLUCOVANCE

AB	BRISTOL MYERS SQUIBB	1.25MG;250MG	N21178 001	Jul 31, 2000	Feb CFTG
AB		2.5MG;500MG	N21178 002	Jul 31, 2000	Feb CFTG
AB	+	5MG;500MG	N21178 003	Jul 31, 2000	Feb CFTG
	GLYBURIDE AND METFORMIN HCL				
AB	IVAX PHARMS	1.25MG;250MG	N76345 001	Feb 18, 2004	Feb NEWA
AB		2.5MG;500MG	N76345 002	Feb 18, 2004	Feb NEWA
AB		5MG;500MG	N76345 003	Feb 18, 2004	Feb NEWA

GLYCINESOLUTION; IRRIGATION

GLYCINE 1.5% IN PLASTIC CONTAINER

AT	HOSPIRA	1.5GM/100ML	N17633 001	May	CAHN
AT		1.5GM/100ML	N18315 001	May	CAHN

GLYCOPYRROLATEINJECTABLE; INJECTION

GLYCOPYRROLATE

@ HOSPIRA	0.2MG/ML	N89393 001	Jun 15, 1988	May CAHN
-----------	----------	------------	--------------	----------

GONADORELIN HYDROCHLORIDEINJECTABLE; INJECTION

FACTREL

@ BAXTER HLTHCARE CORP	EQ 0.1MG BASE/VIAL	N18123 001	Sep 30, 1982	Jun DISC
------------------------	--------------------	------------	--------------	----------

GRISEOFULVIN, ULTRAMICROCRYSTALLINETABLET; ORAL

FULVICIN P/G

@ SCHERRING	125MG	N61996 001	Jun	DISC
@	250MG	N61996 002	Jun	DISC

FULVICIN P/G 165

@ SCHERRING	165MG	N61996 003	Apr 06, 1982	Jun DISC
-------------	-------	------------	--------------	----------

## TABLET; ORAL

FULVICIN P/G 330 @ SCHERING	330MG	N61996 004 Apr 06, 1982 Jun DISC
GRIS-PEG + PEDINOL	250MG	N50475 002 Jun CRLD

HALAZEPAM

## TABLET; ORAL

PAXIPAM @ SCHERING	20MG	N17736 003 Apr DISC
@	40MG	N17736 004 Apr DISC

HALOPERIDOL DECANOATE

## INJECTABLE; INJECTION

## HALOPERIDOL DECANOATE

@ MAYNE PHARMA USA	EQ 50MG BASE/ML	N75176 001 Feb 09, 2000 Apr CAHN
@	EQ 100MG BASE/ML	N75176 002 Feb 09, 2000 Apr CAHN

HALOTHANE

## LIQUID; INHALATION

## HALOTHANE

AN + HOSPIRA	99.99%	N83254 001 May CAHN
--------------	--------	---------------------

HEPARIN SODIUM

## INJECTABLE; INJECTION

## HEPARIN LOCK FLUSH

AP HOSPIRA	10 UNITS/ML	N05264 001 May CAHN
AP	10 UNITS/ML	N40082 001 Feb 28, 1995 May CAHN
AP	10 UNITS/ML	N88097 001 Apr 28, 1983 May CAHN
AP	10 UNITS/ML	N88346 001 May 18, 1983 May CAHN
@	100 UNITS/ML	N05264 010 May CAHN
AP	100 UNITS/ML	N40082 002 Feb 28, 1995 May CAHN
AP	100 UNITS/ML	N88098 001 Apr 28, 1983 May CAHN
AP	100 UNITS/ML	N88347 001 May 18, 1983 May CAHN

## HEPARIN LOCK FLUSH IN PLASTIC CONTAINER

AP HOSPIRA	10 UNITS/ML	N05264 015 May 21, 1985 May CAHN
AP	100 UNITS/ML	N05264 016 May 21, 1985 May CAHN

## HEPARIN SODIUM

AP + HOSPIRA	2,500 UNITS/ML	N88099 001 Apr 28, 1983 May CAHN
AP	5,000 UNITS/ML	N88100 001 Apr 28, 1983 May CAHN
@	10,000 UNITS/ML	N40095 001 Jul 26, 1996 May CAHN
@ LILLY	10,000 UNITS/ML	N05521 002 Jun DISC

## HEPARIN SODIUM 1,000 UNITS IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER

AP HOSPIRA	200 UNITS/100ML	N18916 010 Jun 23, 1989 May CAHN
HEPARIN SODIUM 10,000 UNITS IN DEXTROSE 5%		

## @ HOSPIRA 10,000 UNITS/100ML

N18911 006 Jan 30, 1985 May CAHN

HEPARIN SODIUM 10,000 UNITS IN DEXTROSE 5% IN PLASTIC CONTAINER		
AP HOSPIRA	10,000 UNITS/100ML	N19339 003 Mar 27, 1985 May CAHN

## HEPARIN SODIUM 10,000 UNITS IN SODIUM CHLORIDE 0.45%

@ HOSPIRA	10,000 UNITS/100ML	N18911 001 Jan 30, 1985 May CAHN
@	10,000 UNITS/100ML	N18916 005 Jan 31, 1984 May CAHN

## HEPARIN SODIUM 10,000 UNITS IN SODIUM CHLORIDE 0.9%

@ HOSPIRA	10,000 UNITS/100ML	N18911 003 Jan 30, 1985 May CAHN
@	10,000 UNITS/100ML	N18916 002 Jan 31, 1984 May CAHN

## HEPARIN SODIUM 12,500 UNITS IN DEXTROSE 5%

@ HOSPIRA	5,000 UNITS/100ML	N18911 007 Jan 30, 1985 May CAHN
-----------	-------------------	----------------------------------

INJECTABLE; INJECTION

HEPARIN SODIUM 12,500 UNITS IN DEXTROSE 5% IN PLASTIC CONTAINER  
 HOSPIRA 5,000 UNITS/100ML N19339 001 Mar 27, 1985 May CAHN  
 HEPARIN SODIUM 12,500 UNITS IN SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER  
 HOSPIRA 5,000 UNITS/100ML N18916 006 Jan 31, 1984 May CAHN  
 HEPARIN SODIUM 12,500 UNITS IN SODIUM CHLORIDE 0.9%  
 @ HOSPIRA 5,000 UNITS/100ML N18911 005 Jan 30, 1985 May CAHN  
 @ 5,000 UNITS/100ML N18916 003 Jan 31, 1984 May CAHN  
 HEPARIN SODIUM 2,000 UNITS IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER  
 AP HOSPIRA 200 UNITS/100ML N18916 011 Jun 23, 1989 May CAHN  
 HEPARIN SODIUM 20,000 UNITS IN DEXTROSE 5% IN PLASTIC CONTAINER  
 AP HOSPIRA 4,000 UNITS/100ML N19805 001 Jan 25, 1989 May CAHN  
 HEPARIN SODIUM 25,000 UNITS IN DEXTROSE 5%  
 @ HOSPIRA 5,000 UNITS/100ML N18911 009 Jan 30, 1985 May CAHN  
 @ 10,000 UNITS/100ML N18911 008 Jan 30, 1985 May CAHN  
 HEPARIN SODIUM 25,000 UNITS IN DEXTROSE 5% IN PLASTIC CONTAINER  
 AP HOSPIRA 5,000 UNITS/100ML N19339 004 Mar 27, 1985 May CAHN  
 AP 5,000 UNITS/100ML N19805 002 Jan 25, 1989 May CAHN  
 AP 10,000 UNITS/100ML N19339 002 Mar 27, 1985 May CAHN  
 HEPARIN SODIUM 25,000 UNITS IN SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER  
 HOSPIRA 5,000 UNITS/100ML N18916 007 Jan 31, 1984 May CAHN  
 10,000 UNITS/100ML N18916 008 Jan 31, 1984 May CAHN  
 HEPARIN SODIUM 25,000 UNITS IN SODIUM CHLORIDE 0.9%  
 @ HOSPIRA 5,000 UNITS/100ML N18911 004 Jan 30, 1985 May CAHN  
 HEPARIN SODIUM 25,000 UNITS IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER  
 @ HOSPIRA 5,000 UNITS/100ML N18916 009 Jan 31, 1984 May CAHN  
 HEPARIN SODIUM 5,000 UNITS IN SODIUM CHLORIDE 0.45%  
 @ HOSPIRA 100 UNITS/ML N18911 002 Jan 30, 1985 May CAHN  
 @ 100 UNITS/ML N18916 004 Jan 31, 1984 May CAHN  
 HEPARIN SODIUM 5,000 UNITS IN SODIUM CHLORIDE 0.9%  
 @ HOSPIRA 1,000 UNITS/100ML N18916 001 Jan 31, 1984 May CAHN  
 HEPARIN SODIUM PRESERVATIVE FREE  
 + HOSPIRA 2,000 UNITS/ML N05264 013 Apr 07, 1986 May CAHN  
 AP + 2,500 UNITS/ML N05264 014 Apr 07, 1986 May CAHN  
 AP + 10,000 UNITS/ML N89522 001 May 04, 1987 May CAHN  
 PANHEPRIN  
 @ HOSPIRA 1,000 UNITS/ML N05264 004 May CAHN  
 @ 5,000 UNITS/ML N05264 006 May CAHN  
 @ 10,000 UNITS/ML N05264 007 May CAHN  
 @ 20,000 UNITS/ML N05264 008 May CAHN  
 @ 40,000 UNITS/ML N05264 009 May CAHN

HYALURONIDASEINJECTABLE; INJECTION

## VITRASE

+ ISTA PHARMS 6,200 UNITS/VIAL N21640 001 May 05, 2004 May NEWA

HYDROCHLOROTHIAZIDE; QUINAPRIL HYDROCHLORIDETABLET; ORAL

## ACCURETIC

AB	PFIZER PHARMS	12.5MG;EQ 10MG BASE	N20125 001 Dec 28, 1999 Mar CFTG
AB		12.5MG;EQ 20MG BASE	N20125 002 Dec 28, 1999 Mar CFTG
AB	+	25MG;EQ 20MG BASE	N20125 003 Dec 28, 1999 Mar CFTG
QUINARETIC			
AB	AMIDE PHARM	12.5MG;EQ 10MG BASE	N76374 001 Mar 31, 2004 Mar NEWA
AB		12.5MG;EQ 20MG BASE	N76374 002 Mar 31, 2004 Mar NEWA
AB		25MG;EQ 20MG BASE	N76374 003 Mar 31, 2004 Mar NEWA

HYDROCHLOROTHIAZIDE; TELMISARTAN

TABLET; ORAL

MICARDIS HCT

BOEHRINGER INGELHEIM 12.5MG;80MG

+ 25MG;80MG

N21162 002 Nov 17, 2000 May CRLD

N21162 003 Apr 19, 2004 May NEWA

HYDROCODONE BITARTRATE; IBUPROFEN

TABLET; ORAL

HYDROCODONE BITARTRATE AND IBUPROFEN

+ INTERPHARM 5MG;200MG

N76642 002 Mar 18, 2004 Mar NEWA

HYDROCORTISONE

CREAM; TOPICAL

HYDROCORTISONE

AT VINTAGE PHARMS 2.5%

N40503 001 Mar 12, 2004 Mar NEWA

HYDROCORTISONE ACETATE; PRAMOXINE HYDROCHLORIDE

AEROSOL, METERED; TOPICAL

HYDROCORTISONE ACETATE 1% AND PRAMOXINE HCL 1%

BX BOCA PHARMA 1%;1%

N89440 001 May 17, 1988 Apr CAHN

HYDROCORTISONE BUTYRATE

SOLUTION; TOPICAL

HYDROCORTISONE BUTYRATE

AT TARO PHARM INDS 0.1%

N76364 001 Jan 14, 2004 Jan NEWA

LOCOID

AT + FERNDALE LABS 0.1%

N19116 001 Feb 25, 1987 Jan CFTG

HYDROCORTISONE SODIUM SUCCINATE

INJECTABLE; INJECTION

A-HYDROCORT

AP HOSPIRA EQ 100MG BASE/VIAL

N85929 001 May CAHN

AP EQ 250MG BASE/VIAL

N85930 001 May CAHN

AP EQ 500MG BASE/VIAL

N85931 001 May CAHN

AP EQ 1GM BASE/VIAL

N85932 001 May CAHN

HYDROMORPHONE HYDROCHLORIDE

INJECTABLE; INJECTION

HYDROMORPHONE HCL

AP HOSPIRA 10MG/ML

N74598 001 Jun 19, 1997 May CAHN

HYDROXYZINE HYDROCHLORIDE

INJECTABLE; INJECTION

HYDROXYZINE HCL

AP HOSPIRA 25MG/ML

N87416 001 May CAHN

@ 50MG/ML

N86821 001 May CAHN

AP 50MG/ML

N87546 001 May CAHN

TABLET; ORAL

HYDROXYZINE HCL

&gt;A&gt; AB ABLE 10MG

N40559 001 Jul 22, 2004 Jul NEWA

&gt;A&gt; AB 25MG

N40562 001 Jul 22, 2004 Jul NEWA

&gt;A&gt; AB 50MG

N40563 001 Jul 22, 2004 Jul NEWA

IDARUBICIN HYDROCHLORIDE

INJECTABLE; INJECTION

IDARUBICIN HCL

+ GENSIA SICOR PHARMS 5MG/VIAL

N65037 003 May 01, 2002 Feb CTEC

INAMRINONE LACTATE

INJECTABLE; INJECTION

AMRINONE

AP + HOSPIRA EQ 5MG BASE/ML

N74616 001 Aug 03, 1998 May CAHN

INSULIN ASPART RECOMBINANT

INJECTABLE; SUBCUTANEOUS

NOVOLOG

+ NOVO NORDISK 100 UNITS/ML

N20986 001 Jun 07, 2000 May CAIN

INSULIN GLARGINE RECOMBINANT

INJECTABLE; INJECTION

LANTUS

+ AVENTIS PHARMS 100 UNITS/ML

N21081 001 Apr 20, 2000 May CAIN

INSULIN GLULISINE RECOMBINANT

INJECTABLE; SUBCUTANEOUS

APIDRA

+ AVENTIS PHARMS 100 UNITS/ML

N21629 001 Apr 16, 2004 Apr NEWA

@ 100 UNITS/ML

N21629 001 Apr 16, 2004 Jun DISC

INSULIN LISPRO PROTAMINE RECOMBINANT; INSULIN LISPRO RECOMBINANT

INJECTABLE; INJECTION

HUMALOG MIX 50/50

+ LILLY 50 UNITS/ML;50 UNITS/ML

N21018 001 Dec 22, 1999 May CAIN

HUMALOG MIX 75/25

+ LILLY 75 UNITS/ML;25 UNITS/ML

N21017 001 Dec 22, 1999 May CAIN

INSULIN LISPRO RECOMBINANT

INJECTABLE; INJECTION

HUMALOG

+ LILLY 100 UNITS/ML

N20563 001 Jun 14, 1996 May CAIN

HUMALOG PEN

+ LILLY 100 UNITS/ML

N20563 002 Aug 06, 1998 May CAIN

IODIXANOL

INJECTABLE; INJECTION

VISIPAQUE 270

GE HEALTHCARE 55%

N20808 001 Aug 29, 1997 Jun CMFD

VISIPAQUE 320

GE HEALTHCARE 65.2%

N20808 002 Aug 29, 1997 Jun CMFD

IOPAMIDOL

INJECTABLE; INJECTION

IOPAMIDOL-200

AP HOSPIRA 41%

N74898 001 Dec 30, 1997 May CAHN

IOPAMIDOL-200 IN PLASTIC CONTAINER

AP HOSPIRA 41%

N74636 001 Dec 30, 1997 May CAHN

IOPAMIDOL-250

AP HOSPIRA 51%

N74898 002 Dec 30, 1997 May CAHN

INJECTABLE; INJECTION

AP	IOPAMIDOL-250 HOSPIRA	51%	N75005 001 Feb 24, 1998 May CAHN
AP	IOPAMIDOL-250 IN PLASTIC CONTAINER HOSPIRA	51%	N74636 002 Dec 30, 1997 May CAHN
AP	IOPAMIDOL-300 HOSPIRA	61%	N74898 003 Dec 30, 1997 May CAHN
AP		61%	N75005 002 Feb 24, 1998 May CAHN
AP	IOPAMIDOL-300 IN PLASTIC CONTAINER HOSPIRA	61%	N74636 003 Dec 30, 1997 May CAHN
AP		61%	N74637 001 Apr 03, 1997 May CAHN
AP	IOPAMIDOL-370 HOSPIRA	76%	N74898 004 Dec 30, 1997 May CAHN
AP		76%	N75005 003 Feb 24, 1998 May CAHN
AP	IOPAMIDOL-370 IN PLASTIC CONTAINER HOSPIRA	76%	N74636 004 Dec 30, 1997 May CAHN

IOPANOIC ACID

TABLET; ORAL TELEPAQUE @ GE HEALTHCARE	500MG	N08032 001	May DISC
--	-------	------------	----------

IOPROMIDE

INJECTABLE; INJECTION ULTRAVIST (PHARMACY BULK)			
+ BERLEX	49.9%	N21425 003 Mar 12, 2004 Mar NEWA	
+	62.3%	N21425 001 Sep 20, 2002 Mar CPOT	
+	76.9%	N21425 002 Sep 20, 2002 Mar CPOT	

IOTHALAMATE MEGLUMINE; IOTHALAMATE SODIUM

INJECTABLE; INJECTION VASCORAY @ MALLINCKRODT	52%;26%	N16783 001	Jun DISC
---	---------	------------	----------

IPRATROPIUM BROMIDE

SOLUTION; INHALATION IPRATROPIUM BROMIDE AN HOLOPACK INTL	0.02%	N75693 001 Jan 26, 2001 Apr CAHN	
---	-------	----------------------------------	--

ISOFLURANE

LIQUID; INHALATION ISOFLURANE AN HOSPIRA	99.9%	N74097 001 Jan 25, 1993 May CAHN	
--	-------	----------------------------------	--

ISONIAZID

INJECTABLE; INJECTION NYDRAZID + SANDOZ	100MG/ML	N08662 001	Feb CAHN
---	----------	------------	----------

ISOPROTERENOL HYDROCHLORIDE

INJECTABLE; INJECTION ISOPROTERENOL HCL AP HOSPIRA	0.02MG/ML 0.2MG/ML	N83283 001 N83346 001	May CAHN May CAHN
AP ISUPREL AP + HOSPIRA	0.2MG/ML	N10515 001	May CAHN

ISOSORBIDE MONONITRATE

TABLET, EXTENDED RELEASE; ORAL

IMDUR

AB	SCHERING PLOUGH	30MG 60MG	N20225 001 Aug 12, 1993 Apr CRLD N20225 002 Aug 12, 1993 Apr CRLD
AB			

ITRACONAZOLE

CAPSULE; ORAL

ITRACONAZOLE

AB	EON	100MG	N76104 001 May 28, 2004 May NEWA
AB	+ JANSSEN PHARMA	100MG	N20083 001 Sep 11, 1992 May CFTG

KETAMINE HYDROCHLORIDE

INJECTABLE; INJECTION

KETAMINE HCL

AP	HOSPIRA	EQ 50MG BASE/ML	N74549 001 Jun 27, 1996 May CAHN
AP		EQ 100MG BASE/ML	N74549 002 Jun 27, 1996 May CAHN

KETOCONAZOLE

CREAM; TOPICAL

KETOCONAZOLE

AB	ALTANA	2%	N76294 001 Apr 28, 2004 Apr NEWA
AB	+ TEVA	2%	N75581 001 Apr 25, 2000 Apr CRLD

NIZORAL

@ JANSSEN PHARMA

2%

N19084 001 Dec 31, 1985 Apr DISC

SHAMPOO; TOPICAL

KETOCONAZOLE

AB	CLAY PARK	2%	N76419 001 Jan 07, 2004 Jan NEWA
AB	+ MCNEIL CONS SPECLT	2%	N19927 001 Aug 31, 1990 Jan CFTG

SUSPENSION; ORAL

NIZORAL

@ JANSSEN

100MG/5ML

N70767 001 Nov 07, 1986 Jul CAHN

100MG/5ML

N70767 001 Nov 07, 1986 Jul CAHN

TABLET; ORAL

NIZORAL

200MG

N18533 001 Jul CAHN

200MG

N18533 001 Jul CAHN

KETOROLAC TROMETHAMINE

INJECTABLE; INJECTION

KETOROLAC TROMETHAMINE

>A>	AP	AMPHASTAR PHARM	15MG/ML 30MG/ML	N76209 001 Jul 21, 2004 Jul NEWA N76209 002 Jul 21, 2004 Jul NEWA
>A>	AP	APOTEX	15MG/ML 30MG/ML	N76722 001 Jul 27, 2004 Jul NEWA N76722 002 Jul 27, 2004 Jul NEWA
>A>	AP	BAXTER HLTHCARE	15MG/ML 30MG/ML	N75772 001 Jul 21, 2004 Jul NEWA N75772 002 Jul 21, 2004 Jul NEWA
>A>	AP	BEDFORD	15MG/ML 30MG/ML	N75222 001 Apr 26, 1999 Jan CRLD N75222 002 Apr 26, 1999 Jan CRLD
	AP	+ HOSPIRA	15MG/ML 15MG/ML 30MG/ML	N74801 001 Jun 05, 1997 May CAHN N74802 001 Jun 05, 1997 May CAHN N74993 001 Jan 27, 1999 May CAHN N74801 002 Jun 05, 1997 May CAHN

INJECTABLE; INJECTION

	IOPAMIDOL-250					
AP	HOSPIRA	51%		N75005	001	Feb 24, 1998 May CAHN
	IOPAMIDOL-250 IN PLASTIC CONTAINER					
AP	HOSPIRA	51%		N74636	002	Dec 30, 1997 May CAHN
	IOPAMIDOL-300					
AP	HOSPIRA	61%		N74898	003	Dec 30, 1997 May CAHN
AP		61%		N75005	002	Feb 24, 1998 May CAHN
	IOPAMIDOL-300 IN PLASTIC CONTAINER					
AP	HOSPIRA	61%		N74636	003	Dec 30, 1997 May CAHN
AP		61%		N74637	001	Apr 03, 1997 May CAHN
	IOPAMIDOL-370					
AP	HOSPIRA	76%		N74898	004	Dec 30, 1997 May CAHN
AP		76%		N75005	003	Feb 24, 1998 May CAHN
	IOPAMIDOL-370 IN PLASTIC CONTAINER					
AP	HOSPIRA	76%		N74636	004	Dec 30, 1997 May CAHN

IOPANOIC ACIDTABLET; ORAL

TELEPAQUE						
@ GE HEALTHCARE	500MG			N08032	001	May DISC

IOPROMIDEINJECTABLE; INJECTION

ULTRAVIST (PHARMACY BULK)						
+ BERLEX	49.9%			N21425	003	Mar 12, 2004 Mar NEWA
+	62.3%			N21425	001	Sep 20, 2002 Mar CPOT
+	76.9%			N21425	002	Sep 20, 2002 Mar CPOT

IOTHALAMATE MEGLUMINE; IOTHALAMATE SODIUMINJECTABLE; INJECTION

VASCORAY						
@ MALLINCKRODT	52%;26%			N16783	001	Jun DISC

IPRATROPIUM BROMIDESOLUTION; INHALATION

IPRATROPIUM BROMIDE						
AN HOLOPACK INTL	0.02%			N75693	001	Jan 26, 2001 Apr CAHN

ISOFLURANELIQUID; INHALATION

ISOFLURANE						
AN HOSPIRA	99.9%			N74097	001	Jan 25, 1993 May CAHN

ISONIAZIDINJECTABLE; INJECTION

NYDRAZID						
+ SANDOZ	100MG/ML			N08662	001	Feb CAHN

ISOPROTERENOL HYDROCHLORIDEINJECTABLE; INJECTION

ISOPROTERENOL HCL						
AP HOSPIRA	0.02MG/ML			N83283	001	May CAHN
	0.2MG/ML			N83346	001	May CAHN
	ISUPREL					
AP + HOSPIRA	0.2MG/ML			N10515	001	May CAHN

ISOSORBIDE MONONITRATE

TABLET, EXTENDED RELEASE; ORAL  
IMDUR

AB	SCHERING PLOUGH	30MG	N20225 001 Aug 12, 1993 Apr CRLD
AB		60MG	N20225 002 Aug 12, 1993 Apr CRLD

ITRACONAZOLE

CAPSULE; ORAL  
ITRACONAZOLE

AB	EON	100MG	N76104 001 May 28, 2004 May NEWA
	SPORANOX		
AB	+ JANSSEN PHARMA	100MG	N20083 001 Sep 11, 1992 May CFTG

KETAMINE HYDROCHLORIDE

INJECTABLE; INJECTION  
KETAMINE HCL

AP	HOSPIRA	EQ 50MG BASE/ML	N74549 001 Jun 27, 1996 May CAHN
AP		EQ 100MG BASE/ML	N74549 002 Jun 27, 1996 May CAHN

KETOCONAZOLE

CREAM; TOPICAL  
KETOCONAZOLE

AB	ALTANA	2%	N76294 001 Apr 28, 2004 Apr NEWA
AB	+ TEVA	2%	N75581 001 Apr 25, 2000 Apr CRLD

NIZORAL  
@ JANSSEN PHARMA

2% N19084 001 Dec 31, 1985 Apr DISC

SHAMPOO; TOPICAL  
KETOCONAZOLE

AB	CLAY PARK	2%	N76419 001 Jan 07, 2004 Jan NEWA
	NIZORAL		

AB	+ MCNEIL CONS SPECLT	2%	N19927 001 Aug 31, 1990 Jan CFTG
----	----------------------	----	----------------------------------

SUSPENSION; ORAL

NIZORAL

>D>	@ JANSSEN	100MG/5ML	N70767 001 Nov 07, 1986 Jul CAHN
-----	-----------	-----------	----------------------------------

>A>	@ JANSSEN PHARMA	100MG/5ML	N70767 001 Nov 07, 1986 Jul CAHN
-----	------------------	-----------	----------------------------------

TABLET; ORAL

NIZORAL

>D> AB	+ JANSSEN	200MG	N18533 001 Jul CAHN
--------	-----------	-------	---------------------

>A> AB	+ JANSSEN PHARMA	200MG	N18533 001 Jul CAHN
--------	------------------	-------	---------------------

KETOROLAC TROMETHAMINE

INJECTABLE; INJECTION

KETOROLAC TROMETHAMINE

>A> AP	AMPHASTAR PHARM	15MG/ML	N76209 001 Jul 21, 2004 Jul NEWA
--------	-----------------	---------	----------------------------------

>A> AP		30MG/ML	N76209 002 Jul 21, 2004 Jul NEWA
--------	--	---------	----------------------------------

>A> AP	APOTEX	15MG/ML	N76722 001 Jul 27, 2004 Jul NEWA
--------	--------	---------	----------------------------------

>A> AP		30MG/ML	N76722 002 Jul 27, 2004 Jul NEWA
--------	--	---------	----------------------------------

>A> AP	BAXTER HLTHCARE	15MG/ML	N75772 001 Jul 21, 2004 Jul NEWA
--------	-----------------	---------	----------------------------------

>A> AP		30MG/ML	N75772 002 Jul 21, 2004 Jul NEWA
--------	--	---------	----------------------------------

AP	+ BEDFORD	15MG/ML	N75222 001 Apr 26, 1999 Jan CRLD
----	-----------	---------	----------------------------------

AP	+	30MG/ML	N75222 002 Apr 26, 1999 Jan CRLD
----	---	---------	----------------------------------

@ HOSPIRA

AP		15MG/ML	N74801 001 Jun 05, 1997 May CAHN
----	--	---------	----------------------------------

AP		15MG/ML	N74802 001 Jun 05, 1997 May CAHN
----	--	---------	----------------------------------

@

		30MG/ML	N74993 001 Jan 27, 1999 May CAHN
--	--	---------	----------------------------------

			N74801 002 Jun 05, 1997 May CAHN
--	--	--	----------------------------------

INJECTABLE; INJECTION

KETOROLAC TROMETHAMINE				
AP HOSPIRA	30MG/ML	N74802	002	Jun 05, 1997 May CAHN
AP	30MG/ML	N74993	002	Jan 27, 1999 May CAHN
TORADOL				
@ ROCHE PALO	15MG/ML	N19698	001	Nov 30, 1989 Jan DISC
@	30MG/ML	N19698	002	Nov 30, 1989 Jan DISC

KETOTIFEN FUMARATESOLUTION/DROPS; OPHTHALMIC

ZADITOR				
+ NOVARTIS	EQ 0.025% BASE	N21066	001	Jul 02, 1999 Feb CAHN

LABETALOL HYDROCHLORIDEINJECTABLE; INJECTIONLABETALOL HCL

AP HOSPIRA	5MG/ML	N75239	001	Nov 29, 1999 May CAHN
AP	5MG/ML	N75240	001	Nov 29, 1999 May CAHN

LAMIVUDINETABLET; ORALEPIVIR

GLAXOSMITHKLINE	150MG	N20564	001	Nov 17, 1995 May CRLD
+	300MG	N20564	003	Jun 24, 2002 May CRLD

LAMOTRIGINETABLET; ORALLAMICTAL

+ GLAXOSMITHKLINE	25MG	N20241	005	Dec 27, 1994 Apr CRLD
	200MG	N20241	003	Dec 27, 1994 Apr CRLD

LANSOPRAZOLE

## &gt;A&gt; FOR SUSPENSION, DELAYED RELEASE; ORAL

## &gt;A&gt; PREVACID

TAP PHARM	15MG/PACKET	N21281	001	May 03, 2001 Jul CDFR
-----------	-------------	--------	-----	-----------------------

+ +	30MG/PACKET	N21281	002	May 03, 2001 Jul CDFR
-----	-------------	--------	-----	-----------------------

## &gt;D&gt; FOR SUSPENSION, EXTENDED RELEASE; ORAL

## &gt;D&gt; PREVACID

TAP PHARM	15MG/PACKET	N21281	001	May 03, 2001 Jul CDFR
-----------	-------------	--------	-----	-----------------------

+ +	30MG/PACKET	N21281	002	May 03, 2001 Jul CDFR
-----	-------------	--------	-----	-----------------------

INJECTABLE; INTRAVENOUSPREVACID IV

+ TAP PHARM	30MG/VIAL	N21566	001	May 27, 2004 May NEWA
-------------	-----------	--------	-----	-----------------------

## &gt;A&gt; TABLET, DELAYED RELEASE, ORALLY DISINTEGRATING; ORAL

## &gt;A&gt; PREVACID

TAP PHARM	15MG	N21428	001	Aug 30, 2002 Jul CDFR
-----------	------	--------	-----	-----------------------

+ +	30MG	N21428	002	Aug 30, 2002 Jul CDFR
-----	------	--------	-----	-----------------------

## &gt;D&gt; TABLET, ORALLY DISINTEGRATING; ORAL

## &gt;D&gt; PREVACID

TAP PHARM	15MG	N21428	001	Aug 30, 2002 Jul CDFR
-----------	------	--------	-----	-----------------------

+ +	30MG	N21428	002	Aug 30, 2002 Jul CDFR
-----	------	--------	-----	-----------------------

LEFLUNOMIDETABLET; ORALARAVA

>D> @ AVENTIS PHARMS	100MG	N20905	003	Sep 10, 1998 Jul CMFD
----------------------	-------	--------	-----	-----------------------

## TABLET; ORAL

ARAVA

&gt;A+ AVENTIS PHARMS 100MG N20905 003 Sep 10, 1998 Jul CMFD

LEUCOVORIN CALCIUM

## INJECTABLE; INJECTION

LEUCOVORIN CALCIUM PRESERVATIVE FREE

>D+ AP BIGMAR	EQ 200MG BASE/VIAL	N40258 001	Feb 26, 1999	Jul	CAHN
>D+ +	EQ 500MG BASE/VIAL	N40286 001	Feb 26, 1999	Jul	CAHN
>A+ AP BIGMAR BIOREN PHARMS	EQ 200MG BASE/VIAL	N40258 001	Feb 26, 1999	Jul	CAHN
>A+ +	EQ 500MG BASE/VIAL	N40286 001	Feb 26, 1999	Jul	CAHN
AP + HOSPIRA	EQ 10MG BASE/ML	N40147 001	Jun 25, 1997	May	CAHN

LEVOBUPIVACAINE HYDROCHLORIDE

## INJECTABLE; INJECTION

CHIROCAINE

@ PURDUE PHARMA LP	EQ 2.5MG BASE/ML	N20997 001	Aug 05, 1999	May	DISC
@	EQ 5MG BASE/ML	N20997 002	Aug 05, 1999	May	DISC
@	EQ 7.5MG BASE/ML	N20997 003	Aug 05, 1999	May	DISC

LEVOCABASTINE HYDROCHLORIDE

## SUSPENSION/DROPS; OPHTHALMIC

LIVOSTIN	
+ NOVARTIS	EQ 0.05% BASE

N20219 001 Nov 10, 1993 Feb CAHN

LEVOFLOXACIN

## SOLUTION/DROPS; OPHTHALMIC

IQUIX	
+ SANTEN	1.5%

N21571 001 Mar 01, 2004 Mar NEWA

LEVONORGESTREL

## TABLET; ORAL

PLAN B	
+ DURAMED	0.75MG

N21045 001 Jul 28, 1999 Feb CAHN

LEVOTHYROXINE SODIUM

## TABLET; ORAL

LEVOLET

>A+ BX VINTAGE	0.025MG	N21137 001	Jun 06, 2003	Jul	CAHN
>A+ BX	0.05MG	N21137 002	Jun 06, 2003	Jul	CAHN
>A+ BX	0.075MG	N21137 003	Jun 06, 2003	Jul	CAHN
>A+ BX	0.088MG	N21137 004	Jun 06, 2003	Jul	CAHN
>A+ BX	0.1MG	N21137 005	Jun 06, 2003	Jul	CAHN
>A+ BX	0.112MG	N21137 006	Jun 06, 2003	Jul	CAHN
>A+ BX	0.125MG	N21137 007	Jun 06, 2003	Jul	CAHN
>A+ BX	0.137MG	N21137 008	Jun 06, 2003	Jul	CAHN
>A+ BX	0.15MG	N21137 009	Jun 06, 2003	Jul	CAHN
>A+ BX	0.175MG	N21137 010	Jun 06, 2003	Jul	CAHN
>A+ BX	0.2MG	N21137 011	Jun 06, 2003	Jul	CAHN
>A+ BX	0.3MG	N21137 012	Jun 06, 2003	Jul	CAHN
>D+ BX VINTAGE PHARMS	0.025MG	N21137 001	Jun 06, 2003	Jul	CAHN
>D+ BX	0.05MG	N21137 002	Jun 06, 2003	Jul	CAHN
>D+ BX	0.075MG	N21137 003	Jun 06, 2003	Jul	CAHN
>D+ BX	0.088MG	N21137 004	Jun 06, 2003	Jul	CAHN
>D+ BX	0.1MG	N21137 005	Jun 06, 2003	Jul	CAHN
>D+ BX	0.112MG	N21137 006	Jun 06, 2003	Jul	CAHN

TABLET; ORAL  
LEVOLET

>D>	BX	VINTAGE PHARMS	0.125MG	N21137 007 Jun 06, 2003 Jul CAHN
>D>	BX		0.137MG	N21137 008 Jun 06, 2003 Jul CAHN
>D>	BX		0.15MG	N21137 009 Jun 06, 2003 Jul CAHN
>D>	BX		0.175MG	N21137 010 Jun 06, 2003 Jul CAHN
>D>	BX		0.2MG	N21137 011 Jun 06, 2003 Jul CAHN
>D>	BX		0.3MG	N21137 012 Jun 06, 2003 Jul CAHN
LEVO-T				
AB2,		ALARA PHARM	0.025MG	N21342 001 Mar 01, 2002 Jun CTEC
AB3,			0.05MG	N21342 002 Mar 01, 2002 Jun CTEC
AB2,			0.075MG	N21342 003 Mar 01, 2002 Jun CTEC
AB2,			0.088MG	N21342 004 Mar 01, 2002 Jun CTEC
AB2,			0.1MG	N21342 005 Mar 01, 2002 Jun CTEC
AB2,			0.112MG	N21342 006 Mar 01, 2002 Jun CTEC
AB2,			0.125MG	N21342 007 Mar 01, 2002 Jun CTEC
AB2,			0.137MG	N21342 012 Dec 08, 2003 Jun CTEC
AB2,			0.15MG	N21342 008 Mar 01, 2002 Jun CTEC
AB2,			0.175MG	N21342 009 Mar 01, 2002 Jun CTEC
AB2,			0.2MG	N21342 010 Mar 01, 2002 Jun CTEC
AB2,			0.3MG	N21342 011 Mar 01, 2002 Jun CTEC
AB2, +				
AB3				
LEVOTHYROXINE SODIUM				
AB1,		MYLAN	0.025MG	N76187 001 Jun 05, 2002 Jun CTEC
AB2,			0.05MG	N76187 002 Jun 05, 2002 Jun CTEC
AB3				
AB1,			0.075MG	N76187 003 Jun 05, 2002 Jun CTEC
AB2,			0.088MG	N76187 004 Jun 05, 2002 Jun CTEC
AB3			0.1MG	N76187 005 Jun 05, 2002 Jun CTEC
AB1,			0.112MG	N76187 006 Jun 05, 2002 Jun CTEC
AB2,			0.125MG	N76187 007 Jun 05, 2002 Jun CTEC
AB3			0.15MG	N76187 008 Jun 05, 2002 Jun CTEC
AB1,			0.175MG	N76187 009 Jun 05, 2002 Jun CTEC
AB2,			0.2MG	N76187 010 Jun 05, 2002 Jun CTEC
AB3			0.3MG	N76187 011 Jun 05, 2002 Jun CTEC
LEVOXYL				
AB1,		JONES PHARMA	0.025MG	N21301 001 May 25, 2001 Jun CTE
AB3				

## TABLET; ORAL

## LEVOXYL

JONES PHARMA

0.05MG

N21301 002 May 25, 2001 Jun CTEC

AB1, 0.075MG

N21301 003 May 25, 2001 Jun CTEC

AB1, 0.088MG

N21301 004 May 25, 2001 Jun CTEC

AB1, 0.1MG

N21301 005 May 25, 2001 Jun CTEC

AB1, 0.112MG

N21301 006 May 25, 2001 Jun CTEC

AB1, 0.125MG

N21301 007 May 25, 2001 Jun CTEC

AB1, 0.137MG

N21301 008 May 25, 2001 Jul CTEC

&gt;D&gt; AB1, 0.137MG

N21301 008 May 25, 2001 Jul CTEC

&gt;D&gt; AB3 0.137MG

N21301 008 May 25, 2001 Jun CTEC

&gt;A&gt; AB3 0.137MG

N21301 009 May 25, 2001 Jun CTEC

AB1, 0.15MG

N21301 010 May 25, 2001 Jun CTEC

AB1, 0.175MG

N21301 011 May 25, 2001 Jun CTEC

AB1, 0.2MG

N21301 012 May 25, 2001 Jun CTEC

AB1, + 0.3MG

N21301 012 May 25, 2001 Jun CTEC

## SYNTHROID

ABBOTT

0.025MG

N21402 001 Jul 24, 2002 Jun CFTG

AB2 0.05MG

N21402 002 Jul 24, 2002 Jun CFTG

AB2 0.075MG

N21402 003 Jul 24, 2002 Jun CFTG

AB2 0.088MG

N21402 004 Jul 24, 2002 Jun CFTG

AB2 0.1MG

N21402 005 Jul 24, 2002 Jun CFTG

AB2 0.112MG

N21402 006 Jul 24, 2002 Jun CFTG

AB2 0.125MG

N21402 007 Jul 24, 2002 Jun CFTG

AB2 0.137MG

N21402 008 Jul 24, 2002 Jun CFTG

AB2 0.15MG

N21402 009 Jul 24, 2002 Jun CFTG

AB2 0.175MG

N21402 010 Jul 24, 2002 Jun CFTG

AB2 0.2MG

N21402 012 Jul 24, 2002 Jun CFTG

AB2 + 0.3MG

N21402 011 Jul 24, 2002 Jun CFTG

## UNITHROID

STEVENS J

0.025MG

N21210 001 Aug 21, 2000 Jun CTEC

AB1, 0.05MG

N21210 002 Aug 21, 2000 Jun CTEC

AB1, 0.075MG

N21210 003 Aug 21, 2000 Jun CTEC

AB1, 0.088MG

N21210 004 Aug 21, 2000 Jun CTEC

AB1, 0.1MG

N21210 005 Aug 21, 2000 Jun CTEC

AB1, 0.112MG

N21210 006 Aug 21, 2000 Jun CTEC

AB1, 0.125MG

N21210 007 Aug 21, 2000 Jun CTEC

AB1, 0.15MG

N21210 008 Aug 21, 2000 Jun CTEC

AB1, 0.175MG

N21210 009 Aug 21, 2000 Jun CTEC

AB1, 0.2MG

N21210 010 Aug 21, 2000 Jun CTEC

AB1, + 0.3MG

N21210 011 Aug 21, 2000 Jun CTEC

LIDOCAINE HYDROCHLORIDE

## INJECTABLE; INJECTION

## LIDOCAINE HCL

AP	HOSPIRA	0.5%	N88328 001	May 17, 1984	May	CAHN
AP		1%	N40013 001	Jun 23, 1995	May	CAHN
AP		1%	N83158 001		May	CAHN
AP		1%	N88329 001	May 17, 1984	May	CAHN
	@	1.5%	N88330 001	May 17, 1984	May	CAHN
AP		2%	N40078 001	Jun 23, 1995	May	CAHN
AP		2%	N83158 002		May	CAHN
AP		2%	N88294 001	May 17, 1984	May	CAHN
AP		2%	N88331 001	May 17, 1984	May	CAHN
AP		20%	N83158 003		May	CAHN
	LIDOCAINE HCL 0.2% AND DEXTROSE 5% IN PLASTIC CONTAINER					
	@ B BRAUN	200MG/100ML	N18967 001	Mar 30, 1984	Apr	DISC
	LIDOCAINE HCL 0.2% IN DEXTROSE 5%					
AP	HOSPIRA	200MG/100ML	N83158 005		May	CAHN
	LIDOCAINE HCL 0.2% IN DEXTROSE 5% IN PLASTIC CONTAINER					
AP	HOSPIRA	200MG/100ML	N18388 001		May	CAHN
	LIDOCAINE HCL 0.4% AND DEXTROSE 5% IN PLASTIC CONTAINER					
	@ B BRAUN	400MG/100ML	N18967 002	Mar 30, 1984	Apr	DISC
	LIDOCAINE HCL 0.4% IN DEXTROSE 5%					
AP	HOSPIRA	400MG/100ML	N83158 006		May	CAHN
	LIDOCAINE HCL 0.4% IN DEXTROSE 5% IN PLASTIC CONTAINER					
AP	HOSPIRA	400MG/100ML	N18388 002		May	CAHN
	LIDOCAINE HCL 0.8% AND DEXTROSE 5% IN PLASTIC CONTAINER					
	@ B BRAUN	800MG/100ML	N18967 003	Mar 30, 1984	Apr	DISC
	LIDOCAINE HCL 0.8% IN DEXTROSE 5% IN PLASTIC CONTAINER					
AP	HOSPIRA	800MG/100ML	N18388 003	Nov 05, 1982	May	CAHN
	LIDOCAINE HCL IN PLASTIC CONTAINER					
AP	HOSPIRA	0.5%	N88325 001	Jul 31, 1984	May	CAHN
AP		1%	N88299 001	Jul 31, 1984	May	CAHN
AP		1.5%	N88326 001	Jul 31, 1984	May	CAHN
AP		2%	N88327 001	Jul 31, 1984	May	CAHN
AP		10%	N88367 001	Jul 31, 1984	May	CAHN
AP		20%	N88368 001	Jul 31, 1984	May	CAHN
	LIDOCAINE HCL PRESERVATIVE FREE					
AP	HOSPIRA	1%	N80408 001		May	CAHN
AP		1.5%	N80408 002		May	CAHN
AP		4%	N88295 001	May 17, 1984	May	CAHN
	LIDOCAINE HCL PRESERVATIVE FREE IN PLASTIC CONTAINER					
AP	HOSPIRA	1%	N40302 001	Sep 28, 1998	May	CAHN
AP		2%	N40302 002	Sep 28, 1998	May	CAHN
	INJECTABLE; SPINAL					
	LIDOCAINE HCL 5% AND DEXTROSE 7.5%					
+	HOSPIRA	5%	N83914 001		May	CAHN
	SOLUTION; TOPICAL					
	LTA II KIT					
AT	HOSPIRA	4%	N80409 001		May	CAHN
AT		4%	N88542 001	Jul 31, 1984	May	CAHN
	PEDIATRIC LTA KIT					
AT	HOSPIRA	2%	N85995 001		May	CAHN

LIDOCAINE HYDROCHLORIDE; OXYTETRACYCLINE

INJECTABLE; INJECTION

TERRAMYCIN

+ PFIZER	2%;50MG/ML	N60567 001	Feb	CRLD
+	2%;125MG/ML	N60567 002	Feb	CRLD

LITHIUM CARBONATE

CAPSULE; ORAL

LITHIUM CARBONATE

AB ABLE	150MG	N76823 001	Jun 29, 2004	Jun	NEWA
AB	300MG	N76823 002	Jun 29, 2004	Jun	NEWA
AB	600MG	N76823 003	Jun 29, 2004	Jun	NEWA
AB + ROXANE	600MG	N17812 003	Jan 28, 1987	Jun	CFTG
TABLET, EXTENDED RELEASE; ORAL					
LITHIUM CARBONATE					
AB ROXANE	450MG	N76691 001	Jan 05, 2004	Jan	NEWA

LOPERAMIDE HYDROCHLORIDE

SOLUTION; ORAL

IMODIUM

>D@ JANSSEN	1MG/5ML	N19037 001	Jul 31, 1984	Jul	CAHN
>A@ JANSSEN PHARMA	1MG/5ML	N19037 001	Jul 31, 1984	Jul	CAHN

LORAZEPAM

INJECTABLE; INJECTION

LORAZEPAM

AP HOSPIRA	2MG/ML	N74243 001	Apr 12, 1994	May	CAHN
AP	2MG/ML	N74280 001	May 27, 1994	May	CAHN
AP	2MG/ML	N74282 001	May 27, 1994	May	CAHN
AP	2MG/ML	N74300 001	Apr 12, 1994	May	CAHN
AP	4MG/ML	N74243 002	Apr 12, 1994	May	CAHN
AP	4MG/ML	N74280 002	May 27, 1994	May	CAHN
AP	4MG/ML	N74282 002	May 27, 1994	May	CAHN
AP	4MG/ML	N74300 003	Mar 19, 1997	May	CAHN

LOVASTATIN

TABLET, EXTENDED RELEASE; ORAL

>D@ ALTOCOR	10MG	N21316 001	Jun 26, 2002	Jul	CTNA
>D@ ANDRX	20MG	N21316 002	Jun 26, 2002	Jul	CTNA
>D@	40MG	N21316 003	Jun 26, 2002	Jul	CTNA
>D@ +	60MG	N21316 004	Jun 26, 2002	Jul	CTNA
>A@ ALTOPREV					
>A@ ANDRX	10MG	N21316 001	Jun 26, 2002	Jul	CTNA
>A@	20MG	N21316 002	Jun 26, 2002	Jul	CTNA
>A@	40MG	N21316 003	Jun 26, 2002	Jul	CTNA
>A@ +	60MG	N21316 004	Jun 26, 2002	Jul	CTNA

LOVASTATIN; NIACIN

TABLET, EXTENDED RELEASE; ORAL

ADVICOR

+ KOS	20MG;500MG	N21249 001	Dec 17, 2001	Feb	CRLD
+	20MG;750MG	N21249 002	Dec 17, 2001	Jul	DISC
@	20MG;750MG	N21249 002	Dec 17, 2001	Jul	DISC
+	20MG;750MG	N21249 002	Dec 17, 2001	Feb	CRLD

MAGNESIUM CHLORIDE; POTASSIUM CHLORIDE; SODIUM ACETATE; SODIUM CHLORIDE; SODIUM GLUCONATE

## INJECTABLE; INJECTION

## NORMOSOL-R IN PLASTIC CONTAINER

HOSPIRA	30MG/100ML;37MG/100ML;222MG/100ML ;526MG/100ML;502MG/100ML	N17586 001	May CAHN
---------	---	------------	----------

## SOLUTION; IRRIGATION

## PHYSIOSOL IN PLASTIC CONTAINER

@ HOSPIRA	14MG/100ML;37MG/100ML;222MG/100ML ;526MG/100ML;502MG/100ML	N18406 001	May CAHN
	30MG/100ML;37MG/100ML;222MG/100ML ;526MG/100ML;502MG/100ML	N17637 002	Jul 08, 1982 May CAHN

## PHYSIOSOL PH 7.4 IN PLASTIC CONTAINER

HOSPIRA	30MG/100ML;37MG/100ML;222MG/100ML ;526MG/100ML;502MG/100ML	N18406 002	Jul 08, 1982 May CAHN
---------	---	------------	-----------------------

MAGNESIUM SULFATE

## INJECTABLE; INJECTION

## MAGNESIUM SULFATE

AP HOSPIRA	500MG/ML	N75151 001	Apr 25, 2000 May CAHN
MAGNESIUM SULFATE IN DEXTROSE 5% IN PLASTIC CONTAINER			
+ HOSPIRA	1GM/100ML	N20488 001	Jul 11, 1995 May CAHN
+ HOSPIRA	2GM/100ML	N20488 002	Jul 11, 1995 May CAHN
MAGNESIUM SULFATE IN PLASTIC CONTAINER			
+ HOSPIRA	80MG/ML	N20309 002	Jun 24, 1994 May CAHN
+ HOSPIRA	4GM/100ML	N20309 001	Jun 24, 1994 May CAHN

MALATHION

## LOTION; TOPICAL

## OVIDE

+ TARO PHARMS NORTH	0.5%	N18613 001	Aug 02, 1982 Jun CAHN
---------------------	------	------------	-----------------------

MANGANESE CHLORIDE

## INJECTABLE; INJECTION

## MANGANESE CHLORIDE IN PLASTIC CONTAINER

HOSPIRA	EQ 0.1MG MANGANESE/ML	N18962 001	Jun 26, 1986 May CAHN
---------	-----------------------	------------	-----------------------

MANNITOL

## INJECTABLE; INJECTION

## MANNITOL 10%

@ HOSPIRA	10GM/100ML	N16269 002	May CAHN
-----------	------------	------------	----------

## MANNITOL 10% IN PLASTIC CONTAINER

AP HOSPIRA	10GM/100ML	N19603 002	Jan 08, 1987 May CAHN
------------	------------	------------	-----------------------

## MANNITOL 15%

@ HOSPIRA	15GM/100ML	N16269 003	May CAHN
-----------	------------	------------	----------

## MANNITOL 15% IN PLASTIC CONTAINER

AP HOSPIRA	15GM/100ML	N19603 003	Jan 08, 1990 May CAHN
------------	------------	------------	-----------------------

## MANNITOL 20%

@ HOSPIRA	20GM/100ML	N16269 004	May CAHN
-----------	------------	------------	----------

## MANNITOL 20% IN PLASTIC CONTAINER

AP HOSPIRA	20GM/100ML	N19603 004	Jan 08, 1990 May CAHN
------------	------------	------------	-----------------------

## MANNITOL 25%

@ HOSPIRA	12.5GM/50ML	N16269 005	May CAHN
-----------	-------------	------------	----------

AP HOSPIRA	12.5GM/50ML	N16269 006	Aug 25, 1994 May CAHN
------------	-------------	------------	-----------------------

## MANNITOL 5%

@ HOSPIRA	5GM/100ML	N16269 001	May CAHN
-----------	-----------	------------	----------

## MANNITOL 5% IN PLASTIC CONTAINER

AP HOSPIRA	5GM/100ML	N19603 001	Jan 08, 1987 May CAHN
------------	-----------	------------	-----------------------

MANNITOL; SORBITOL

SOLUTION; IRRIGATION

SORBITOL-MANNITOL

@ HOSPIRA	540MG/100ML; 2.7GM/100ML	N80224 001	May CAHN
SORBITOL-MANNITOL IN PLASTIC CONTAINER			
AT HOSPIRA	540MG/100ML; 2.7GM/100ML	N17636 001	May CAHN
AT	540MG/100ML; 2.7GM/100ML	N18316 001	May CAHN

MAPROTILINE HYDROCHLORIDE

TABLET; ORAL

LUDIOMIL

@ NOVARTIS	25MG	N17543 001	Jun DISC
@	50MG	N17543 002	Jun DISC
@	75MG	N17543 003 Sep 30, 1982	Jun DISC
MAPROTILINE HCL			
AB + MYLAN	50MG	N72285 001 Oct 03, 1988	Jun CRLD

MEDROXYPROGESTERONE ACETATE

INJECTABLE; INJECTION

DEPO-PROVERA

>D>	+ PHARMACIA AND UPJOHN	150MG/ML	N20246 001 Oct 29, 1992	Jul CFTG
>A> AB	+	150MG/ML	N20246 001 Oct 29, 1992	Jul CFTG
>A> MEDROXYPROGESTERONE ACETATE				
>A> AB	GENSIA SICOR PHARMS	150MG/ML	N76553 001 Jul 28, 2004	Jul NEWA

MELOXICAM

SUSPENSION; ORAL

MOBIC

+ BOEHRINGER INGELHEIM	7.5MG/5ML	N21530 001 Jun 01, 2004	Jun NEWA
------------------------	-----------	-------------------------	----------

MENOTROPINS (FSH; LH)

INJECTABLE; INJECTION

PERGONAL

@ SERONO	75 IU/AMP; 75 IU/AMP	N17646 001	May DISC
+ FERRING	75 IU/VIAL; 75 IU/VIAL	N21047 001 Aug 27, 1999	May CTEC

MEPERIDINE HYDROCHLORIDE

INJECTABLE; INJECTION

DEMEROL

AP + HOSPIRA	25MG/ML	N21171 001	May CAHN
AP +	50MG/ML	N21171 002	May CAHN
AP +	75MG/ML	N21171 003	May CAHN
AP +	100MG/ML	N21171 004	May CAHN
MEPERIDINE HCL PRESERVATIVE FREE			
AP + HOSPIRA	10MG/ML	N88432 001 Aug 16, 1984	May CAHN

MEPIVACAINE HYDROCHLORIDE

INJECTABLE; INJECTION

CARBOCAINE

AP + HOSPIRA	1%	N12250 001	May CAHN
AP +	1.5%	N12250 005	May CAHN
AP +	2%	N12250 002	May CAHN

MERCAPTOPURINE

TABLET; ORAL				
MERCAPTOPURINE				
AB PROMETHEUS LABS	50MG	N40461	001	Feb 11, 2004
AB ROXANE	50MG	N40528	001	Feb 13, 2004
PURINETHOL				
AB + TEVA	50MG	N09053	002	Feb CPTG

MESNA

INJECTABLE; INTRAVENOUS				
MESNA				
AP BEDFORD	100MG/ML	N75739	001	Jan 09, 2004

MESORIDAZINE BESYLATE

CONCENTRATE; ORAL				
SERENTIL				
@ NOVARTIS	EQ 25MG BASE/ML	N16997	001	May DISC
TABLET; ORAL				
SERENTIL				
@ NOVARTIS	EQ 25MG BASE	N16774	002	May DISC
@	EQ 100MG BASE	N16774	004	May DISC

METFORMIN HYDROCHLORIDE

TABLET, EXTENDED RELEASE; ORAL				
FORTAMET				
BX ANDRX	500MG	N21574	001	Apr 27, 2004
+	1GM	N21574	002	Apr 27, 2004
GLUCOPHAGE XR				
AB BRISTOL MYERS SQUIBB	500MG	N21202	001	Oct 13, 2000
METFORMIN HCL				
AB ANDRX PHARMS	500MG	N76172	001	Jun 16, 2004
>A> AB IMPAX LABS	500MG	N76249	001	Jul 30, 2004
AB IVAX PHARMS	500MG	N76545	001	Dec 01, 2003
AB RANBAXY	500MG	N76413	001	Jun 18, 2004
AB TEVA	500MG	N76269	001	Jun 18, 2004

METHADONE HYDROCHLORIDE

TABLET; ORAL				
METHADONE HCL				
AA MALLINCKRODT	5MG	N40517	001	Apr 27, 2004
AA	10MG	N40517	002	Apr 27, 2004

METHAMPHETAMINE HYDROCHLORIDE

TABLET; ORAL				
DESOXYN				
AB + OVATION PHARMS	5MG	N05378	002	Feb CPTG
METHAMPHETAMINE HCL				
AB ABLE	5MG	N40529	001	Feb 25, 2004

METHIMAZOLE

TABLET; ORAL				
TAPAZOLE				
AB KING PHARMS	5MG	N07517	002	Mar CAHN
AB *	10MG	N07517	004	Mar CAHN

METHOTREXATE SODIUM

INJECTABLE; INJECTION

METHOTREXATE

>D>	AP	BIGMAR	EQ 25MG BASE/ML	N40263 001	Feb 26, 1999	Jul	CAHN
>A>	AP	BIGMAR BIOREN PHARMS	EQ 25MG BASE/ML	N40263 001	Feb 26, 1999	Jul	CAHN
		METHOTREXATE PRESERVATIVE FREE					
>D>	AP	BIGMAR	EQ 25MG BASE/ML	N40265 001	Feb 26, 1999	Jul	CAHN
>D>	AP		EQ 1GM BASE/VIAL	N40266 001	Feb 26, 1999	Jul	CAHN
>A>	AP	BIGMAR BIOREN PHARMS	EQ 25MG BASE/ML	N40265 001	Feb 26, 1999	Jul	CAHN
>A>	AP		EQ 1GM BASE/VIAL	N40266 001	Feb 26, 1999	Jul	CAHN

METHYL AMINOLEVULINATE HYDROCHLORIDE

>A>		CREAM; TOPICAL					
>A>		METHYL AMINOLEVULINATE					
>A>	+	PHOTOCURE ASA	16.8%	N21415 001	Jul 27, 2004	Jul	NEWA

METHYLDOPA

TABLET; ORAL

METHYLDOPA

@ ACCORD HEALTH

AB		125MG	N70070 003	Oct 15, 1985	Jun	CAHN
AB		250MG	N70084 001	Oct 15, 1985	Jun	CAHN
AB		500MG	N70085 001	Oct 15, 1985	Jun	CAHN

METHYLDOPATE HYDROCHLORIDE

INJECTABLE; INJECTION

METHYLDOPATE HCL

AP	HOSPIRA	50MG/ML	N70698 001	Jun 15, 1987	May	CAHN
AP		50MG/ML	N70699 001	Jun 15, 1987	May	CAHN

METHYLPHENIDATE HYDROCHLORIDE

CAPSULE, EXTENDED RELEASE; ORAL

METADATE CD

BX	CELLTECH PHARMS	10MG	N21259 003	May 27, 2003	May	CTEC
	RITALIN LA					
	NOVARTIS	10MG	N21284 004	Apr 10, 2004	Apr	NEWA

BX		10MG	N21284 004	Apr 10, 2004	May	CTEC
----	--	------	------------	--------------	-----	------

METHYLPREDNISOLONE SODIUM SUCCINATE

INJECTABLE; INJECTION

A-METHAPRED

AP	HOSPIRA	EQ 40MG BASE/VIAL	N85853 001		May	CAHN	
AP		EQ 125MG BASE/VIAL	N85855 001		May	CAHN	
AP		EQ 500MG BASE/VIAL	N85854 001		May	CAHN	
AP		EQ 500MG BASE/VIAL	N89173 001	Aug 18, 1987	May	CAHN	
AP		EQ 1GM BASE/VIAL	N85852 001		May	CAHN	
AP		EQ 1GM BASE/VIAL	N89174 001	Aug 18, 1987	May	CAHN	
	METHYLPREDNISOLONE SODIUM SUCCINATE						
>A>	AP	AM PHARM	EQ 40MG BASE/VIAL	N40583 001	Jul 30, 2004	Jul	NEWA
>A>	AP		EQ 125MG BASE/VIAL	N40583 002	Jul 30, 2004	Jul	NEWA

METOCLOPRAMIDE HYDROCHLORIDE

INJECTABLE; INJECTION

METOCLOPRAMIDE HCL

AP	HOSPIRA	EQ 5MG BASE/ML	N70505 001	Jun 23, 1989	May	CAHN
	@	EQ 5MG BASE/ML	N70506 001	Jun 22, 1989	May	CAHN

INJECTABLE; INJECTION

METOCLOPRAMIDE HCL

AP	HOSPIRA	EQ 5MG BASE/ML
AP		EQ 5MG BASE/ML
AP		EQ 5MG BASE/ML

N73117 001	Jan 17, 1991	May CAHN
N73118 001	Jan 17, 1991	May CAHN
N74147 001	Aug 02, 1996	May CAHN

METOLAZONE

TABLET; ORAL

METOLAZONE

AB	ROXANE	10MG
AB	TEVA	2.5MG
AB		5MG
>A> AB	WATSON LABS	10MG
	MYKROX	
	@ CELLTECH PHARMS	0.5MG

N76482 002	Apr 29, 2004	Apr NEWA
N76600 001	Jan 06, 2004	Jan NEWA
N76833 001	Mar 01, 2004	Mar NEWA
N76891 001	Jul 21, 2004	Jul NEWA
N19532 001	Oct 30, 1987	Jan DISC

METOPROLOL TARTRATE

INJECTABLE; INJECTION

METOPROLOL TARTRATE

AP	HOSPIRA	1MG/ML
AP		1MG/ML

N74133 001	Dec 21, 1993	May CAHN
N75160 001	Jul 06, 1998	May CAHN

TABLET; ORAL

LOPRESSOR

AB	NOVARTIS	100MG
	METOPROLOL TARTRATE	
AB	CARACO	25MG
		25MG
AB	MYLAN	25MG
+		25MG
AB		50MG
AB	+	100MG
AB		100MG

N17963 002	Mar	CRLD
N76670 001	Jan 15, 2004	Mar CTEC
N76670 001	Jan 15, 2004	Jan NEWA
N76704 001	Jan 16, 2004	Mar CTEC
N76704 001	Jan 16, 2004	Jan NEWA
N76704 002	Jan 16, 2004	Jan NEWA
N76704 003	Jan 16, 2004	Mar CRLD
N76704 003	Jan 16, 2004	Jan NEWA

METRONIDAZOLE

CAPSULE; ORAL

METRONIDAZOLE

AB	KALI LABS	375MG
----	-----------	-------

N76522 001	Jan 29, 2004	Jan NEWA
------------	--------------	----------

CREAM; TOPICAL

METROCREAM

AB	+ GALDERMA LABS LP	0.75%
----	--------------------	-------

N20531 001	Sep 20, 1995	May CFTG
------------	--------------	----------

METRONIDAZOLE

AB	ALTANA	0.75%
----	--------	-------

N76408 001	May 28, 2004	May NEWA
------------	--------------	----------

INJECTABLE; INJECTION

METRONIDAZOLE IN PLASTIC CONTAINER

AP	+ HOSPIRA	500MG/100ML
----	-----------	-------------

N18890 002	Nov 18, 1983	May CAHN
------------	--------------	----------

MICONAZOLE

INJECTABLE; INJECTION

MONISTAT

>D>	@ JANSSEN	10MG/ML
>A>	@ JANSSEN PHARMA	10MG/ML

N18040 001	Jul	CAHN
------------	-----	------

N18040 001	Jul	CAHN
------------	-----	------

MIDAZOLAM HYDROCHLORIDE

INJECTABLE; INJECTION

MIDAZOLAM HCL

@ HOSPIRA

EQ 1MG BASE/ML

N75293 001	Jun 20, 2000	May DISC
------------	--------------	----------

INJECTABLE; INJECTION

## MIDAZOLAM HCL

AP	HOSPIRA	EQ 1MG BASE/ML	N75409 002	Jun 20, 2000	May	CAHN
AP		EQ 1MG BASE/ML	N75856 001	Jun 13, 2002	May	CAHN
AP	+	EQ 1MG BASE/ML	N75857 001	Jul 22, 2002	May	CAHN
	@	EQ 5MG BASE/ML	N75293 002	Jun 20, 2000	May	DISC
AP		EQ 5MG BASE/ML	N75409 001	Jun 20, 2000	May	CAHN
AP		EQ 5MG BASE/ML	N75856 002	Jun 13, 2002	May	CAHN
AP	+	EQ 5MG BASE/ML	N75857 002	Jul 22, 2002	May	CAHN
>A>	AP	INTL MEDICATION	N76020 001	Jul 16, 2004	Jul	NEWA
>A>	AP		N76020 002	Jul 16, 2004	Jul	NEWA

MIDODRINE HYDROCHLORIDE

## TABLET; ORAL

## MIDODRINE HCL

>A>	AB	EON	10MG	N76514 003	Jul 02, 2004	Jul	NEWA
	AB	IMPAK PHARMS	2.5MG	N76449 001	May 27, 2004	May	NEWA
	AB		5MG	N76449 002	May 27, 2004	May	NEWA

MILRINONE LACTATE

## INJECTABLE; INJECTION

## MILRINONE LACTATE

AP	HOSPIRA	EQ 1MG BASE/ML	N75884 001	May 28, 2002	May	CAHN
AP	MILRINONE LACTATE IN DEXTROSE 5% IN PLASTIC CONTAINER	EQ 20MG BASE/100ML	N75885 001	May 28, 2002	May	CAHN

MINOCYCLINE HYDROCHLORIDE

## TABLET; ORAL

## MINOCYCLINE HCL

AB	MEDICIS	EQ 50MG BASE	N65131 001	Apr 16, 2003	Jan	CFTG
AB		EQ 75MG BASE	N65131 002	Apr 16, 2003	Jan	CFTG
AB	+	EQ 100MG BASE	N65131 003	Apr 16, 2003	Jan	CFTG
AB	RANBAXY	EQ 50MG BASE	N65156 001	Jan 06, 2004	Jan	NEWA
AB		EQ 75MG BASE	N65156 002	Jan 06, 2004	Jan	NEWA
AB		EQ 100MG BASE	N65156 003	Jan 06, 2004	Jan	NEWA

MIRTAZAPINE

## TABLET; ORAL

## MIRTAZAPINE

AB	CARACO	7.5MG	N76541 004	Apr 22, 2004	Apr	NEWA
AB		15MG	N76541 001	Apr 22, 2004	Apr	NEWA
AB		30MG	N76541 002	Apr 22, 2004	Apr	NEWA
AB		45MG	N76541 003	Apr 22, 2004	Apr	NEWA

MOLINDONE HYDROCHLORIDE

## CONCENTRATE; ORAL

## MOBAN

@ ENDO PHARMS

20MG/ML

N17938 001

May DISC

## TABLET; ORAL

## MOBAN

@ ENDO PHARMS

100MG

N17111 008

May DISC

MORPHINE SULFATE

## INJECTABLE, LIPOSOMAL; EPIDURAL

## DEPODUR

SKYEPHARMA

10MG/ML

N21671 001 May 18, 2004 May NEWA

## RX DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 7 - July 2004

INJECTABLE, LIPOSOMAL; EPIDURAL  
DEPODUR SKYEPHARMA 15MG/1.5ML(10MG/ML)  
20MG/2ML(10MG/ML)

+  
INJECTABLE; INJECTION  
MORPHINE SULFATE  
AP + HOSPIRA 0.5MG/ML  
AP 0.5MG/ML  
AP 0.5MG/ML  
AP + 1MG/ML  
AP 1MG/ML  
AP 1MG/ML

TABLET, EXTENDED RELEASE; ORAL  
MORPHINE SULFATE  
AB KV PHARM 15MG  
AB 60MG

BC + ORAMORPH SR 60MG  
AAIPHARMA

MYCOPHENOLIC ACID  
TABLET, EXTENDED RELEASE; ORAL  
MYFORTIC  
NOVARTIS 180MG  
360MG

+

N21671 002 May 18, 2004 May NEWA  
N21671 003 May 18, 2004 May NEWA

N19917 001 Oct 30, 1992 May CAHN  
N71849 001 May 11, 1988 May CAHN  
N73509 001 Sep 30, 1992 May CAHN  
N19916 001 Oct 30, 1992 May CAHN  
N71850 001 May 11, 1988 May CAHN  
N73510 001 Sep 30, 1992 May CAHN

N76733 001 May 19, 2004 May NEWA  
N76720 001 May 19, 2004 May NEWA

N19977 002 Aug 15, 1991 Mar CRLD

N50791 001 Feb 27, 2004 Feb NEWA  
N50791 002 Feb 27, 2004 Feb NEWA

NABILONE

CAPSULE; ORAL  
CESAMET  
@ VALEANT 1MG

N18677 001 Dec 26, 1985 Jan CAHN

NAFCILLIN SODIUM

INJECTABLE; INJECTION  
NAFCILLIN SODIUM  
+ SANDOZ EQ 500MG BASE/VIAL  
AP EQ 1GM BASE/VIAL  
AP EQ 2GM BASE/VIAL  
AP EQ 10GM BASE/VIAL

N62527 001 Aug 02, 1984 Jun CAHN  
N62527 002 Aug 02, 1984 Jun CAHN  
N62527 003 Aug 02, 1984 Jun CAHN  
N62527 004 Aug 02, 1984 Jun CAHN

NAFTIFINE HYDROCHLORIDE

>D> CREAM; TOPICAL  
NAFTIN  
ALLERGAN HERBERT 1%  
>A> MERZ PHARMS  
  
>D> GEL; TOPICAL  
NAFTIN  
+ ALLERGAN HERBERT 1%  
>A> + MERZ PHARMS 1%

N19599 001 Feb 29, 1988 Jul CAHN  
N19599 001 Feb 29, 1988 Jul CAHN

N19356 001 Jun 18, 1990 Jul CAHN  
N19356 001 Jun 18, 1990 Jul CAHN

NALBUPHINE HYDROCHLORIDE

INJECTABLE; INJECTION  
NALBUPHINE HCL  
AP HOSPIRA 10MG/ML  
AP 10MG/ML  
AP 20MG/ML  
AP 20MG/ML  
AP 10MG/ML  
@ KING PHARMS

N70914 001 Feb 03, 1989 May CAHN  
N70915 001 Feb 03, 1989 May CAHN  
N70916 001 Feb 03, 1989 May CAHN  
N70918 001 Feb 03, 1989 May CAHN  
N74471 001 Mar 19, 1998 Mar DISC

RX DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 7 - July 2004

NALOXONE HYDROCHLORIDE

INJECTABLE; INJECTION

NALOXONE HCL

HOSPIRA

0.02MG/ML  
0.02MG/ML  
0.02MG/ML  
0.4MG/ML  
0.4MG/ML  
0.4MG/ML  
0.4MG/ML  
0.4MG/ML

N70171 001 Sep 24, 1986 May CAHN  
N70252 001 Jan 16, 1987 May CAHN  
N70253 001 Jan 16, 1987 May CAHN  
N70172 001 Sep 24, 1986 May CAHN  
N70254 001 Jan 07, 1987 May CAHN  
N70255 001 Jan 07, 1987 May CAHN  
N70256 001 Jan 07, 1987 May CAHN  
N70257 001 Jan 07, 1987 May CAHN

AP

AP

AP

AP

AP

AP

AP

NAPROXEN

TABLET; ORAL

NAPROXEN

WESTWARD

250MG  
375MG  
500MG

N76494 001 Jan 14, 2004 Jan NEWA  
N76494 002 Jan 14, 2004 Jan NEWA  
N76494 003 Jan 14, 2004 Jan NEWA

AB

AB

AB

NAPROXEN SODIUM

TABLET, EXTENDED RELEASE; ORAL

NAPRELAN

STAT TRADE

EQ 375MG BASE  
EQ 500MG BASE  
EQ 750MG BASE

N20353 001 Jan 05, 1996 Jun CAHN  
N20353 002 Jan 05, 1996 Jun CAHN  
N20353 003 Jan 05, 1996 Jun CAHN

@

NEDOCROMIL SODIUM

AEROSOL, METERED; INHALATION

TILADE

+ KING PHARMS

1.75MG/INH

N19660 001 Dec 30, 1992 Jan CAHN

NEFAZODONE HYDROCHLORIDE

TABLET; ORAL

NEFAZODONE HCL  
ROXANE

50MG  
50MG  
100MG  
100MG  
150MG  
150MG  
200MG  
200MG  
250MG  
250MG

N76196 001 Sep 16, 2003 Jul DISC  
N76196 001 Sep 16, 2003 Jul DISC  
N76196 002 Sep 16, 2003 Jul DISC  
N76196 002 Sep 16, 2003 Jul DISC  
N76196 003 Sep 16, 2003 Jul DISC  
N76196 003 Sep 16, 2003 Jul DISC  
N76196 004 Sep 16, 2003 Jul DISC  
N76196 004 Sep 16, 2003 Jul DISC  
N76196 005 Sep 16, 2003 Jul DISC  
N76196 005 Sep 16, 2003 Jul DISC

&gt;D&gt;

&gt;A&gt;

&gt;D&gt;

&gt;A&gt;

&gt;D&gt;

&gt;A&gt;

&gt;D&gt;

&gt;A&gt;

&gt;D&gt;

&gt;A&gt;

NIACIN

TABLET; ORAL

NIACIN  
@ MK LABS  
@ TABLICAPS500MG  
500MG

N83525 001 Feb DISC  
N84237 001 Feb DISC

AA + NIACOR  
UPSHER SMITH 500MG

N40378 001 May 03, 2000 Feb CRLD

CAHN  
CAHN  
CAHN  
DISC

NIFEDIPINE

TABLET, EXTENDED RELEASE; ORAL  
 NIFEDIPINE  
 AB2 MARTEC 90MG N75414 003 Mar 23, 2004 Mar NEWA  
 PROCARDIA XL  
 AB2 + PFIZER 90MG N19684 003 Sep 06, 1989 Mar CFTG

NITAZOXANIDE

>A> TABLET; ORAL  
 >A> ALINIA  
 >A> + ROMARK 500MG N21497 001 Jul 21, 2004 Jul NEWA

NITROFURANTOIN; NITROFURANTOIN, MACROCRYSTALLINE

CAPSULE; ORAL  
 MACROBID  
 AB + PROCTER AND GAMBLE 75MG;25MG N20064 001 Dec 24, 1991 Mar CFTG  
 NITROFURANTOIN (MONOHYDRATE/MACROCRYSTALS)  
 AB MYLAN 75MG;25MG N76648 001 Mar 22, 2004 Apr CPOT  
 AB EQ 75MG BASE;25MG N76648 001 Mar 22, 2004 Mar NEWA

NITROGLYCERIN

INJECTABLE; INJECTION  
 NITROGLYCERIN  
 AP + HOSPIRA 5MG/ML N18531 001 May CAHN  
 NITROGLYCERIN IN DEXTROSE 5%  
 AP HOSPIRA 0.1MG/ML N74083 001 Oct 26, 1994 May CAHN  
 AP 10MG/100ML N71846 001 Aug 31, 1990 May CAHN  
 AP 20MG/100ML N71847 001 Aug 31, 1990 May CAHN  
 AP 40MG/100ML N71848 001 Aug 31, 1990 May CAHN

NIZATIDINE

SOLUTION; ORAL  
 AXID  
 + RELIANT PHARMS 15MG/ML N21494 001 May 25, 2004 May NEWA

NOREPINEPHRINE BITARTRATE

INJECTABLE; INJECTION  
 LEVOPHED  
 AP + HOSPIRA EQ 1MG BASE/ML N07513 001 May CAHN

NORTRIPTYLINE HYDROCHLORIDE

CAPSULE; ORAL  
 AVENTYL HCL  
 @ LILLY EQ 10MG BASE N14684 001 Jun DISC  
 @ EQ 25MG BASE N14684 002 Jun DISC

NYSTATIN

PASTILLE; ORAL  
 MYCOSTATIN  
 @ BRISTOL MYERS SQUIBB 200,000 UNITS N50619 001 Apr 09, 1987 Jun DISC  
 POWDER; TOPICAL  
 NYSTATIN  
 >A> AT KALI LABS 100,000 UNITS/GM N65138 001 Jul 23, 2004 Jul NEWA  
 >A> AT TANON 100,000 UNITS/GM N65203 001 Jul 15, 2004 Jul NEWA

## SUSPENSION; ORAL

NILSTAT

>D>	AA	+	CLONMEL HLTHCARE	100,000 UNITS/ML	N50299 001	Jul	CAHN
>A>	AA	+	GLENMARK PHARMA	100,000 UNITS/ML	N50299 001	Jul	CAHN

OFLOXACIN

SOLUTION/DROPS; OPHTHALMIC

OCUFLOX

AT	+	ALLERGAN	0.3%	N19921 001	Jul 30, 1993	May	CFTG
AT		OFLOXACIN					
AT		ALCON	0.3%	N76231 001	May 14, 2004	May	NEWA
AT		BAUSCH AND LOMB	0.3%	N76622 001	May 14, 2004	May	NEWA
AT		HI TECH PHARMA	0.3%	N76615 001	May 14, 2004	May	NEWA
AT		NOVEX	0.3%	N76513 001	May 14, 2004	May	NEWA
		SOLUTION/DROPS; OTIC					
		FLOXIN OTIC					
	+	DAIICHI	0.3%	N20799 001	Dec 16, 1997	Jun	CTNA

OLANZAPINE

INJECTABLE; INTRAMUSCULAR

ZYPREXA

+	LILLY	10MG/VIAL	N21253 001	Mar 29, 2004	Mar	NEWA
---	-------	-----------	------------	--------------	-----	------

OLESALAZINE SODIUM

CAPSULE; ORAL

DIPENTUM

+	CELLTECH PHARMS	250MG	N19715 001	Jul 31, 1990	Jun	CAHN
---	-----------------	-------	------------	--------------	-----	------

OMEPRAZOLE

FOR SUSPENSION; ORAL

ZEGERID

+	SANTARUS	20MG/PACKET	N21636 001	Jun 15, 2004	Jun	NEWA
---	----------	-------------	------------	--------------	-----	------

OXACILLIN SODIUM

INJECTABLE; INJECTION

OXACILLIN SODIUM

AP	+	APOTHECON	EQ 250MG BASE/VIAL	N61490 001	Mar	CRLD	
AP	+		EQ 2GM BASE/VIAL	N61490 004	Mar	NEWA	
AP			EQ 2GM BASE/VIAL	N62737 002	Dec 23, 1986	Mar	CRLD
AP	+	SANDOZ	EQ 250MG BASE/VIAL	N61490 001	Jun	CAHN	
AP	+		EQ 500MG BASE/VIAL	N61490 002	Jun	CAHN	
AP	+		EQ 1GM BASE/VIAL	N61490 003	Jun	CAHN	
AP	+		EQ 2GM BASE/VIAL	N61490 004	Jun	CAHN	
AP	+		EQ 10GM BASE/VIAL	N61490 006	May 09, 1991	Jun	CAHN

OXAMNIQUINE

CAPSULE; ORAL

VANSIL

@	PFIZER	250MG	N18069 001	Mar	DISC
---	--------	-------	------------	-----	------

OXYCODONE HYDROCHLORIDE

TABLET, EXTENDED RELEASE; ORAL

OXYCODONE HCL

AB		ENDO PHARMS	10MG	N75923 001	Mar 23, 2004	Mar	NEWA
AB			20MG	N75923 002	Mar 23, 2004	Mar	NEWA
AB			40MG	N75923 003	Mar 23, 2004	Mar	NEWA

TABLET, EXTENDED RELEASE; ORAL  
OXYCODONE HCL

AB	TEVA	80MG	N76168 001 Mar 23, 2004 Mar NEWA
	OXYCONTIN		
AB	PURDUE PHARMA LP	10MG	N20553 001 Dec 12, 1995 Mar CFTG
AB		20MG	N20553 002 Dec 12, 1995 Mar CFTG
AB	+	40MG	N20553 003 Dec 12, 1995 Mar CFTG
AB	+	80MG	N20553 004 Jan 06, 1997 Mar CFTG
AB		80MG	N20553 004 Jan 06, 1997 Jun CRLD
	TABLET; ORAL		
	OXYCODONE HCL		
AB	AMIDE PHARM	15MG	N76636 001 Feb 06, 2004 Feb NEWA
AB		30MG	N76636 002 Feb 06, 2004 Feb NEWA
AB	MALLINCKRODT	15MG	N76758 001 Jun 30, 2004 Jun NEWA
AB		30MG	N76758 002 Jun 30, 2004 Jun NEWA
	ROXICODONE		
AB	AAIPHARMA	15MG	N21011 001 Aug 31, 2000 Feb CFTG
AB		30MG	N21011 002 Aug 31, 2000 Feb CFTG

PANCURONIUM BROMIDE

	INJECTABLE; INJECTION		
	PANCURONIUM BROMIDE		
AP	HOSPIRA	1MG/ML	N72320 001 Jan 19, 1989 May CAHN
AP		2MG/ML	N72321 001 Jan 19, 1989 May CAHN

PARICALCITOL

	INJECTABLE; INJECTION		
	ZEMPLAR		
	ABBOTT	0.002MG/ML	N20819 002 Feb 01, 2000 Mar NEWA

PAROXETINE HYDROCHLORIDE

	TABLET; ORAL		
	PAROXETINE HCL		
AB	ALPHAPHARM	EQ 10MG BASE	N75716 001 Mar 08, 2004 Mar NEWA
AB		EQ 20MG BASE	N75716 002 Mar 08, 2004 Mar NEWA
AB		EQ 30MG BASE	N75716 003 Mar 08, 2004 Mar NEWA
AB		EQ 40MG BASE	N75716 004 Mar 08, 2004 Mar NEWA
AB	SANDOZ	EQ 10MG BASE	N75566 001 Mar 08, 2004 Mar NEWA
AB		EQ 20MG BASE	N75566 002 Mar 08, 2004 Mar NEWA
AB		EQ 30MG BASE	N75566 003 Mar 08, 2004 Mar NEWA
AB		EQ 40MG BASE	N75566 004 Mar 08, 2004 Mar NEWA

PEMETREXED DISODIUM

	INJECTABLE; IV (INFUSION)		
	ALIMTA		
+	LILLY	EQ 500MG BASE/VIAL	N21462 001 Feb 04, 2004 Feb NEWA

PENTAMIDINE ISETHIONATE

	INJECTABLE; INJECTION		
	PENTAMIDINE ISETHIONATE		
AP	HOSPIRA	300MG/VIAL	N73479 001 Jun 30, 1992 May CAHN

PENTAZOCINE LACTATE

	INJECTABLE; INJECTION		
	TALWIN		
+	HOSPIRA	EQ 30MG BASE/ML	N16194 001 May CAHN

PENTOBARBITAL SODIUM

CAPSULE; ORAL			
NEMBUTAL SODIUM			
@ OVATION PHARMS	30MG	N84095 001	May DISC
@	100MG	N83245 001	May DISC
SODIUM PENTOBARBITAL			
+ VALEANT PHARM INTL	100MG	N83264 001	May CRLD

PENTOSAN POLYSULFATE SODIUM

CAPSULE; ORAL			
ELMIRON			
+ ORTHO MCNEIL PHARM	100MG	N20193 001	Sep 26, 1996 Jun CAHN

PHENYTOIN

SUSPENSION; ORAL			
PHENYTOIN			
AB TARO	125MG/5ML	N40521 001	Mar 08, 2004 Mar NEWA

PHENYTOIN SODIUM

INJECTABLE; INJECTION			
PHENYTOIN SODIUM			
@ HOSPIRA	50MG/ML	N89521 001	Mar 17, 1987 May CAHN
@	50MG/ML	N89744 001	Dec 18, 1987 May CAHN

PHYTONADIONE

INJECTABLE; INJECTION			
VITAMIN K1			
BP HOSPIRA	1MG/0.5ML	N87954 001	Jul 25, 1983 May CAHN
BP	10MG/ML	N87955 001	Jul 25, 1983 May CAHN
@	10MG/ML	N87956 001	Jul 25, 1983 May CAHN

PIPERACILLIN SODIUM

INJECTABLE; INJECTION			
PIPERACILLIN			
>A> + AM PHARM	EQ 40GM BASE/VIAL	N65157 001	Jul 12, 2004 Jul NEWA

>D> PIPERAZINE CITRATE

>D> SYRUP; ORAL			
>D> MULTIFUGE			
>D> + BLULINE	EQ 500MG BASE/5ML	N09452 001	Jul DISC
>A> @	EQ 500MG BASE/5ML	N09452 001	Jul DISC

POLYETHYLENE GLYCOL 3350

FOR SOLUTION; ORAL			
>A> GLYCOLAX			
>A> AA SCHWARZ PHARMA	17GM/SCOOPFUL	N76652 001	Jul 02, 2004 Jul NEWA
MIRALAX			
>D> + BRAINTREE	17GM/SCOOPFUL	N20698 001	Feb 18, 1999 Jul CFTG
>A> AA +	17GM/SCOOPFUL	N20698 001	Feb 18, 1999 Jul CFTG

POLYETHYLENE GLYCOL 3350; POTASSIUM CHLORIDE; SODIUM BICARBONATE; SODIUM CHLORIDE

FOR SOLUTION; ORAL			
NULYTLY			
AA + BRAINTREE	420GM/BOT;1.48GM/BOT;5.72GM/BOT;1 1.2GM/BOT	N19797 001	Apr 22, 1991 Feb CFTG

FOR SOLUTION; ORAL  
NULYTELY-FLAVORED

AA + BRAINTREE 420GM/BOT;1.48GM/BOT;5.72GM/BOT;1 N19797 002 Nov 18, 1994 Feb CFTG  
1.2GM/BOT

TRILYTE

AA SCHWARZ PHARMA 420GM/BOT;1.48GM/BOT;5.72GM/BOT;1 N76491 001 Feb 05, 2004 Feb NEWA  
1.2GM/BOT

POLYETHYLENE GLYCOL 3350; POTASSIUM CHLORIDE; SODIUM BICARBONATE; SODIUM CHLORIDE; SODIUM SULFATE

SOLUTION; ORAL

OCL  
+ HOSPIRA 6GM/100ML;75MG/100ML;168MG/100ML; N19284 001 Apr 30, 1986 May CAHN  
146MG/100ML;1.29GM/100ML

POTASSIUM ACETATE

INJECTABLE; INJECTION

POTASSIUM ACETATE IN PLASTIC CONTAINER  
+ HOSPIRA 2MEQ/ML

N18896 001 Jul 20, 1984 May CAHN

POTASSIUM CHLORIDE

INJECTABLE; INJECTION

POTASSIUM CHLORIDE

@ HOSPIRA	1MEQ/ML	N80205 003	May CAHN
@	1MEQ/ML	N83345 003	May CAHN
+	1.5MEQ/ML	N83345 001	May CAHN
AP +	2MEQ/ML	N80205 001	May CAHN
AP	2MEQ/ML	N83345 002	May CAHN
@	2.4MEQ/ML	N80205 004	May CAHN
@	3.2MEQ/ML	N80205 005	May CAHN
POTASSIUM CHLORIDE 10MEQ IN PLASTIC CONTAINER			
@ HOSPIRA	14.9MG/ML	N20161 005 Nov 30, 1992 May CAHN	
@	745MG/100ML	N20161 001 Nov 30, 1992 May CAHN	
POTASSIUM CHLORIDE 20MEQ IN PLASTIC CONTAINER			
AP + HOSPIRA	29.8MG/ML	N20161 006 Aug 11, 1998 May CAHN	
@	1.49GM/100ML	N20161 002 Nov 30, 1992 May CAHN	
POTASSIUM CHLORIDE 30MEQ IN PLASTIC CONTAINER			
AP + HOSPIRA	2.24GM/100ML	N20161 003 Aug 11, 1998 May CAHN	
POTASSIUM CHLORIDE 40MEQ IN PLASTIC CONTAINER			
AP + HOSPIRA	2.98GM/100ML	N20161 004 Aug 11, 1998 May CAHN	

POTASSIUM CHLORIDE; SODIUM CHLORIDE

INJECTABLE; INJECTION

POTASSIUM CHLORIDE 20MEQ IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER			
AP HOSPIRA	149MG/100ML;900MG/100ML	N19686 001 Oct 17, 1988 May CAHN	
POTASSIUM CHLORIDE 40MEQ IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER			
AP HOSPIRA	298MG/100ML;900MG/100ML	N19686 002 Oct 17, 1988 May CAHN	

POTASSIUM CHLORIDE; SODIUM CHLORIDE; TROMETHAMINE

INJECTABLE; INJECTION

THAM-E			
@ HOSPIRA	370MG/VIAL;1.75GM/VIAL;36GM/VIAL	N13025 001	May CAHN

PREDNISOLONE

TABLET; ORAL

PREDNISOLONE

@ EVERYLIFE	2.5MG	N84439 002	May DISC
@	5MG	N84439 003	May DISC

## TABLET; ORAL

## PREDNISOLONE

@ SPERTI	1MG	N80358 001	May DISC
@	2.5MG	N80358 002	May DISC
@	5MG	N80358 003	May DISC

PREDNISOLONE SODIUM PHOSPHATE

## SOLUTION; ORAL

## PREDNISOLONE SODIUM PHOSPHATE

AA	PADDICK	EQ 5MG BASE/5ML	N75988 001 May 25, 2004 May NEWA
----	---------	-----------------	----------------------------------

PREDNISONE

## TABLET; ORAL

## DELTASONE

>D>	AB	+	PHARMACIA AND UPJOHN	20MG	N09986 007	Jul DISC
>A>		@		20MG	N09986 007	Jul DISC
			PREDNISONE			
>D>	AB		ROXANE	20MG	N87342 001	Jul CRLD
>A>	AB	+		20MG	N87342 001	Jul CRLD
	AB		WEST WARD	2.5MG	N40538 001 Jan 08, 2004	Jan NEWA

PROCAINAMIDE HYDROCHLORIDE

## INJECTABLE; INJECTION

## PROCAINAMIDE HCL

AP	HOSPIRA	100MG/ML	N89069 001 Feb 12, 1986 May CAHN
AP		500MG/ML	N89070 001 Feb 12, 1986 May CAHN
AP		500MG/ML	N89537 001 Aug 25, 1987 May CAHN

PROCAINE HYDROCHLORIDE

## INJECTABLE; INJECTION

## NOVOCAIN

AP	+	HOSPIRA	1%	N85362 003	May CAHN
AP	+		2%	N85362 004	May CAHN
	+		10%	N86797 001	May CAHN
		PROCAINE HCL			
AP		HOSPIRA	1%	N80416 001	May CAHN
AP			2%	N80416 002	May CAHN

PROCHLORPERAZINE EDISYLATE

## INJECTABLE; INJECTION

## PROCHLORPERAZINE EDISYLATE

AP	BEDFORD	EQ 5MG BASE/ML	N40540 001 May 28, 2004 May NEWA
AP	HOSPIRA	EQ 5MG BASE/ML	N89703 001 Apr 07, 1988 May CAHN

PROMETHAZINE HYDROCHLORIDE

## INJECTABLE; INJECTION

## PROMETHAZINE HCL

AP	BEDFORD LABS	25MG/ML	N40524 001 Mar 17, 2004 Mar NEWA
AP		50MG/ML	N40524 002 Mar 17, 2004 Mar NEWA
AP	HOSPIRA	25MG/ML	N40372 001 Jun 08, 2000 May CAHN
AP		50MG/ML	N40372 002 Jun 08, 2000 May CAHN
AP		50MG/ML	N83838 002 May CAHN

## SYRUP; ORAL

## PROMETH PLAIN

@ ALPHARMA	6.25MG/5ML	N85953 001	Feb DISC
------------	------------	------------	----------

SYRUP; ORAL

AA	+ HI TECH PHARMA	PROMETHAZINE HCL 6.25MG/5ML 6.25MG/5ML	N40026 001 Sep 25, 1998 Feb CRLD N40026 001 Sep 25, 1998 May CRLD
AA	PROMETHAZINE PLAIN	6.25MG/5ML	N87953 001 Nov 15, 1982 May CRLD
AA	+ MORTON GROVE	6.25MG/5ML	
<u>TABLET; ORAL</u>			
PHENERGAN			
>D>	WYETH PHARMS INC	12.5MG 12.5MG	N07935 002 Jul CFTG N07935 002 Jul CFTG
>A> AB		25MG	N07935 003 Jul CTEC
>D> BP		25MG	N07935 003 Jul CTEC
>A> AB		50MG	N07935 004 Jul CTEC
>D> BP +		50MG	N07935 004 Jul CTEC
>A> AB +			
>A>	PROMETHAZINE HCL	12.5MG	N40558 001 Jul 01, 2004 Jul NEWA
>A> AB ABLE		25MG	N40558 002 Jul 01, 2004 Jul NEWA
>A> AB		50MG	N40558 003 Jul 01, 2004 Jul NEWA
>A> AB			

PROPAFENONE HYDROCHLORIDE

<u>TABLET; ORAL</u>			
PROPAFENONE HCL			
AB	PLIVA	150MG 225MG 300MG	N76550 001 Apr 23, 2004 Apr NEWA N76550 002 Apr 23, 2004 Apr NEWA N76550 003 Apr 23, 2004 Apr NEWA
AB			
AB			

PROPRANOLOL HYDROCHLORIDE

<u>INJECTABLE; INJECTION</u>			
PROPRANOLOL			
AP	AM PHARM PARTNERS	1MG/ML	N75826 001 Aug 31, 2001 Jan NEWA

PROTAMINE SULFATE

<u>INJECTABLE; INJECTION</u>			
PROTAMINE SULFATE			
+ @ LILLY	AM PHARM PARTNERS	10MG/ML 10MG/ML	N89454 001 Apr 07, 1987 Mar CRLD N06460 002 Mar DISC

PROTRIPTYLINE HYDROCHLORIDE

<u>TABLET; ORAL</u>			
VIVACTIL			
AP	@ ODYSSEY PHARMS	5MG 10MG	N16012 001 Jun CAHN N16012 002 Jun CAHN

RANITIDINE HYDROCHLORIDE

<u>TABLET, EFFERVESCENT; ORAL</u>			
ZANTAC 25			
GLAXOSMITHKLINE EQ 25MG BASE			
			N20251 003 Apr 01, 2004 Apr NEWA

RIBAVIRIN

<u>CAPSULE; ORAL</u>			
REBETOL			
AB	+ SCHERING PLOUGH RES	200MG	N20903 002 Jul 25, 2001 Apr CFTG
AB	RIBASPHERE	200MG	N76203 001 Apr 06, 2004 Apr NEWA
AB	THREE RIVERS PHARMS	200MG	
AB	RIBAVIRIN	200MG	N76192 001 Apr 06, 2004 Apr NEWA
AB	SANDOZ	200MG	

RIFAXIMIN

TABLET; ORAL  
XIFAXAN  
+ SALIX PHARMS 200MG

N21361 001 May 25, 2004 May NEWA

RISPERIDONE

INJECTABLE; INTRAMUSCULAR

RISPERDAL CONSTA  
JANSSEN PHARMA 25MG/VIAL  
37.5MG/VIAL  
50MG/VIAL  
JOHNSON AND JOHNSON 25MG/VIAL  
37.5MG/VIAL  
50MG/VIAL

N21346 001 Oct 29, 2003 Jul CAHN  
N21346 002 Oct 29, 2003 Jul CAHN  
N21346 003 Oct 29, 2003 Jul CAHN  
N21346 001 Oct 29, 2003 Jul CAHN  
N21346 002 Oct 29, 2003 Jul CAHN  
N21346 003 Oct 29, 2003 Jul CAHN

TABLET, ORALLY DISINTEGRATING; ORAL

RISPERDAL  
JANSSEN PHARMA 0.5MG  
1MG  
2MG

N21444 001 Apr 02, 2003 Jun CAHN  
N21444 002 Apr 02, 2003 Jun CAHN  
N21444 003 Apr 02, 2003 Jun CAHN

RITODRINE HYDROCHLORIDE

INJECTABLE; INJECTION

RITODRINE HCL  
+ HOSPIRA 10MG/ML  
15MG/ML  
RITODRINE HCL IN DEXTROSE 5% IN PLASTIC CONTAINER  
+ HOSPIRA 30MG/100ML

N71618 001 Feb 28, 1991 May CAHN  
N71619 001 Feb 28, 1991 May CAHN  
N71438 001 Jan 22, 1991 May CAHN

ROCURONIUM BROMIDE

INJECTABLE; INJECTION

ZEMURON  
ORGANON USA INC 10MG/ML  
10MG/ML  
10MG/ML  
ZEMURON (P/F)  
+ ORGANON USA INC 10MG/ML  
50MG/5ML (10MG/ML)  
+ 100MG/10ML (10MG/ML)

N20214 002 Mar 17, 1994 Jul DISC  
N20214 002 Mar 17, 1994 Jul DISC  
N20214 002 Mar 17, 1994 Jun CMFD  
N20214 001 Mar 17, 1994 Jul CPOT  
N20214 001 Mar 17, 1994 Jul CPOT  
N20214 003 Mar 17, 1994 Jul NEWA

ROPINIROLE HYDROCHLORIDE

TABLET; ORAL

REQUIP  
GLAXOSMITHKLINE EQ 5MG BASE

N20658 005 Sep 19, 1997 May CRLD

SAFFLOWER OIL; SOYBEAN OIL

INJECTABLE; INJECTION

LIPOSYN II 10%  
+ HOSPIRA 5%;5% (5GM/100ML)  
LIPOSYN II 20%  
+ HOSPIRA 10%;10% (10GM/100ML)

N18997 001 Aug 27, 1984 May CAHN  
N18991 001 Aug 27, 1984 May CAHN

SECRETIN

FOR SOLUTION; INTRAVENOUS

SECREFLO  
+ CHIRHOCLIN 16UGM/VIAL

N21136 001 Apr 04, 2002 Jul CAIN

SECRETIN SYNTHETIC HUMAN

FOR SOLUTION; INTRAVENOUS  
HUMAN SECRETIN  
+ CHIRHOCLIN 16UGM/VIAL

N21256 001 Apr 09, 2004 Apr NEWA

>A> SECRETIN SYNTHETIC PORCINE

>A> FOR SOLUTION; INTRAVENOUS  
>A> SECREMAX  
>A> + CHIRHOCLIN 16UGM/VIAL

N21136 001 Apr 04, 2002 Jul CAIN

SEVELAMER HYDROCHLORIDE

CAPSULE; ORAL  
RENAGEL  
@ GENZYME 403MG

N20926 001 Oct 30, 1998 Jun DISC

SIROLIMUS

TABLET; ORAL  
RAPAMUNE  
WYETH PHARMS INC 2MG  
+ 5MG

N21110 002 Aug 22, 2002 Feb CRLD

N21110 003 Feb 23, 2004 Feb NEWA

SODIUM ACETATE, ANHYDROUS

INJECTABLE; INJECTION  
SODIUM ACETATE IN PLASTIC CONTAINER  
+ HOSPIRA 2MEQ/ML

N18893 001 May 04, 1983 May CAHN

SODIUM CHLORIDE

INJECTABLE; INJECTION  
BACTERIOSTATIC SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER

N18800 001 Oct 29, 1982 May CAHN

AP + HOSPIRA 9MG/ML

SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER

N18090 001 May CAHN

AP HOSPIRA 450MG/100ML

N19759 001 Jun 08, 1988 May CAHN

AP 450MG/100ML

SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER

N18803 001 Oct 29, 1982 May CAHN

AP HOSPIRA 9MG/ML

N19217 001 Jul 13, 1984 Jul CRLD

&gt;D&gt; AP 9MG/ML

N19217 001 Jul 13, 1984 Jul CRLD

&gt;A&gt; AP + 9MG/ML

N19217 001 Jul 13, 1984 May CAHN

AP 9MG/ML

N19217 001 Jul 13, 1984 May CAHN

AP 900MG/100ML

N19465 002 Jul 15, 1985 May CAHN

AP 900MG/100ML

N16366 001 May CAHN

AP 900MG/100ML

N19465 001 Jul 15, 1985 May CAHN

SODIUM CHLORIDE IN PLASTIC CONTAINER

N19480 001 Sep 17, 1985 May CAHN

HOSPIRA 2.5MEQ/ML

N18897 001 Jul 20, 1984 May CAHN

SOLUTION; IRRIGATION

SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER

N17670 001 May CAHN

AT HOSPIRA 450MG/100ML

N18380 001 May CAHN

@ 450MG/100ML

SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER

N17514 001 May CAHN

AT HOSPIRA 900MG/100ML

N18314 001 May CAHN

900MG/100ML

SODIUM FERRIC GLUCONATE COMPLEX

INJECTABLE; INJECTION  
 FERRLECIT  
 + WATSON PHARMS 62.5MG/5ML N20955 001 Feb 18, 1999 Feb CAHN

SODIUM IODIDE, I-131

SOLUTION; ORAL  
 SODIUM IODIDE I 131  
 @ CIS 50mCi/ML N17315 001 Apr DISC

SODIUM LACTATE

INJECTABLE; INJECTION  
 SODIUM LACTATE 0.167 MOLAR IN PLASTIC CONTAINER  
 AP HOSPIRA 1.87GM/100ML N18249 001 May CAHN  
 SODIUM LACTATE IN PLASTIC CONTAINER  
 HOSPIRA 5MEQ/ML N18947 001 Sep 05, 1984 May CAHN

SODIUM NITROPRUSSIDE

INJECTABLE; INJECTION  
 NITROPRESS  
 AP + HOSPIRA 25MG/ML N71961 001 Aug 01, 1988 May CAHN  
 + 50MG/VIAL N70566 001 Jun 09, 1986 May CAHN

SODIUM PHOSPHATE, DIBASIC, HEPTAHYDRATE; SODIUM PHOSPHATE, MONOBASIC, ANHYDROUS

INJECTABLE; INJECTION  
 SODIUM PHOSPHATES IN PLASTIC CONTAINER  
 HOSPIRA 142MG/ML;276MG/ML N18892 001 May 10, 1983 May CAHN

SOMATROPIN RECOMBINANT

INJECTABLE; INJECTION  
 SAIZEN  
 @ SERONO 6MG/VIAL N19764 001 Oct 08, 1996 May DISC  
 SEROSTIM  
 BX SERONO 4MG/VIAL N20604 003 Jul 25, 1997 Jan CTEC  
 @ 8.8MG/VIAL N20604 004 Sep 06, 2001 Jan DISC  
 ZORBTIVE  
 @ SERONO INC 4MG/VIAL N21597 001 Dec 01, 2003 May DISC  
 @ 5MG/VIAL N21597 002 Dec 01, 2003 May DISC  
 @ 6MG/VIAL N21597 003 Dec 01, 2003 May DISC

SOTALOL HYDROCHLORIDE

TABLET; ORAL  
 SOTALOL HCL  
 AB2 MUTUAL PHARM 80MG N76576 001 Apr 08, 2004 Apr NEWA  
 AB2 120MG N76576 002 Apr 08, 2004 Apr NEWA  
 AB2 160MG N76576 003 Apr 08, 2004 Apr NEWA  
 >AB2 AB2 TEVA 80MG N76883 001 Jul 26, 2004 Jul NEWA  
 >AB2 AB2 120MG N76883 002 Jul 26, 2004 Jul NEWA  
 >AB2 AB2 160MG N76883 003 Jul 26, 2004 Jul NEWA

SOYBEAN OIL

INJECTABLE; INJECTION  
 LIPOSYN III 10%  
 AP + HOSPIRA 10% N18969 001 Sep 24, 1984 May CAHN

## INJECTABLE; INJECTION

	LIPOSYN III 20%				
AP	+	HOSPIRA	20%	N18970	001 Sep 25, 1984 May CAHN
		LIPOSYN III 30%			
AP	+	HOSPIRA	30%	N20181	001 Jan 13, 1998 May CAHN

SPARFLOXACIN

## TABLET; ORAL

ZAGAM					
@ MYLAN		200MG		N20677	001 Dec 19, 1996 Mar DISC

STAVUDINE

## CAPSULE, EXTENDED RELEASE; ORAL

ZERIT XR					
@ BRISTOL MYERS SQUIBB	37.5MG		N21453	001 Dec 31, 2002 Jun DISC	
@	50MG		N21453	002 Dec 31, 2002 Jun DISC	
@	75MG		N21453	003 Dec 31, 2002 Jun DISC	
@	100MG		N21453	004 Dec 31, 2002 Jun DISC	

SUCCINYLCHOLINE CHLORIDE

## INJECTABLE; INJECTION

## ANECTINE

>D>	AP	+	GLAXOSMITHKLINE	20MG/ML	N08453 002 Jul CAHN
>D>			@	50MG/ML	N08453 003 Jul CAHN
>D>		+		500MG/VIAL	N08453 001 Jul CAHN
>D>		+		1GM/VIAL	N08453 004 Jul CAHN
>A>	AP	+	SABEX 2002	20MG/ML	N08453 002 Jul CAHN
>A>			@	50MG/ML	N08453 003 Jul CAHN
>A>		+		500MG/VIAL	N08453 001 Jul CAHN
>A>		+		1GM/VIAL	N08453 004 Jul CAHN
			QUELICIN		
	AP	+	HOSPIRA	20MG/ML	N08845 006 May CAHN
			QUELICIN PRESERVATIVE FREE		
	AP	+	HOSPIRA	20MG/ML	N08845 001 May CAHN
			@	50MG/ML	N08845 002 May CAHN
		+		100MG/ML	N08845 004 May CAHN

SUCRALFATE

## TABLET; ORAL

## CARAFATE

AB	+	AXCAN SCANDIPHARM	1GM	N18333 001 Feb CAHN
----	---	-------------------	-----	---------------------

SUFENTANIL CITRATE

## INJECTABLE; INJECTION

## SUFENTANIL CITRATE

AP		HOSPIRA	EQ 0.05MG BASE/ML	N74534 001 Dec 11, 1996 May CAHN
----	--	---------	-------------------	----------------------------------

SULFACETAMIDE SODIUM

## SOLUTION/DROPS; OPHTHALMIC

## SULF-10

AT		NOVARTIS	10%	N80025 001 Mar CMFD
----	--	----------	-----	---------------------

SULFAMETHOXAZOLE; TRIMETHOPRIM

## INJECTABLE; INJECTION

## SULFAMETHOXAZOLE AND TRIMETHOPRIM

AP		HOSPIRA	80MG/ML;16MG/ML	N73199 001 Sep 11, 1992 May CAHN
----	--	---------	-----------------	----------------------------------

TECHNETIUM TC-99M APCITIDE

INJECTABLE; INJECTION

ACUTECT

BERLEX LABS

N/A

N20887 001 Sep 14, 1998 Jun CAHN

TECHNETIUM TC-99M DEPREOTIDE

INJECTABLE; INJECTION

NEO TECT KIT

+ BERLEX LABS

N/A

N21012 001 Aug 03, 1999 Jun CAHN

TECHNETIUM TC-99M MEDRONATE KIT

INJECTABLE; INJECTION

DRAXIMAGE MDP

AP + DRAXIMAGE

N/A

N18035 001 May CTNA

TECHNETIUM TC-99M SESTAMIBI KIT

INJECTABLE; INJECTION

CARDIOLITE

&gt;D&gt;

BRISTOL MYERS SQUIBB N/A

N19785 001 Dec 21, 1990 Jul CRLD

&gt;A&gt;

+ N/A

N19785 001 Dec 21, 1990 Jul CRLD

TELITHROMYCIN

TABLET; ORAL

KETEK

+ AVENTIS PHARMS

400MG

N21144 001 Apr 01, 2004 Apr NEWA

TERBINAFINE

GEL; TOPICAL

LAMISIL

NOVARTIS

1%

N20846 001 Apr 29, 1998 Jan CMFD

TERBUTALINE SULFATE

INJECTABLE; INJECTION

BRETHINE

AP + AAIPHARMA LLC

1MG/ML

N18571 001 Apr CFTG

TERBUTALINE SULFATE

AP AM PHARM

1MG/ML

N76887 001 May 26, 2004 May NEWA

AP BEDFORD

1MG/ML

N76770 001 Apr 23, 2004 Apr NEWA

&gt;A&gt; AP SICOR PHARMS

1MG/ML

N76853 001 Jul 20, 2004 Jul NEWA

TERCONAZOLE

CREAM; VAGINAL

TERAZOL 3

AB + ORTHO MCNEIL PHARM 0.8%

N19964 001 Feb 21, 1991 Apr CFTG

TERCONAZOLE

AB TARO

0.8%

N75953 001 Apr 06, 2004 Apr NEWA

THEOPHYLLINE

CAPSULE, EXTENDED RELEASE; ORAL

AEROLATE III

@ FLEMING PHARMS

65MG

N85075 003 Nov 24, 1986 Jun DISC

AEROLATE JR

@ FLEMING PHARMS

130MG

N85075 002 Nov 24, 1986 Jun DISC

AEROLATE SR

@ FLEMING PHARMS

260MG

N85075 001 Nov 24, 1986 Jun DISC

INJECTABLE; INJECTIONTHEOPHYLLINE IN DEXTROSE 5% IN PLASTIC CONTAINER

AP	+	HOSPIRA	4MG/ML	N19211 007	Dec 14, 1984	May	CAHN
AP	+		40MG/100ML	N19211 001	Dec 14, 1984	May	CAHN
AP	+		80MG/100ML	N19211 002	Dec 14, 1984	May	CAHN
AP	+		160MG/100ML	N19211 003	Dec 14, 1984	May	CAHN
AP	+		200MG/100ML	N19211 004	Dec 14, 1984	May	CAHN
AP	+		320MG/100ML	N19211 006	Jan 20, 1988	May	CAHN
AP	+		400MG/100ML	N19211 005	Dec 14, 1984	May	CAHN

SOLUTION; ORALAEROLATE

@ FLEMING PHARMS	150MG/15ML	N89141 001	Dec 03, 1986	Jun	DISC
------------------	------------	------------	--------------	-----	------

TABLET, EXTENDED RELEASE; ORALTHEOLAIR-SR

@ 3M	200MG	N88369 001	Jul 16, 1987	Jun	DISC
@	250MG	N86363 002	Jul 16, 1987	Jun	DISC
@	300MG	N88364 001	Jul 16, 1987	Jun	DISC
@	500MG	N89132 001	Jul 16, 1987	Jun	DISC

THEOPHYLLINE

AB	ABLE	300MG	N40548 001	Apr 30, 2004	Apr	NEWA	
AB		400MG	N40543 001	Apr 27, 2004	Apr	NEWA	
AB		450MG	N40546 001	Apr 30, 2004	Apr	NEWA	
AB		600MG	N40539 001	Apr 27, 2004	Apr	NEWA	
	UNIPHYL						
AB	+	PURDUE FREDERICK	400MG	N87571 001	Sep 01, 1982	Apr	CFTG
AB	+		600MG	N40086 001	Apr 15, 1996	Apr	CFTG

THIAMINE HYDROCHLORIDEINJECTABLE; INJECTION

AP		THIAMINE HCL					
AP		HOSPIRA	100MG/ML	N40079 001	May 03, 1996	May	CAHN

TIMOLOL MALEATE

	SOLUTION/DROPS; OPHTHALMIC						
	ISTALOL						
+	SENJU	EQ 0.5% BASE	N21516 001	Jun 04, 2004	Jun	NEWA	
	TIMOLOL MALEATE						
AT	HI TECH PHARMA	EQ 0.5% BASE	N75163 001	Sep 10, 2002	Jun	CDFR	

TINIDAZOLETABLET; ORALTINDAMAX

PRESUTTI LABS	250MG	N21618 001	May 17, 2004	May	NEWA
+	500MG	N21618 002	May 17, 2004	May	NEWA

TIOTROPIUM BROMIDE MONOHYDRATECAPSULE; INHALATIONSPIRIVA

+	BOEHRINGER INGELHEIM	EQ 0.018MG BASE	N21395 001	Jan 30, 2004	Jan	NEWA
---	----------------------	-----------------	------------	--------------	-----	------

TIZANIDINE HYDROCHLORIDETABLET; ORALTIZANIDINE HCL

AB	TORPHARM	EQ 2MG BASE	N76533 001	Jan 16, 2004	Jan	NEWA
AB		EQ 4MG BASE	N76533 002	Jan 16, 2004	Jan	NEWA

TOBRAMYCIN SULFATE

## INJECTABLE; INJECTION

NEBCIN

@ LILLY

EQ 10MG BASE/ML

N50477 005

Jun DISC

@

EQ 10MG BASE/ML

N62008 004

Jun DISC

@

EQ 10MG BASE/ML

N62707 001

Apr 29, 1987 Jun DISC

@

EQ 40MG BASE/ML

N62008 001

Jun DISC

@

EQ 1.2GM BASE/VIAL

N50519 001

Jun DISC

TOBRAMYCIN

>A> AM PHARM  
>D> AP + PHARMA TEK

EQ 1.2GM BASE/VIAL

N50789 001 Jul 13, 2004 Jul NEWA

EQ 1.2GM BASE/VIAL

N65013 001 Aug 17, 2001 Jul CTEC

>A> AP +  
AP +

EQ 1.2GM BASE/VIAL

N65013 001 Aug 17, 2001 Jul CTEC

EQ 1.2GM BASE/VIAL

N65013 001 Aug 17, 2001 Jun CRLD

TOBRAMYCIN SULFATE

AP + HOSPIRA

EQ 10MG BASE/ML

N63080 001 Apr 30, 1991 Jun CRLD

AP +

EQ 10MG BASE/ML

N63080 001 Apr 30, 1991 May CAHN

AP +

EQ 10MG BASE/ML

N63112 001 Apr 30, 1991 May CAHN

AP +

EQ 40MG BASE/ML

N63111 001 Apr 30, 1991 May CAHN

AP +

EQ 40MG BASE/ML

N63116 001 May 18, 1992 May CAHN

AP +

EQ 40MG BASE/ML

N63161 001 May 29, 1991 May CAHN

TOBRAMYCIN SULFATE IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER

+ HOSPIRA

EQ 1.2MG BASE/ML

N63081 003 Jul 31, 1990 May CAHN

+ +

EQ 1.6MG BASE/ML

N63081 006 Jun 02, 1993 May CAHN

+ +

EQ 80MG BASE/100ML

N63081 001 Jul 31, 1990 May CAHN

TOPIRAMATE

## CAPSULE; ORAL

TOPAMAX SPRINKLE

&gt;D&gt; ORTHO MCNEIL

15MG

N20844 001 Oct 26, 1998 Jul CAHN

&gt;D&gt; +

25MG

N20844 002 Oct 26, 1998 Jul CAHN

&gt;D&gt; @

50MG

N20844 003 Oct 26, 1998 Jul CAHN

&gt;A&gt; ORTHO MCNEIL PHARM

15MG

N20844 001 Oct 26, 1998 Jul CAHN

&gt;A&gt; +

25MG

N20844 002 Oct 26, 1998 Jul CAHN

&gt;A&gt; @

50MG

N20844 003 Oct 26, 1998 Jul CAHN

## TABLET; ORAL

TOPAMAX

ORTHO MCNEIL PHARM 50MG

N20505 005 Dec 24, 1996 Jun CMFD

TRAVOPROST

## SOLUTION/DROPS; OPHTHALMIC

TRAVATAN

+ ALCON

0.004%

N21257 001 Mar 16, 2001 May CAHN

TRIAMCINOLONE

## TABLET; ORAL

ARISTOCORT

BP + FUJISAWA HLTHCARE

4MG

N11161 007

Jun CRLD

KENACORT

@ BRISTOL MYERS SQUIBB

8MG

N11283 010

Jun DISC

TRIAMCINOLONE

@ WATSON LABS

4MG

N84270 001

Jun DISC

TRIAMCINOLONE ACETONIDE

AEROSOL, METERED; INHALATION

AZMACORT

+ KOS 0.1MG/INH

N18117 001 Apr 23, 1982 Apr CAHN

SPRAY, METERED; NASAL

NASACORT HFA

+ AVENTIS PHARMS 0.055MG/SPRAY

N20784 001 Apr 07, 2004 Apr NEWA

TRIAMCINOLONE DIACETATE

INJECTABLE; INJECTION

ARISTOCORT

@ SABEX 2002 25MG/ML

N11685 003

Jun DISC

@ 40MG/ML

N12802 001

Jun DISC

TRIMETHOBENZAMIDE HYDROCHLORIDE

INJECTABLE; INJECTION

TRIMETHOBENZAMIDE HCL

AP HOSPIRA 100MG/ML

N88804 001 Apr 03, 1987 May CAHN

TRIMIPRAMINE MALEATE

CAPSULE; ORAL

SURMONTIL

ODYSSEY PHARMS EQ 25MG BASE

N16792 001

Jun CAHN

EQ 50MG BASE

N16792 002

Jun CAHN

+ EQ 100MG BASE

N16792 003 Sep 15, 1982 Jun CAHN

TROLAMINE POLYPEPTIDE OLEATE CONDENSATE

SOLUTION/DROPS; OTIC

CERUMENEX

@ PURDUE FREDERICK 10%

N11340 002

May DISC

TROMETHAMINE

INJECTABLE; INJECTION

THAM

+ HOSPIRA 3.6GM/100ML

N13025 002

May CAHN

TROSPiUM CHLORIDE

TABLET; ORAL

SANCTURA

+ INDEVUS 20MG

N21595 001 May 28, 2004 May NEWA

TROVAFLOXACIN MESYLATE

TABLET; ORAL

TROVAN

@ PFIZER EQ 100MG BASE

N20759 001 Dec 18, 1997 Jun DISC

@ EQ 200MG BASE

N20759 002 Dec 18, 1997 Jun DISC

## &gt;D &lt;u&gt;TUBOCURARINE CHLORIDE&lt;/u&gt;

&gt;D &lt;u&gt;INJECTABLE; INJECTION&lt;/u&gt;

&gt;D &lt;u&gt;TUBOCURARINE CHLORIDE&lt;/u&gt;

&gt;D + BRISTOL MYERS SQUIBB 3MG/ML

N05657 001

Jul DISC

&gt;A &gt; @ 3MG/ML

N05657 001

Jul DISC

AP + HOSPIRA 3MG/ML

N06095 001

May CAHN

@ 3MG/ML

N06095 001

Jun DISC

UREA

INJECTABLE; INJECTION

STERILE UREA

@ HOSPIRA

40GM/VIAL

N17698 001

May CAHN

UREAPHIL

+ HOSPIRA

40GM/VIAL

N12154 001

May CAHN

URSODIOL

TABLET; ORAL

URSO

>D>	+ AXCAN SCANDIPHARM	250MG	N20675 001	Dec 10, 1997	Jul CTNA
>A>	URSO 250				
>A>	AXCAN SCANDIPHARM	250MG	N20675 001	Dec 10, 1997	Jul CTNA
>A>	URSODIOL				
	+ AXCAN SCANDIPHARM	500MG	N20675 002	Jul 21, 2004	Jul NEWA

VALACYCLOVIR HYDROCHLORIDE

TABLET; ORAL

VALTREX

+ GLAXOSMITHKLINE

EQ 1GM BASE

N20487 002 Jun 23, 1995 Feb CRLD

VANCOMYCIN HYDROCHLORIDE

FOR SOLUTION; ORAL

VANCOCIN HCL

@ LILLY

EQ 250MG BASE/5ML

N61667 002 Jul 13, 1983 Jun DISC

@

EQ 500MG BASE/6ML

N61667 001 Jun DISC

INJECTABLE; INJECTION

VANCOCIN HCL

@ LILLY

EQ 500MG BASE/VIAL

N60180 001 Jun DISC

@

EQ 500MG BASE/VIAL

N62476 001 Mar 15, 1984 Jun DISC

@

EQ 500MG BASE/VIAL

N62716 001 Mar 13, 1987 Jun DISC

@

EQ 500MG BASE/VIAL

N62812 001 Nov 17, 1987 Jun DISC

@

EQ 1GM BASE/VIAL

N60180 002 Mar 21, 1986 Jun DISC

@

EQ 1GM BASE/VIAL

N62476 002 Mar 21, 1986 Jun DISC

@

EQ 1GM BASE/VIAL

N62716 002 Mar 13, 1987 Jun DISC

@

EQ 1GM BASE/VIAL

N62812 002 Nov 17, 1987 Jun DISC

@

EQ 10GM BASE/VIAL

N62812 003 Nov 17, 1987 Jun DISC

VANCOMYCIN HCL

AP HOSPIRA

EQ 500MG BASE/VIAL

N62911 001 Aug 04, 1988 May CAHN

AP

EQ 500MG BASE/VIAL

N62931 001 Oct 29, 1992 May CAHN

AP

EQ 1GM BASE/VIAL

N62912 001 Aug 04, 1988 May CAHN

AP

EQ 1GM BASE/VIAL

N62933 001 Oct 29, 1992 May CAHN

AP

EQ 5GM BASE/VIAL

N63076 001 Dec 21, 1990 May CAHN

VECURONIUM BROMIDE

INJECTABLE; INJECTION

VECURONIUM BROMIDE

+ ABBOTT

4MG/VIAL

N75558 001 Sep 11, 2001 Apr CAHN

+ HOSPIRA

4MG/VIAL

N75558 001 Sep 11, 2001 May CAHN

AP

10MG/VIAL

N75164 001 Oct 21, 1999 May CAHN

AP

20MG/VIAL

N75164 002 Oct 21, 1999 May CAHN

VENLAFAXINE HYDROCHLORIDE

TABLET; ORAL			
EFFEXOR			
WYETH PHARMS INC	EQ 50MG BASE	N20151 003	Dec 28, 1993 May CRLD
+	EQ 100MG BASE	N20151 005	Dec 28, 1993 May CRLD

VERAPAMIL HYDROCHLORIDE

INJECTABLE; INJECTION			
VERAPAMIL HCL			
AP HOSPIRA	2.5MG/ML	N70577 001	Feb 02, 1987 May CAHN
AP	2.5MG/ML	N70737 001	May 06, 1987 May CAHN
AP	2.5MG/ML	N70738 001	May 06, 1987 May CAHN
AP	2.5MG/ML	N70739 001	May 06, 1987 May CAHN
AP	2.5MG/ML	N70740 001	May 06, 1987 May CAHN
AP	2.5MG/ML	N75136 001	Oct 20, 1998 May CAHN
TABLET, EXTENDED RELEASE; ORAL			
VERAPAMIL HCL			
AB BARR	120MG	N75072 001	May 25, 1999 May CMFD
AB	240MG	N75072 003	May 25, 1999 May CMFD

VINCRISTINE SULFATE

INJECTABLE; INJECTION			
ONCOVIN			
@ LILLY	1MG/ML	N14103 003	Mar 07, 1984 Mar DISC

VITAMIN A PALMITATE

INJECTABLE; INJECTION			
AQUASOL A			
+ MAYNE PHARMA USA	EQ 50,000 UNITS BASE/ML	N06823 001	Apr CAHN

WATER FOR INJECTION, STERILE

LIQUID; N/A			
BACTERIOSTATIC WATER FOR INJECTION IN PLASTIC CONTAINER			
AP HOSPIRA	100%	N18802 001	Oct 27, 1982 May CAHN
STERILE WATER FOR INJECTION IN PLASTIC CONTAINER			
@ B BRAUN	100%	N19077 001	Mar 02, 1984 May DISC
AP HOSPIRA	100%	N18233 001	May CAHN
AP	100%	N18801 001	Oct 27, 1982 May CAHN
AP	100%	N19869 001	Dec 26, 1989 May CAHN

WATER FOR IRRIGATION, STERILE

LIQUID; IRRIGATION			
STERILE WATER IN PLASTIC CONTAINER			
AT HOSPIRA	100%	N17513 001	May CAHN
AT	100%	N18313 001	May CAHN

ZIDOVUDINE

SYRUP; ORAL			
RETROVIR			
>D> GLAXOSMITHKLINE	50MG/5ML	N19910 001	Sep 28, 1989 Jul CRLD
>A> +	50MG/5ML	N19910 001	Sep 28, 1989 Jul CRLD

ZILEUTON

TABLET; ORAL

ZYFLO

>D>	@ ABBOTT	300MG	N20471 001 Dec 09, 1996 Jul CAHN
>D>	+	600MG	N20471 003 Dec 09, 1996 Jul CAHN
>A>	@ CRITICAL	300MG	N20471 001 Dec 09, 1996 Jul CAHN
>A>	+	600MG	N20471 003 Dec 09, 1996 Jul CAHN

ZINC CHLORIDE

INJECTABLE; INJECTION

ZINC CHLORIDE IN PLASTIC CONTAINER

+ HOSPIRA	EQ 1MG ZINC/ML	N18959 001 Jun 26, 1986 May CAHN
-----------	----------------	----------------------------------

ZOLPIDEM TARTRATE

TABLET; ORAL

AMBIEN

SANOFI SYNTHELABO	5MG	N19908 001 Dec 16, 1992 Apr CAHN
+	10MG	N19908 002 Dec 16, 1992 Apr CAHN

ANTAZOLINE PHOSPHATE; NAPHAZOLINE HYDROCHLORIDE

SOLUTION/DROPS; OPHTHALMIC  
VASOCON-A  
+ NOVARTIS 0.5%;0.05%

N18746 002 Jul 11, 1994 Feb CAHN

BUTOCONAZOLE NITRATE

CREAM; VAGINAL  
FEMSTAT 3  
+ BAYER 2%

N20421 001 Dec 21, 1995 Jun CAHN

CHLORHEXIDINE GLUCONATE; ISOPROPYL ALCOHOL

SPONGE; TOPICAL  
CHLORAPREP ONE-STEP FREPP  
+ MEDI FLEX HOSP 2%;70%  
SWAB; TOPICAL  
CHLORAPREP ONE-STEP SEPP  
+ MEDI FLEX HOSP 2%;70%

N20832 001 Jul 14, 2000 Jun CTNA

N21555 001 Oct 07, 2002 Jun CAIN

CHLORPHENIRAMINE MALEATE

CAPSULE, EXTENDED RELEASE; ORAL  
CHLORPHENIRAMINE MALEATE  
@ SANDOZ 12MG  
TABLET, EXTENDED RELEASE; ORAL  
EFIDAC 24 CHLORPHENIRAMINE MALEATE  
+ ALZA 16MG

N70797 001 Aug 12, 1988 Apr DISC

N19746 002 Nov 18, 1994 Mar CRLD

CHLORPHENIRAMINE MALEATE; IBUPROFEN; PSEUDOEPHEDRINE HYDROCHLORIDE

SUSPENSION; ORAL  
CHILDREN'S ADVIL ALLERGY SINUS  
+ WYETH CONS 1MG/5ML;100MG/5ML;15MG/5ML

N21587 001 Feb 24, 2004 Feb NEWA

DEXTROMETHORPHAN HYDROBROMIDE; GUAIFENESIN

TABLET, EXTENDED RELEASE; ORAL  
MUCINEX DM  
ADAMS LABS 30MG;600MG  
+ 60MG;1.2GM

N21620 002 Apr 29, 2004 Apr NEWA

N21620 001 Apr 29, 2004 Apr NEWA

GUAIFENESIN; PSEUDOEPHEDRINE HYDROCHLORIDE

TABLET, EXTENDED RELEASE; ORAL  
MUCINEX D  
ADAMS 600MG;60MG  
+ 1.2GM;120MG

N21585 001 Jun 22, 2004 Jun NEWA

N21585 002 Jun 22, 2004 Jun NEWA

IBUPROFEN

SUSPENSION; ORAL  
CHILDREN'S ELIXSURE  
TARO 100MG/5ML  
TABLET, CHEWABLE; ORAL  
IBUPROFEN  
PERRIGO 50MG  
100MG

N21604 001 Jan 07, 2004 Jan NEWA

N76359 001 Jan 16, 2004 Jan NEWA

N76359 002 Jan 16, 2004 Jan NEWA

TABLET; ORAL  
 IBUPROFEN  
 LNK 100MG N76741 001 Jun 17, 2004 Jun NEWA

IBUPROFEN POTASSIUM; PSEUDOEPHEDRINE HYDROCHLORIDE

CAPSULE; ORAL  
 ADVIL COLD AND SINUS  
 + WYETH CONS 200MG;30MG N21374 001 May 30, 2002 Mar CAIN

LORATADINE

TABLET; ORAL  
 LORATADINE  
 PERRIGO 10MG N21512 001 Jun 24, 2004 Jun NEWA  
 10MG N76301 001 Jun 25, 2004 Jun NEWA

LORATADINE; PSEUDOEPHEDRINE SULFATE

TABLET, EXTENDED RELEASE; ORAL  
 LORATADINE AND PSEUDOEPHEDRINE SULFATE  
 ANDRX PHARMS 5MG;120MG N76208 001 Jan 28, 2004 Jan NEWA  
 IMPAX LABS 10MG;240MG N75989 001 Mar 04, 2004 Mar NEWA

MICONAZOLE NITRATE

CREAM, SUPPOSITORY; TOPICAL, VAGINAL  
 MICONAZOLE 7 COMBINATION PACK  
 G AND W LABS 2%,100MG N76585 001 Mar 26, 2004 Mar NEWA  
 CREAM; TOPICAL, VAGINAL  
 MICONAZOLE 3 COMBINATION PACK  
 PERRIGO 2%,4% N76357 001 Mar 30, 2004 Mar NEWA

NAPROXEN SODIUM; PSEUDOEPHEDRINE HYDROCHLORIDE

TABLET, EXTENDED RELEASE; ORAL  
 NAPROXEN SODIUM AND PSEUDOEPHEDRINE HCL  
 PERRIGO EQ 200MG BASE;120MG N76518 001 Mar 17, 2004 Mar NEWA

NICOTINE POLACRILEX

GUM, CHEWING; BUCCAL  
 NICOTINE POLACRILEX  
 WATSON LABS EQ 2MG BASE N76568 001 Jul 29, 2004 Jul NEWA  
 EQ 2MG BASE N76569 001 Jul 29, 2004 Jul NEWA  
 EQ 4MG BASE N76568 002 Jul 29, 2004 Jul NEWA  
 EQ 4MG BASE N76569 002 Jul 29, 2004 Jul NEWA

TERBINAFINE HYDROCHLORIDE

SPRAY; TOPICAL  
 LAMISIL AT  
 + NOVARTIS 1% N21124 002 Mar 17, 2000 Feb NEWA

**DRUG PRODUCTS WITH APPROVAL UNDER SECTION 505 OF THE ACT ADMINISTERED BY THE  
CENTER FOR BIOLOGICS EVALUATION AND RESEARCH LIST**

**CUMULATIVE SUPPLEMENT NUMBER 7 JULY 2004**

---

**NO JULY 2004 APPROVALS**

**This data is provided to the Office of Generic Drugs from  
the Office of Orphan Products Development and it is not edited prior to publication.**

Orphan Products Designations and Approvals List  
July 2004

Generic Name: Indication Designated:  
 (1S)-1-(9-deazahypoxanthin-9-yl)-1,4-dideoxy-1,4-imino-D-ribitol-hydrochloride Treatment of T-cell non-Hodgkin's lymphoma

Trade Name (if present): Sponsor and Address  
 Date Designated: 1/29/2004 BioCryst Pharmaceuticals, Inc.  
 Marketing Exclusivity Date: 2190 Parkway Lake Drive  
 Birmingham AL 35244

\*\*\*\*\*  
 Generic Name: Indication Designated:  
 1-Deoxygalactonojirimycin Treatment of Fabry Disease

Trade Name (if present): Sponsor and Address  
 Date Designated: 2/25/2004 Amicus Therapeutics, Inc.  
 Marketing Exclusivity Date: 675 US Route 1  
 North Brunswick NJ 08902

\*\*\*\*\*  
 Generic Name: Indication Designated:  
 3-4'aminoisoindoline-1'-one)-1-piperidine-2,6-dione (CC-5013) Treatment of myelodysplastic syndromes

Trade Name (if present): Sponsor and Address  
 REVIMID Celgene Corporation  
 Date Designated: 1/29/2004 7 Powder Horn Drive  
 Marketing Exclusivity Date: Warren NJ 07059

\*\*\*\*\*  
 Generic Name: Indication Designated:  
 5-methyl-1-phenyl-2-(1H)-pyridone(CAS 53179-13-8) Treatment of idiopathic pulmonary fibrosis

Trade Name (if present): Sponsor and Address  
 Pirfenidone InterMune, Inc.  
 Date Designated: 3/5/2004 3280 Bayshore Blvd  
 Marketing Exclusivity Date: Brisbane CA 94005

**Orphan Products Designations and Approvals List**  
July 2004

Generic Name:  
90Y-hPAMA4

Indication Designated:  
Treatment of pancreatic cancer

Trade Name (if present):  
PAN-Cide

Sponsor and Address  
Immunomedics, Inc.  
300 American Road  
Morris Plains NJ 07950

Date Designated: 1/29/2004  
Marketing Exclusivity Date:

\*\*\*\*\*  
Generic Name:  
alpha-1-acid glycoprotein

Indication Designated:  
Treatment of cocaine overdose

Trade Name (if present):

Sponsor and Address  
Bio Products Laboratory  
Dagger Lane, Elstree  
Hertfordshire

Date Designated: 3/5/2004  
Marketing Exclusivity Date:

UNITED KINGDOM

\*\*\*\*\*  
Generic Name:  
Alpha-1-acid glycoprotein

Indication Designated:  
Treatment of tricyclic antidepressant poisoning

Trade Name (if present):

Sponsor and Address  
Bio Products Laboratory  
Dagger Lane  
Elstree, Hertfordshire

Date Designated: 3/17/2004  
Marketing Exclusivity Date:

UNITED KINGDOM

\*\*\*\*\*  
Generic Name:  
Ambrisentan

Indication Designated:  
Treatment of pulmonary arterial hypertension

Trade Name (if present):

Sponsor and Address  
Myogen, Inc.  
7575 West 103rd Avenue  
Suite 102  
Westminster CO 80021-5426

Date Designated: 7/16/2004  
Marketing Exclusivity Date:

\*\*\*\*\*  
Generic Name:  
antivenin crotaline (pit-viper) equine immune  
F(ab)2

Indication Designated:  
Treatment of envenomation by Crotaline snakes

Trade Name (if present):  
Antivipmyn

Sponsor and Address  
Rare Disease Therapeutics, Inc.  
1101 Kermit Drive,  
Suite 608  
Nashville TN 37217

Date Designated: 1/29/2004  
Marketing Exclusivity Date:

## Orphan Products Designations and Approvals List

July 2004

---

\*\*\*\*\*  
**Generic Name:** Aplidin **Indication Designated:**  
 Treatment of Acute Lymphoblastic Leukemia

**Trade Name (if present):** **Sponsor and Address**  
 PharmaMar USA, Inc  
 320 Putnam Avenue  
 Cambridge MA 02139  
**Date Designated:** 6/18/2004  
**Marketing Exclusivity Date:**

---

**Generic Name:** C1 esterase inhibitor (human) **Indication Designated:**  
 Treatment of Angioedema

**Trade Name (if present):** **Sponsor and Address**  
 Lev Pharmaceuticals, Inc.  
 236 Old Lancaster Road  
 Merion Station PA 19066  
**Date Designated:** 7/16/2004  
**Marketing Exclusivity Date:**

---

**Generic Name:** chenodeoxycholic acid **Indication Designated:**  
 Treatment of cerebrotendinous xanthomatosis

**Trade Name (if present):** Chenofalk **Sponsor and Address**  
 Dr. Falk Pharma GmbH  
 Leinenweberstrasse 5  
 Postfach 6529  
**Date Designated:** 1/29/2004  
**Marketing Exclusivity Date:**

**GERMANY**

---

**Generic Name:** Coagulation factor VIIa (recombinant) **Indication Designated:**  
 to Prevention of bleeding episodes in patients with acquired inhibitors  
**Factor VIII or Factor IX**

**Trade Name (if present):** NovoSeven **Sponsor and Address**  
 Novo Nordisk Pharmaceuticals, Inc.  
 100 College Road West  
 Princeton NJ 08540  
**Date Designated:** 7/21/2004  
**Marketing Exclusivity Date:**

---

**Generic Name:** Coagulation factor VIIa (recombinant) **Indication Designated:**  
 Prevention of bleeding episodes in Glanzmann's thrombasthenia

**Trade Name (if present):** NovoSeven **Sponsor and Address**  
 Novo Nordisk Pharmaceuticals, Inc.  
 100 College Road West

## Orphan Products Designations and Approvals List

July 2004

Date Designated: 6/18/2004  
 Marketing Exclusivity Date:

Princeton NJ 08540

\*\*\*\*\*  
 Generic Name:  
 Coagulation Factor VIIa (Recombinant)  
 to

Indication Designated:  
 Treatment of bleeding episodes in patients with acquired inhibitors  
 Factor VIII or Factor IX

Trade Name (if present):  
 NovoSeven

Sponsor and Address  
 Novo Nordisk Pharmaceuticals, Inc.  
 100 College Road West  
 Princeton NJ 08540

Date Designated: 7/16/2004  
 Marketing Exclusivity Date:

\*\*\*\*\*  
 Generic Name:  
 Coagulation factor VIIa (recombinant)  
 B,

Indication Designated:  
 Prevention of bleeding episodes in patients with hemophilia A or  
 with or without inhibitors

Trade Name (if present):  
 NovoSeven

Sponsor and Address  
 Novo Nordisk Pharmaceuticals, Inc.  
 100 College Road West  
 Princeton NJ 08540

Date Designated: 6/18/2004  
 Marketing Exclusivity Date:

\*\*\*\*\*  
 Generic Name:  
 Coagulation factor VIIa (Recombinant)

Indication Designated:  
 Treatment of bleeding episodes in Glanzmann's thrombasthenia

Trade Name (if present):  
 NovoSeven

Sponsor and Address  
 Novo Nordisk Pharmaceuticals, Inc.  
 100 College Road West  
 Princeton NJ 08540

Date Designated: 6/18/2004  
 Marketing Exclusivity Date:

\*\*\*\*\*  
 Generic Name:  
 DEAE-rebeccamycin

Indication Designated:  
 Treatment of bile duct tumors

Trade Name (if present):

Sponsor and Address  
 Exelixis, Inc.  
 170 Harbor Way  
 South San Francisco CA 94083-0511

Date Designated: 3/1/2004  
 Marketing Exclusivity Date:

\*\*\*\*\*

**Orphan Products Designations and Approvals List**  
**July 2004**

Generic Name: Deferitriptin	Indication Designated: For the treatment of iron overload
Trade Name (if present):	Sponsor and Address Genzyme Corporation 153 Second Avenue Waltham MA 02451
Date Designated: 4/14/2004	*****
Marketing Exclusivity Date:	
Generic Name: Dexrazoxane	Indication Designated: Treatment of anthracycline extravasation during chemotherapy
Trade Name (if present):	Sponsor and Address Topo Target A/S Fruebjergvej 3, 2100 Copenhagen
Date Designated: 3/25/2004	*****
Marketing Exclusivity Date:	DENMARK
Generic Name: diethylenetriaminepentaacetate (DPTA)	Indication Designated: For treatment of patients with known or suspected internal contamination with plutonium, americium or curium to increase the rates of elimination.
Trade Name (if present):	Sponsor and Address CIS-US 10 DeAngelo Drive Bedford MA 01730
Date Designated: 4/14/2004	*****
Marketing Exclusivity Date:	
Generic Name: Diethylenetriaminepentaacetic acid (DTPA) contamination	Indication Designated: Treatment of patients with known or suspected internal with plutonium, americum, or curium to increase the rates of elimination.
Trade Name (if present):	Sponsor and Address Hameln Pharmaceuticals gmbh Langes Feld 13 Hameln
Date Designated: 4/28/2004	*****
Marketing Exclusivity Date:	GERMANY
Generic Name: Diethylnorspermine (DENSPM)	Indication Designated: Treatment for hepatocellular carcinoma
Trade Name (if present):	Sponsor and Address Genzyme Corporation 153 Second Avenue

## Orphan Products Designations and Approvals List

July 2004

Date Designated: 5/25/2004  
 Marketing Exclusivity Date:

Waltham MA 02451

\*\*\*\*\*  
 Generic Name:  
 Doripenem

Indication Designated:  
 Treatment of bronchopulmonary infection in patients with cystic fibrosis who are colonized with *Pseudomonas aeruginosa* or *Burkholderia cepacia*.

Trade Name (if present):

Sponsor and Address  
 Peninsula Pharmaceuticals, Inc.  
 1751 Harbor Bay Parkway  
 Alameda CA 94502

Date Designated: 7/16/2004  
 Marketing Exclusivity Date:

\*\*\*\*\*  
 Generic Name:  
 efaproxiral  
 brain

Indication Designated:  
 An adjunct to whole brain radiation therapy for the treatment of metastases in patients with breast cancer.

Trade Name (if present):

Sponsor and Address  
 Allos Therapeutics, Inc.  
 11080 CirclePoint Road  
 Suite 200  
 Westminster CO 80020

Date Designated: 7/28/2004  
 Marketing Exclusivity Date:

\*\*\*\*\*  
 Generic Name:  
 human anti-transforming growth factor-B1,2,3

Indication Designated:  
 Treatment of idiopathic pulmonary fibrosis

Trade Name (if present):

Sponsor and Address  
 Genzyme Corporation  
 500 Kendall Street  
 Cambridge MA 02142

Date Designated: 7/9/2004  
 Marketing Exclusivity Date:

\*\*\*\*\*  
 Generic Name:  
 human immunoglobulin (IgG1k)antiCTLA-4  
 monoclonal antibody

Indication Designated:  
 Treatment of high risk Stage II, Stage III, and Stage IV melanoma

Trade Name (if present):

Sponsor and Address  
 Medarex, Inc.  
 519 Route 173 West  
 Bloomsbury NJ 08804

Date Designated: 6/3/2004  
 Marketing Exclusivity Date:

\*\*\*\*\*  
 Generic Name:  
 hydralazine  
 pressure

Indication Designated:  
 Treatment of severe intrapartum hypertension (diastolic blood pressure greater than or equal to 110 or systolic blood pressure less than or

## Orphan Products Designations and Approvals List

July 2004

Trade Name (if present): equal to 160) associated with severe preeclampsia/eclampsia of pregnancy

Date Designated: 4/9/2004 Sponsor and Address  
Marketing Exclusivity Date: Esp Pharma, Inc.

2035 Lincoln Hwy.  
Suite 2150  
Edison NJ 08817

---

Generic Name: Indication Designated:  
Icatibant acetate Treatment of burn patients hospitalized with burn-induced edema

Trade Name (if present): Sponsor and Address  
Date Designated: 5/5/2004 Jerini AG  
Marketing Exclusivity Date: Invalidenstr, 130  
10115 Berlin

**GERMANY**

---

Generic Name: Indication Designated:  
Idebenone (INN) Treatment of cardiomyopathy associated with Friedreich's ataxia

Trade Name (if present): Sponsor and Address  
Date Designated: 3/25/2004 MyoContract Ltd.  
Marketing Exclusivity Date: Hammerstrasse 25  
CH-4410 Liestal

**SWITZERLAND**

---

Generic Name: Indication Designated:  
Immortalized human liver cells found in the Treatment of fulminant hepatic failure (acute liver failure)  
extracorporeal liver assist device

Trade Name (if present): Sponsor and Address  
ELAD Vital Therapies, Inc.  
Date Designated: 7/16/2004 15222 Avenue of Science  
Marketing Exclusivity Date: Suite C  
San Diego CA 92128

---

Generic Name: Indication Designated:  
Immune Globulin (Human) Treatment of chronic inflammatory demyelinating polyneuropathy

Trade Name (if present): Sponsor and Address  
Gamunex Bayer Corporation  
Date Designated: 7/27/2004 800 Dwight Way  
Marketing Exclusivity Date: Berkley CA 94701-1986

**Orphan Products Designations and Approvals List**  
July 2004

Generic Name:  
Immune Globulin (Human) containing high titers  
of West Nile virus antibodies

Indication Designated:  
Treatment of the West Nile virus infection

Trade Name (if present):  
Omr-IgG-am (tm) 5% (WNV)

Sponsor and Address  
OMRIX Biopharmaceuticals, Ltd.  
Plasma Fractionation Institute  
Ramat Gan 52621

Date Designated: 3/17/2004  
Marketing Exclusivity Date:

ISRAEL

\*\*\*\*\*  
Generic Name:  
Immune Globulin Intravenous (human)

Indication Designated:  
Treatment for Guillain Barre Syndrome

Trade Name (if present):  
Carimune NF

Sponsor and Address  
ZLB Bioplasma AG  
Wankdorffstrasse 10  
CH-3000 Bern 22

Date Designated: 5/4/2004  
Marketing Exclusivity Date:

SWITZERLAND

\*\*\*\*\*  
Generic Name:  
Liarozole

Indication Designated:  
The treatment of congenital ichthyosis

Trade Name (if present):

Sponsor and Address  
Barrier Therapeutics, Inc  
600 College Road East  
Princeton NJ 08540

Date Designated: 6/18/2004  
Marketing Exclusivity Date:

\*\*\*\*\*  
Generic Name:  
mannopentaose phosphate sulfate

Indication Designated:  
Treatment of high-risk Stage II, Stage III, and Stage IV melanoma

Trade Name (if present):

Sponsor and Address  
Progen Industries Limited  
P. O. Box 28  
Richlands 4077

Date Designated: 4/27/2004  
Marketing Exclusivity Date:

AUSTRALIA

\*\*\*\*\*  
Generic Name:  
Melatonin

Indication Designated:  
Treatment of non-24-hour sleep-wake disorder in blind individuals  
without light perception

Trade Name (if present):  
Circadin

Sponsor and Address  
Neurim Pharmaceuticals, Ltd.  
8 Hanechoshet St.  
Tel-Aviv

Date Designated: 7/9/2004

## Orphan Products Designations and Approvals List

July 2004

Marketing Exclusivity Date:

ISRAEL

\*\*\*\*\*  
**Generic Name:**  
 mepolizumab  
 syndrome

**Indication Designated:**  
 For first-line treatment in patients with hypereosinophilic

Trade Name (if present):

**Sponsor and Address**  
 GlaxoSmithKline Pharmaceuticals  
 P.O. Box 7929  
 Philadelphia PA 19101

Date Designated: 5/28/2004

Marketing Exclusivity Date:

\*\*\*\*\*  
**Generic Name:**  
 Multi-ligand somatostatin analogue

**Indication Designated:**  
 Treatment of patients with functional gastroenteropancreatic (GEP)  
 neuroendocrine tumors (specifically, carcinoid, insulinoma,  
 gastrinoma, somastatinoma, GRFoma, VIPoma and glucagonoma.)

Trade Name (if present):

**Sponsor and Address**  
 Novartis Pharmaceuticals Corporation  
 One Health Plaza  
 East Hanover NJ 07936-1080

Date Designated: 7/27/2004

Marketing Exclusivity Date:

\*\*\*\*\*  
**Generic Name:**  
 multi-vitamin infusion without vitamin K  
 complications

**Indication Designated:**  
 Prevention of vitamin deficiency and thromboembolic  
 in people receiving home parenteral nutrition and warfarin-type  
 anticoagulant therapy

Trade Name (if present):  
 M.V.I.-12

**Sponsor and Address**  
 Mayne Pharma (USA) Inc.  
 Mack-Cali Centre II  
 Second Floor  
 Paramus NJ 07652

Date Designated: 3/8/2004  
 Marketing Exclusivity Date:

\*\*\*\*\*  
**Generic Name:**  
 oral unfractionated heparin

**Indication Designated:**  
 Treatment of sickle cell disease

Trade Name (if present):

**Sponsor and Address**  
 TRF Technologies, Inc.  
 108 Eagle Trace Drive  
 Half Moon Bay CA 94019

Date Designated: 1/29/2004  
 Marketing Exclusivity Date:

\*\*\*\*\*  
**Generic Name:**  
 pentetate trisodium  
 contamination

**Indication Designated:**  
 Treatment of patients with known or suspected internal  
 with plutonium, americium, or curium.

**Orphan Products Designations and Approvals List**  
**July 2004**

Trade Name (if present):  
diethylenetriaminepentaacetate

Sponsor and Address  
Heyl Chemisch-Pharmazeutische Fabrik GMBH & Co. KG  
Goerzallee 253

Date Designated: 4/12/2004  
Marketing Exclusivity Date:

Federal of Republic of Germany

GERMANY

Generic Name:  
posaconazole

Indication Designated:  
Treatment of zygomycosis

Trade Name (if present):  
Posoril

Sponsor and Address  
Schering Corporation  
2000 Galloping Hill Road  
Kenilworth NJ 07033

Date Designated: 7/16/2004  
Marketing Exclusivity Date:

Generic Name:  
Quinine Sulfate

Indication Designated:  
Treatment of malaria

Trade Name (if present):

Sponsor and Address  
Mutual Pharmaceutical Company, Inc.  
1100 Orthodox Street  
Philadelphia PA 19124

Date Designated: 6/3/2004  
Marketing Exclusivity Date:

Generic Name: Indication Designated:  
recombinant human fibroblast growth factor-20

Treatment of radiation induced oral mucositis

Trade Name (if present):

Sponsor and Address  
CuraGen Corporation  
322 East Main Street  
Branford CT 06405

Date Designated: 1/29/2004  
Marketing Exclusivity Date:

Generic Name:  
Recombinant Porcine Factor VIII, B-domain  
inhibitor  
Deleted

Indication Designated:  
Treatment and prevention of episodic bleeding in patients with  
antibodies to human coagulation factor VIII

Trade Name (if present):

Sponsor and Address  
Ipsen Limited  
190 Bath Road  
Berkshire S11 3XE

Date Designated: 3/16/2004  
Marketing Exclusivity Date:

UNITED KINGDOM

## Orphan Products Designations and Approvals List

July 2004

**Generic Name:** rh-microplasmin      **Indication Designated:**  
Adjunct to surgery in cases of pediatric vitrectomy

**Trade Name (if present):**

**Date Designated:** 3/16/2004      **Sponsor and Address**  
**Marketing Exclusivity Date:**

ThromboGenics Ltd  
Unit 14  
Bridgecourt Office Park  
Dublin 12  
IRELAND

---

**Generic Name:** Rituximab      **Indication Designated:**  
Treatment of chronic lymphocytic leukemia

**Trade Name (if present):** Rituxan      **Sponsor and Address**  
**Date Designated:** 1/29/2004      Biogen IDEC, Inc.  
**Marketing Exclusivity Date:** 3030 Callan Road  
San Diego CA 92121

---

**Generic Name:** rofecoxib      **Indication Designated:**  
Treatment of juvenile rheumatoid arthritis

**Trade Name (if present):** VIOXX      **Sponsor and Address**  
**Date Designated:** 3/16/2004      MERCK & Co., Inc.  
**Marketing Exclusivity Date:** 126 East Lincoln Ave.  
Rahway NJ 07065

---

**Generic Name:** sarsasapogenin      **Indication Designated:**  
Treatment of amyotrophic lateral sclerosis (ALS)

**Trade Name (if present):**

**Date Designated:** 6/18/2004      **Sponsor and Address**  
**Marketing Exclusivity Date:**

Phytopharm plc  
Corpus Christi House  
Godmanchester, Cambridgeshire PE29 2HY

UNITED KINGDOM

---

**Generic Name:** SGN-30 (anti-CD30 antibody)      **Indication Designated:**  
For the treatment of CD30 positive T-cell lymphomas

**Trade Name (if present):**

**Date Designated:** 2/18/2004      **Sponsor and Address**  
**Marketing Exclusivity Date:**

Seattle Genetics, Inc.  
21823 30th Drive Southeast  
Bothell WA 98021

**Orphan Products Designations and Approvals List**  
July 2004

*****	Generic Name: sodium thiosulfate	Indication Designated: Prevention of platinum-induced ototoxicity in pediatric patients
Trade Name (if present):		Sponsor and Address Adherex Technologies, Inc. 600 Peter Morand Crescent Ottawa, Ontario
Date Designated:	3/17/2004	
Marketing Exclusivity Date:		CANADA
*****		
Generic Name: somatropin	Indication Designated: Treatment of patients with HIV-associated adipose redistribution syndrome	
Trade Name (if present):		Sponsor and Address Serono, Inc. One Technology Place Rockland MA 02370
Date Designated:	3/16/2004	
Marketing Exclusivity Date:		*****
*****		
Generic Name: Staphylococcus aureus Immune Globulin (Human)	Indication Designated: Prophylaxis against Staphylococcus aureus infections in low birth weight neonates	
Trade Name (if present):		Sponsor and Address Nabi Biopharmaceuticals 12276 Wilkins Avenue Rockville MD 20852
Date Designated:	1/29/2004	
Marketing Exclusivity Date:		*****
*****		
Generic Name: Suberoylanilide Hydroxamic Acid	Indication Designated: Treatment of mesothelioma	
Trade Name (if present):		Sponsor and Address Aton Pharma, Inc. 777 Old Saw Mill River Road Tarrytown NY 10591-6717
Date Designated:	3/17/2004	
Marketing Exclusivity Date:		*****
*****		
Generic Name: Suberoylanilide Hydroxamic Acid (SAHA)	Indication Designated: Treatment of T-cell non-Hodgkin's lymphoma	
Trade Name (if present):		Sponsor and Address Aton Pharma, Inc. 777 Old Saw Mill River Road Tarrytown NY 10591-6717
Date Designated:	3/16/2004	

## Orphan Products Designations and Approvals List

July 2004

Marketing Exclusivity Date:

\*\*\*\*\*  
Generic Name:  
temocillin sodium

Indication Designated:  
Treatment of pulmonary infections caused by Burkholderia cepacia

Trade Name (if present):  
Negaban

Sponsor and Address  
Belpharma N.V.  
67 Winston Churchill Avenue  
Brussels

Date Designated: 4/21/2004  
Marketing Exclusivity Date:

\*\*\*\*\*  
BELGIUM

\*\*\*\*\*  
Generic Name:  
tetrahydrobiopterin

Indication Designated:  
For treatment of hyperphenylalaninemia

Trade Name (if present):

Sponsor and Address  
Biomarin Pharmaceutical Inc.  
371 Bel Marin Blvd.  
Novato CA 94949

Date Designated: 1/29/2004  
Marketing Exclusivity Date:

\*\*\*\*\*  
Generic Name:  
Thymosin Beta 4

Indication Designated:  
Treatment of Epidermolysis Bullosa

Trade Name (if present):

Sponsor and Address  
RegeneRx Biopharmaceuticals, Inc.  
3 Bethesda Metro Center  
Suite 700  
Bethesda MD 20814

Date Designated: 5/28/2004  
Marketing Exclusivity Date:

\*\*\*\*\*  
Generic Name:  
Tipifarnib

Indication Designated:  
Treatment of acute myeloid leukemia

Trade Name (if present):  
Zarnestra

Sponsor and Address  
Johnson & Johnson Pharmaceutical Research & Dev.  
920 U.S. Highway 202  
Raritan NJ 08869

Date Designated: 7/6/2004  
Marketing Exclusivity Date:

\*\*\*\*\*  
Generic Name:  
Trisodium zinc Diethylenetriaminepentaacetate  
contamination

Indication Designated:  
Treatment of patients with known or suspected internal  
with plutonium, americium, or curium to increase the rate of  
elimination.

Trade Name (if present):

Sponsor and Address

**Orphan Products Designations and Approvals List**  
July 2004

Date Designated:	2/27/2004	CustomCare Pharmacy 5710 Hoover Blvd Tampa FL 33634
Marketing Exclusivity Date:		
<hr/>		
Generic Name:	Ubiquinol	Indication Designated: Treatment of Huntington's Disease
Trade Name (if present):	Ubi-Q-Nol, Li-Q-Nol	Sponsor and Address Gel-Tec Division of Tishcon Corp P. O. Box 331 Westbury NY 11590
Date Designated:	4/12/2004	
Marketing Exclusivity Date:		
<hr/>		
Generic Name:	ubiquinol, coenzyme Q10, ubiquinone	Indication Designated: Treatment of pediatric congestive heart failure
Trade Name (if present):	UBI-Q-NOL	Sponsor and Address Gel-Tec, Division of TISHCON Corporation 30 New York Avenue P.O. Box 331 Westbury NY 11590
Date Designated:	4/12/2004	
Marketing Exclusivity Date:		
<hr/>		
Generic Name:	Vaccinia Immune Globulin (Human) Intravenous	Indication Designated: Treatment of complications of vaccinia vaccination
Trade Name (if present):	CNJ-016	Sponsor and Address Cangene Corporation 104 Chancellor Matheson Road Winnipeg, Manitoba R3T 5Y3
Date Designated:	6/18/2004	
Marketing Exclusivity Date:		CANADA
<hr/>		
Generic Name:	Vaccinia Immune Globulin (Human) Intravenous	Indication Designated: Treatment of severe complications from the smallpox vaccine
Trade Name (if present):		
Date Designated:	6/18/2004	
Marketing Exclusivity Date:		
<hr/>		
Generic Name:	vapreotide	Indication Designated: Treatment of symptomatic carcinoid tumors

Orphan Products Designations and Approvals List  
July 2004

Trade Name (if present):

Sanvar

Sponsor and Address

H3 Pharma, Inc.

666 Sherbrooke Street West Suite 1400

Montreal, Quebec,

Date Designated: 4/6/2004

CANADA

Marketing Exclusivity Date:

\*\*\*\*\*

DRUG PRODUCTS WHICH MUST DEMONSTRATE *IN VIVO* BIOAVAILABILITY ONLY  
IF PRODUCT FAILS TO ACHIEVE ADEQUATE DISSOLUTION

---

NO JULY 2004 ADDITIONS

## PRESCRIPTION AND OTC DRUG PRODUCT

## PATENT AND EXCLUSIVITY DATA

See report footnotes for information regarding report content

APPL/ PROD NUMBER	INGREDIENT NAME; TRADE NAME	PATENT NUMBER	PATENT/PED EXCL EXPIRES	PATENT CODE (S)	EXCLUS CODE	EXCLUS EXPIRES
>ADD> 020977 001	ABACAVIR SULFATE; ZIAGEN	5968895	DEC 11, 2016	DP	D-40	AUG 02, 2007
>ADD> 020978 001	ABACAVIR SULFATE; ZIAGEN	6180608	DEC 11, 2016	DP	D-40	AUG 02, 2007
>ADD> 021320 001	ABARELIX; PLENAXIS	6423686	JUN 07, 2015	DS		
>ADD>		6455499	JUN 07, 2015	U549		
>ADD>		5843901	DEC 01, 2015	DS DP		
>ADD>		6699833	DEC 11, 2016	DP	NCE ODE	JUL 29, 2009 JAN 23, 2011
>ADD> 021431 001	ACAMPROSATE CALCIUM; CAMPRAL	6723303	APR 20, 2021	DP		
>ADD> 021539 001	ACETYLCYSTEINE; ACETADOTE	6702997	DEC 28, 2021	U558		
>ADD> 020899 001	ALBUMIN HUMAN; OPTISON	6702997	DEC 28, 2021	U558		
>ADD> 020949 001	ALBUTEROL SULFATE; ACCUNEB	6170717	DEC 23, 2017	DP		
>ADD> 020949 002	ALBUTEROL SULFATE; ACCUNEB	6315173	DEC 23, 2017	DP		
>ADD> 020983 001	ALBUTEROL SULFATE; VENTOLIN HFA	6510969	DEC 23, 2017	DP		
>ADD>		6131566	APR 14, 2015	DP U589		
>ADD>		6532955	APR 14, 2015	DP U590	D-87	APR 16, 2007
>ADD> 020560 005	ALENDRONATE SODIUM; FOSAMAX	5932622	AUG 03, 2016	U562	D-87	APR 16, 2007
021575 001	ALENDRONATE SODIUM; FOSAMAX	5273995	DEC 28, 2010	DS DP U162	NC	JAN 30, 2007
020886 001	ALITRETEINOIN; PANRETIN	5273995* PED	JUN 28, 2011			
021540 001	AMLODIPINE BESYLATE; CADUET	6455574	AUG 11, 2018	U552		
>ADD>		5969156	JUL 08, 2016	DS		
>ADD>		5969156* PED	JUN 08, 2016	DS		
>ADD>		5686104	NOV 11, 2014	DP U213		
>ADD>		5686104* PED	MAY 11, 2015	DP		
>ADD>		6126971	JAN 19, 2013	DP		
>ADD>		6126971* PED	JUL 19, 2013	DS DP U161		
>ADD>		4681893	SEP 24, 2009	DS DP U161		
>ADD>		4681893* PED	MAR 24, 2010	DS DP		
>ADD>		4879303	MAR 25, 2007	DS DP		
>ADD>		4879303* PED	SEP 25, 2007	DS DP		
>ADD>		4572909	JUL 31, 2006	DS DP U3		
>ADD>		4572909* PED	JAN 31, 2007	DS DP U161	NC	JAN 30, 2007
021540 002	AMLODIPINE BESYLATE; CADUET	4681893	SEP 24, 2009	DS DP U161		
>ADD>		4681893* PED	MAR 24, 2010	DS DP		
>ADD>		4879303	MAR 25, 2007	DS DP		
>ADD>		4879303* PED	SEP 25, 2007	DS DP		
>ADD>		4572909	JUL 31, 2006	DS DP U3		
>ADD>		4572909* PED	JAN 31, 2007	DS DP U161	NC	JAN 30, 2007
>ADD>		5273995	DEC 28, 2010	DS DP U162		
>ADD>		5273995* PED	JUN 28, 2011	DS DP		
>ADD>		6455574	AUG 11, 2018	U552		
>ADD>		5969156	JUL 08, 2016	DS		
>ADD>		5969156* PED	JAN 08, 2017	DS DP U3		
>ADD>		5686104	NOV 11, 2014	DP U213		
>ADD>		5686104* PED	MAY 11, 2015	DP		
>ADD>		6126971	JAN 19, 2013	DP		
>ADD>		6126971* PED	JUL 19, 2013	DS DP U161	NC	JAN 30, 2007
021540 003	AMLODIPINE BESYLATE; CADUET	4681893	SEP 24, 2009	DS DP U161		
>ADD>		4681893* PED	MAR 24, 2010	DS DP		
>ADD>		4879303	MAR 25, 2007	DS DP		
>ADD>		4879303* PED	SEP 25, 2007	DS DP U3		
>ADD>		4572909	JUL 31, 2006	DS DP U3		
>ADD>		4572909* PED	JAN 31, 2007	DS DP U161	NC	JAN 30, 2007

PREScription AND OTC DRUG PRODUCT  
PATENT AND EXCLUSIVITY DATA

see report footnotes for information regarding raw satudavix data

PREScription AND OTC DRUG PRODUCT

See report footnotes for information regarding report content  
**PARENT AND EXCLUSIVITY DATA**

## PRESCRIPTION AND OTC DRUG PRODUCT

## PATENT AND EXCLUSIVITY DATA

See report footnotes for information regarding report content

APPL/PROD NUMBER	INGREDIENT NAME; TRADE NAME	PATENT NUMBER	PATENT/PED EXCL EXPIRES	PATENT CODE (S)	EXCLUS CODE	EXCLUS EXPIRES
019851 001	BENAZEPRIL HYDROCHLORIDE; LOTENSIN			M-30	MAR 02, 2007	
019851 002	BENAZEPRIL HYDROCHLORIDE; LOTENSIN			PED	SEP 02, 2007	
019851 003	BENAZEPRIL HYDROCHLORIDE; LOTENSIN			M-30	MAR 02, 2007	
019851 004	BENAZEPRIL HYDROCHLORIDE; LOTENSIN			PED	SEP 02, 2007	
021551 001	BISACODYL; HALFLYTELY	6713446	JAN 25, 2022	DP		
021602 001	BORTEZOMIB; VELCADE	6747150	OCT 28, 2014	DP		
020746 001	BUDESONIDE; RHINOCORT	6686346	APR 29, 2017	DP	U557	
020746 002	BUDESONIDE; RHINOCORT	6686346	APR 29, 2017	DP	U557	
019880 001	CARBOPLATIN; PARAPLATIN	4657927	APR 14, 2004	U175		
019880 002	CARBOPLATIN; PARAPLATIN	4657927*PED	OCT 14, 2004	U175		
019880 003	CARBOPLATIN; PARAPLATIN	4657927	APR 14, 2004	U175		
020452 001	CARBOPLATIN; PARAPLATIN	4657927	APR 14, 2004	U175		
020452 002	CARBOPLATIN; PARAPLATIN	4657927	APR 14, 2004	U175		
020452 003	CARBOPLATIN; PARAPLATIN	4657927*PED	OCT 14, 2004	DP	U175	
020452 004	CARBOPLATIN; PARAPLATIN	4657927	OCT 14, 2004	DP	U175	
021621 001	CETIRIZINE HYDROCHLORIDE; ZYRTEC	4657927	APR 14, 2004	DP	U175	
021621 002	CETIRIZINE HYDROCHLORIDE; ZYRTEC	4657927*PED	OCT 14, 2004	DP	U175	
020989 002	CEVIMELINE HYDROCHLORIDE; EVOXAC	4525358	JUN 25, 2007	DS	DP U565	
021587 001	CHLORPHENIRAMINE MALEATE; CHILDREN'S ADVIL ALL	4525358*PED	OCT 14, 2004	DS	DP U565	
021449 002	CHORILOGONADOTROPIN ALFA; OVIDREL	4525358	JUN 25, 2007	DS	DP U565	
021688 001	CINACALCET HYDROCHLORIDE; SENSIPIAR	4525358	OCT 14, 2007	DP		
021688 002	CINACALCET HYDROCHLORIDE; SENSIPIAR	67066681	JUL 02, 2018	DP		
021688 003	CINACALCET HYDROCHLORIDE; SENSIPIAR	6031003	JUL 02, 2018	DP		
021688 004	CINACALCET HYDROCHLORIDE; SENSIPIAR	6211244	JUN 25, 2007	DS	DP U560	
021688 005	CINACALCET HYDROCHLORIDE; SENSIPIAR	6313146	OCT 23, 2015	DS	DP U560	
021688 006	CINACALCET HYDROCHLORIDE; SENSIPIAR	601068	DEC 14, 2016	DS	DP	
021688 007	CINACALCET HYDROCHLORIDE; SENSIPIAR	601068	DEC 14, 2016	ODE	NCE	
021688 008	CINACALCET HYDROCHLORIDE; SENSIPIAR	6031003	DEC 14, 2016	ODE	NCE	
021688 009	CINACALCET HYDROCHLORIDE; SENSIPIAR	6211244	OCT 23, 2015	DS	DP U560	
021688 010	CINACALCET HYDROCHLORIDE; SENSIPIAR	6313146	DEC 14, 2016	DS	DP	
021688 011	CINACALCET HYDROCHLORIDE; SENSIPIAR	601068	DEC 14, 2016	ODE	NCE	
021688 012	CINACALCET HYDROCHLORIDE; SENSIPIAR	6031003	DEC 14, 2016	ODE	NCE	
021688 013	CINACALCET HYDROCHLORIDE; SENSIPIAR	6211244	OCT 23, 2015	DS	DP U560	
021688 014	CINACALCET HYDROCHLORIDE; SENSIPIAR	6313146	DEC 14, 2016	DS	DP	
021688 015	CINACALCET HYDROCHLORIDE; SENSIPIAR	601068	DEC 14, 2016	ODE	NCE	
019537 001	CIPROFLOXACIN HYDROCHLORIDE; CIPRO	I-421	MAR 25, 2007			
019537 002	CIPROFLOXACIN HYDROCHLORIDE; CIPRO	PED	SEP 25, 2007			

## PRESCRIPTION AND OTC DRUG PRODUCT

## PATENT AND EXCLUSIVITY DATA

See report footnotes for information regarding report content

APPL/PROD NUMBER	INGREDIENT NAME; TRADE NAME	PATENT NUMBER	PATENT/PED EXCL EXPIRES	PATENT CODE (S)	EXCLUS CODE	EXCLUS EXPIRES
019537 003	CIPROFLOXACIN HYDROCHLORIDE; CIPRO				I-421	MAR 25, 2007
019537 004	CIPROFLOXACIN HYDROCHLORIDE; CIPRO				PED	SEP 25, 2007
020805 001	CIPROFLOXACIN HYDROCHLORIDE; CIPRO HC	59655549	JUN 06, 2015	DP	I-421	MAR 25, 2007
019847 001	CIPROFLOXACIN; CIPRO				PED	I-421
020780 001	CIPROFLOXACIN; CIPRO				PED	SEP 25, 2007
020780 002	CIPROFLOXACIN; CIPRO IN DEXTROSE 5%				PED	MAR 25, 2007
019857 001	CIPROFLOXACIN; CIPRO IN SODIUM CHLO				PED	SEP 25, 2007
019858 001	CIPROFLOXACIN; CIPRO IN SODIUM CHLO				PED	MAR 25, 2007
021473 002	CIPROFLOXACIN; CIPRO XR				NDF	FEB 05, 2007
021644 001	CLOBETASOL PROPIONATE; CLOBEX	6716867	MAR 31, 2019	U572		
021038 001	DEXMEDIETOMIDINE; PRECEDEX	6528550	DEC 04, 2015	DS DP		
>ADD>	021278 001	6528550	DEC 01, 2015	DS DP		
>ADD>	021278 002	6528550	DEC 01, 2015	DS DP		
>ADD>	021278 003	6528550				
021392 001	DILTIAZEM HYDROCHLORIDE; CARDIZEM LA					
021392 002	DILTIAZEM HYDROCHLORIDE; CARDIZEM LA					
021392 003	DILTIAZEM HYDROCHLORIDE; CARDIZEM LA					
021392 004	DILTIAZEM HYDROCHLORIDE; CARDIZEM LA					
021392 005	DILTIAZEM HYDROCHLORIDE; CARDIZEM LA					
021392 006	DILTIAZEM HYDROCHLORIDE; CARDIZEM LA					
>ADD>	021168 001	DIVALPROEX SODIUM; DEPAKOTE ER				
020449 001	DOCETAXEL; TAXOTERE	4959366	SEP 25, 2007			
020931 001	DOFETILIDE; TIROSYN	4959366	SEP 25, 2007			
020931 002	DOFETILIDE; TIROSYN	4959366	SEP 25, 2007			
020931 003	DORZOLAMIDE HYDROCHLORIDE; COSOPT	6316443	APR 17, 2011	DP U561		
020869 001	DORZOLAMIDE HYDROCHLORIDE; TRUSOPT	4797413	APR 28, 2008	DS DP U103		
020408 001	DORZOLAMIDE HYDROCHLORIDE; TRUSOPT	4619939	OCT 28, 2003	DP U104		
020862 001	DOXERCALCIFEROL; HECTOROL	5869473	AUG 02, 2008	U278	I-424	APR 23, 2007
020862 002	DOXERCALCIFEROL; HECTOROL	6703418	FEB 26, 2011	U563	I-424	APR 23, 2007
>ADD>	018651 001	DRONABINOL; MARINOL				

PREScription AND OTC DRUG PRODUCT  
PATENT AND EXCLUSIVITY DATA

See report footnotes for information regarding report content.

APPL/PROD NUMBER	INGREDIENT NAME; TRADE NAME	PATENT NUMBER	PATENT/PED EXCL EXPIRES	PATENT CODE(S)	EXCLUS CODE	EXCLUS EXPIRES
018651 002	DRONABINOL; MARINOL	6703418	FEB 26, 2011	U563		
018651 003	DRONABINOL; MARINOL	6703418	FEB 26, 2011	U563		
021500 001	EMTRICITABINE; EMTRIVA	6703396	MAR 09, 2021	DS DP		
021504 001	EPINEPHRINE; LIDOSITE TOPICAL SYS					
021437 001	EPLERENONE; INSPRA	6747020	NOV 05, 2019	U587	NP	MAY 04, 2007
021437 002	EPLERENONE; INSPRA	6747020	NOV 05, 2019	U587		
021437 003	EPLERENONE; INSPRA	56229021	JAN 31, 2015	DP	NDF	OCT 09, 2006
021371 001	ESTRADIOL; HEMIHYDRATE; ESTRASORB				NDF	FEB 09, 2007
021166 001	ESTRADIOL; ESTROGEL				NDF	JUN 08, 2007
021674 001	ESTRADIOL; MENOSTAR				NP	
021040 001	ESTRADIOL; PREFEST				NP	
020992 002	ESTROGENS, CONJUGATED SYNTHETIC A; CENESTIN	6747019	MAR 20, 2020	U311	D-85	FEB 05, 2007
020992 003	ESTROGENS, CONJUGATED SYNTHETIC A; CENESTIN				D-85	FEB 05, 2007
020992 004	ESTROGENS, CONJUGATED SYNTHETIC A; CENESTIN				D-85	FEB 05, 2007
020992 006	ESTROGENS, CONJUGATED SYNTHETIC A; CENESTIN				NS	FEB 05, 2007
021443 003	ESTROGENS, CONJUGATED SYNTHETIC B; ENJUVIA				D-85	FEB 05, 2007
021443 004	ESTROGENS, CONJUGATED SYNTHETIC B; ENJUVIA				NP	MAY 10, 2007
>ADD>	021490 001	ETHINYL ESTRADIOL; OVCON-35	66667050	JUN 12, 2021	DP U1	NP
>ADD>	021687 001	EZETIMIBE; VYTORIN				MAY 10, 2007
>ADD>	021687 002	EZETIMIBE; VYTORIN				
>ADD>	021687 003	EZETIMIBE; VYTORIN				
>ADD>	021687 004	EZETIMIBE; VYTORIN				
>ADD>	020363 001	FAMCICLOVIR; FAMVIR				
020363 002	FAMCICLOVIR; FAMVIR					
020363 003	FAMCICLOVIR; FAMVIR					
019922 001	FENOLDOPAM MESYLATE; CORLOPAM	4760071	JUN 19, 2006	DS DP	I-422	APR 01, 2007
020180 001	FINASTERIDE; PROSCAR				DS	
019949 001	FLUCONAZOLE; DIFLUCAN	58866184	NOV 19, 2012			
019949 002	FLUCONAZOLE; DIFLUCAN	6046783	MAR 20, 2011		DS	DP U577
019949 003	FLUCONAZOLE; DIFLUCAN	4404216*	JAN 29, 2004			
019949 004	FLUCONAZOLE; DIFLUCAN	4404216*	JUL 29, 2004			
020090 001	FLUCONAZOLE; DIFLUCAN	4404216*	JAN 29, 2004			
020090 002	FLUCONAZOLE; DIFLUCAN	4404216*	JUL 29, 2004			
019950 003	FLUCONAZOLE; DIFLUCAN IN DEXTROSE	4404216*	JAN 29, 2004			

APPL/ PROD NUMBER	INGREDIENT NAME; TRADE NAME	PATENT NUMBER	PATENT/PED EXCL		PATENT CODE (S)	EXCLUS CODE	EXCLUS EXPIRES
			EXCL EXPIRES	PATENT EXPIRES			
019950 005	FLUCONAZOLE; DIFLUCAN IN DEXTROSE	4404216	JAN 29,	2004			
019950 001	FLUCONAZOLE; DIFLUCAN IN SODIUM C	4404216* PED	JUL 29,	2004			
019950 002	FLUCONAZOLE; DIFLUCAN IN SODIUM C	4404216	JAN 29,	2004			
019950 004	FLUCONAZOLE; DIFLUCAN IN SODIUM C	4404216* PED	JUL 29,	2004			
020985 001	FLUOROURACIL; CARAC	4404216* PED	JAN 29,	2004			
021235 001	FLUOXETINE HYDROCHLORIDE; PROZAC WEEKLY	6670335	JUN 02,	2021	DP U68		
021077 001	FLUTICASONE PROPIONATE; ADVAIR DISKUS 100/50	5910319	MAY 29,	2017	U396		
021433 001	FLUTICASONE PROPIONATE; FLOVENT HFA	5985322	MAY 29,	2017	U397		
021433 002	FLUTICASONE PROPIONATE; FLOVENT HFA	6170717	DEC 23,	2017	M-33	APR 21, 2007	
021433 003	FLUTICASONE PROPIONATE; FLOVENT HFA	6315173	DEC 23,	2017	NP	MAY 14, 2007	
021211 001	FOLLITROPIN ALFA/BETA; FOLLISTIM AQ	6510969	DEC 23,	2017	DP		
021211 002	FOLLITROPIN ALFA/BETA; FOLLISTIM AQ	6743413	JUN 01,	2021	DP U581		
021765 001	FOLLITROPIN ALFA/BETA; GONAL-F	6743762	APR 14,	2015	DP U582		
021765 002	FOLLITROPIN ALFA/BETA; GONAL-F	6546928	APR 14,	2015	DP U583		
021765 003	FOLLITROPIN ALFA/BETA; GONAL-F	6170717	DEC 23,	2017	DP		
021765 001	GATIFLOXACIN; TEQUIN	6315173	DEC 23,	2017	DP		
021061 001	GATIFLOXACIN; TEQUIN	6510969	DEC 23,	2017	DP		
021061 002	GATIFLOXACIN; TEQUIN	6743413	JUN 01,	2021	DP U581		
021062 001	GATIFLOXACIN; TEQUIN	6253762	APR 14,	2015	DP U582		
021062 002	GATIFLOXACIN; TEQUIN	6546928	APR 14,	2015	DP U583		
021062 003	GATIFLOXACIN; TEQUIN	5929028	DEC 23,	2017	DP		
021062 004	GATIFLOXACIN; TEQUIN	5767251	DEC 23,	2017	DP		
021493 001	GATIFLOXACIN; ZYMAR	4589402	JUL 26,	2004	U568		
021765 001	FOLLITROPIN ALFA/BETA; GONAL-F	4589402	JUL 26,	2004	U569		
021765 002	FOLLITROPIN ALFA/BETA; GONAL-F	4589402	JUL 26,	2004	U570		
021765 003	FOLLITROPIN ALFA/BETA; GONAL-F	4589402	JUL 26,	2004	U567		
021062 001	GATIFLOXACIN; TEQUIN	5767251	JUN 16,	2015	DS		
021062 002	GATIFLOXACIN; TEQUIN	4589402	JUL 26,	2004	U568		
021062 003	GATIFLOXACIN; TEQUIN	4589402	JUL 26,	2004	U569		
021062 004	GATIFLOXACIN; TEQUIN	4589402	JUL 26,	2004	U570		
021493 001	GATIFLOXACIN; ZYMAR	4980470	DEC 25,	2007	NP	MAR 25, 2007	
021493 002	GATIFLOXACIN; ZYMAR	6333045	AUG 20,	2019	NP	MAR 25, 2007	
020509 001	GEMCITABINE HYDROCHLORIDE; GEMZAR	4808614	MAY 15,	2010	DP	I-432	MAY 19, 2004

**PRESCRIPTION AND OTC DRUG PRODUCT  
PATENT AND EXCLUSIVITY DATA**

See report footnotes for information regarding report content.

APPL/PROD NUMBER	INGREDIENT NAME; TRADE NAME	PATENT NUMBER	PATENT/PED EXCL EXPIRES	PATENT CODE (S)	EXCLUS CODE	EXCLUS EXPIRES
020509 002	GEMCITABINE HYDROCHLORIDE;GENZAR	4808614	MAY 15, 2010	DS	I-428	MAY 19, 2007
021158 001	GEMIFLOXACIN MESYLATE;FACTIVE	6723734	MAR 20, 2018	DS DP	NCE	JUN 10, 2009
021667 001	GLUTAMINE;NUTRESTORE				PC	OCT 31, 2004
076345 001	GLYBURIDE;GLYBURIDE AND METFOR				PC	OCT 31, 2004
076345 002	GLYBURIDE;GLYBURIDE AND METFOR				PC	OCT 31, 2004
076345 003	GLYBURIDE;GLYBURIDE AND METFOR				PC	OCT 31, 2004
076604 001	HYDROCODONE BITARTRATE;HYDROCODONE BITARTRA				PC	OCT 11, 2004
021604 001	IBUPROFEN;CHILDREN'S ELIXSURE				NP	JAN 07, 2007
076478 001	IBUPROFEN;IBUPROFEN AND PSEUDO				PC	JUL 29, 2004
020723 001	IMIQUIMOD;ALDARA				I-420	MAR 02, 2007
020685 001	INDINAVIR SULFATE;CRIXIVAN	6689761	FEB 10, 2021	U554		
020685 003	INDINAVIR SULFATE;CRIXIVAN	6689761	FEB 10, 2021	U554		
020685 005	INDINAVIR SULFATE;CRIXIVAN	6689761	FEB 10, 2021	U554		
020685 006	INDINAVIR SULFATE;CRIXIVAN	6689761	FEB 10, 2021	U554		
021629 001	INSULIN GLULISINE RECOMBINANT;APIDRA	6221633	JUN 18, 2018	DS DP U471	NCE	APR 16, 2009
020563 001	INSULIN LISPRO RECOMBINANT;HUMALOG				D-86	JUN 02, 2007
020563 002	INSULIN LISPRO RECOMBINANT;HUMALOG PEN				D-86	JUN 02, 2007
021425 003	IOPROMIDE;ULTRAVIST (PHARMACY					
020571 001	IRINOTECAN HYDROCHLORIDE;CAMPOTOSAR					
021281 001	LANSOPRAZOLE;PREVACID	4364921	MAR 06, 2005	DS DP U113	M-34	JUN 24, 2007
021281 002	LANSOPRAZOLE;PREVACID	4604463	AUG 20, 2007	U449	PED	DEC 24, 2007
021428 001	LANSOPRAZOLE;PREVACID	6403569	APR 28, 2020			
021428 002	LANSOPRAZOLE;PREVACID	6403569*PED	FEB 20, 2008			
021566 001	LANSOPRAZOLE;PREVACID IV	6404463*PED	OCT 28, 2020			
020905 001	LEFLUNOMIDE;ARAVA					
020905 002	LEFLUNOMIDE;ARAVA					
020905 003	LEFLUNOMIDE;ARAVA					
>ADD>	020837 004	LEVALBUTEROL HYDROCHLORIDE;XOPENEX				
>ADD>	021571 001	LEVOCARNITINE;CARNTOR	6083993	JAN 05, 2010	U332	
>ADD>	021225 001	LEVOFLOXACIN;IQUIX	6451289	MAR 21, 2021	DP	
>ADD>	021451 001	LEVONORGESTREL;MIRENA	5362755	NOV 08, 2011	U332	
>ADD>	021130 001	LIDOCAINE;ORAQIX	5547994	AUG 20, 2013	U332	
>ADD>	021130 002	LINZEZOOLID;ZYVOX	5760090	JAN 05, 2010	U332	
>ADD>	020182 001	LEVOCARNITINE;CARNTOR	5844002	JAN 05, 2010	U5	
>ADD>	021571 001	LEVOFLOXACIN;IQUIX	6696493	JAN 18, 2021	U433	
>ADD>	021225 001	LEVONORGESTREL;MIRENA	5785053	DEC 05, 2015	DP	
>ADD>	021451 001	LIDOCAINE;ORAQIX	6031007	APR 01, 2017	DP U553	
>ADD>	021130 001	LINZEZOOLID;ZYVOX	5688792	NOV 18, 2014	DS U319	I-431
>ADD>	021130 002	LINZEZOOLID;ZYVOX	6559305	JAN 29, 2021	DS	JUN 23, 2007
>ADD>	021131 001	LINEZOLID;ZYVOX	6559305	JAN 29, 2021	DS	I-431
>ADD>	021132 001	LINEZOLID;ZYVOX	5688792	NOV 18, 2014	DS	JUN 23, 2007
>ADD>	021226 001	LOPINAVIR;KALETRA	6559305	JAN 29, 2021	DS	I-431
			6703403	JUN 26, 2016		U257

## PRESCRIPTION AND OTC DRUG PRODUCT

## PATENT AND EXCLUSIVITY DATA

See report footnotes for information regarding report content

APPL/PROD NUMBER	INGREDIENT NAME; TRADE NAME	PATENT NUMBER	PATENT/PED EXCL. EXPIRES	PATENT CODE (S)	EXCLUS CODE	EXCLUS EXPIRES
021251 001	LOPINAVIR; KALETRA					
075505 001	LORATADINE; LORATADINE					
020386 001	LOSARTAN POTASSIUM; COZAAR					
020386 002	LOSARTAN POTASSIUM; COZAAR					
020386 003	LOSARTAN POTASSIUM; COZAAR					
020803 001	LOTEPREDNOL ETABONATE; ALREX	6703403	JUN 26, 2016	U257	PC	AUG 20, 2004
020583 001	LOTEPREDNOL ETABONATE; LOTEMAX				NPP	MAR 11, 2007
021249 001	LOVASTATIN; ADVICOR				PED	SEP 11, 2007
021249 002	LOVASTATIN; ADVICOR	5747061	OCT 25, 2013	DP U576	NPP	MAR 11, 2007
021249 003	LOVASTATIN; ADVICOR	5747061	OCT 25, 2013	DP U575	PED	SEP 11, 2007
021249 004	LOVASTATIN; ADVICOR	6676967	SEP 20, 2013	U548	NPP	MAR 11, 2007
021249 005	LOVASTATIN; ADVICOR	6746691	SEP 20, 2013	U586	PED	SEP 11, 2007
020938 001	MELOXICAM; MOBIC					
020938 002	MELOXICAM; MOBIC					
021530 001	MELOXICAM; MOBIC					
013217 001	METAXALONE; SKELAXIN	6683102	DEC 03, 2021	U189	PC	JUL 16, 2007
013217 002	METAXALONE; SKELAXIN	6683102	DEC 03, 2021	U189	PC	JUL 16, 2007
021574 001	METFORMIN HYDROCHLORIDE; FORTAMET				NCE	APR 13, 2005
021574 002	METFORMIN HYDROCHLORIDE; FORTAMET				NP	APR 27, 2007
076172 001	METFORMIN HYDROCHLORIDE; METFORMIN HCL				NP	APR 27, 2007
076545 001	METFORMIN HYDROCHLORIDE; METFORMIN HCL				NP	APR 27, 2007
>ADD>	021415 001	METHYL AMINOLEVULINATE HYDROCHLORIDE; METHYL AMINOLEVULINA	5837284	DEC 04, 2015	DP	DEC 14, 2004
>ADD>	021284 001	METHYLPHENIDATE HYDROCHLORIDE; RITALIN LA	6635284	DEC 04, 2015	DP	MAY 29, 2004
>ADD>	021284 002	METHYLPHENIDATE HYDROCHLORIDE; RITALIN LA	5837284	DEC 04, 2015	DP	JUL 27, 2007
>ADD>	021284 003	METHYLPHENIDATE HYDROCHLORIDE; RITALIN LA	6635284	DEC 04, 2015	DP	DEC 14, 2004
>ADD>	021284 004	METHYLPHENIDATE HYDROCHLORIDE; RITALIN LA	5837284	DEC 04, 2015	DP	MAY 29, 2004
>ADD>	021308 001	MICONAZOLE NITRATE; MONISTAT 1 COMBINATI	6635284	DEC 04, 2015	DP	JUL 27, 2007
>ADD>	076307 001	MIRTAZAPINE; MIRTAZAPINE	6635284	DEC 04, 2015	DP	DEC 14, 2004
>ADD>	076307 002	MOMETASONE FUROATE MONOHYDRATE; NASONEX	6723713 *PED	JAN 27, 2014	U574	JUN 14, 2004
021671 001	MORPHINE SULFATE; DEPODUR	5723147	JUL 27, 2014	DP U584	PC	JUN 14, 2004
021671 002	MORPHINE SULFATE; DEPODUR	5807572	SEP 15, 2015	DP	PC	JUN 14, 2004
		5891467	JAN 31, 2017	DP		
		5931089	JUL 14, 2015	U584		
		5997899	SEP 01, 2016	DP		
		5962016	JAN 31, 2017	DP U584		
		6071534	FEB 18, 2008			
		6171613	OCT 01, 2016	DP		
		6193998	SEP 01, 2016	DP		
		6241999	SEP 01, 2016	DP		
		5723147	MAR 03, 2015	DP U584		
		5807572	SEP 15, 2015	DP		
		5891467	JAN 31, 2017	DP		
		5931089	JUL 14, 2015	U584		
		5997899	SEP 01, 2016	DP		
		5962016	JAN 31, 2017	DP U584		
		6071534	FEB 18, 2008			
		6171613	OCT 01, 2016	DP		
		6193998	SEP 01, 2016	DP		
		6241999	SEP 01, 2016	DP		
		5723147	MAR 03, 2015	DP U584		
		5807572	SEP 15, 2015	DP		
		5891467	JAN 31, 2017	DP		
		5931089	JUL 14, 2015	U584		
		5997899	SEP 01, 2016	DP		
		5962016	JAN 31, 2017	DP U584		

PREScription AND OTC DRUG PRODUCT  
PATENT AND EXCLUSIVITY DATA

See report footnotes for information regarding report content

APPL./PROD NUMBER	INGREDIENT NAME; TRADE NAME	PATENT NUMBER	PATENT/PED EXCL EXPIRES	PATENT CODE (S)	EXCLUS CODE	EXCLUS EXPIRES
021671 003	MORPHINE SULFATE; DEPODUR	6071534 6171613 6193998 6241999 5723147 5807572	FEB 18, 2008 OCT 01, 2016 SEP 01, 2016 SEP 01, 2016 MAR 03, 2015 SEP 15, 2015	DP DP DP DP DP DP		U584
		5891467 5931089 5997899 5962016	JAN 31, 2017 JUL 14, 2015 SEP 01, 2016 JAN 31, 2017	DP U584 DP DP		
		6071534	FEB 18, 2008	DP	U584	
021598 001	MOXIPLOXACIN HYDROCHLORIDE; VIGAMOX	6171613 6193998 6241999 6716830* PED	OCT 01, 2016 SEP 01, 2016 SEP 01, 2016 MAR 29, 2020	DP DP DP NCE PED		DEC 10, 2004 JUN 10, 2005
020381 001	NIACIN; NIASPAN	6746691	SEP 20, 2013	U586		
020381 002	NIACIN; NIASPAN	6676967	SEP 20, 2013	U548		
020381 003	NIACIN; NIASPAN	6746691	SEP 20, 2013	U586		
020381 004	NIACIN; NIASPAN	6676967	SEP 20, 2013	U548		
020381 005	NIACIN; NIASPAN TITRATION ST NITAZOXANIDE; ALINIA	6676967 6746691 6746691	SEP 20, 2013 SEP 20, 2013 SEP 20, 2013	U548 U586 U586		
>ADD>				U586		
>ADD>	NITAZOXANIDE; ALINIA					
>ADD>						
021498 001	NITROFURANTOIN (MONO NIZATIDINE; AXID OLANZAPINE; ZYPREXA	5229382	APR 23, 2011	DS DP U149	I-417	JUL 21, 2007
021494 001	OLANZAPINE; ZYPREXA	5229382	APR 23, 2011	DS DP U149	I-417	NOV 22, 2007
020592 001	OLANZAPINE; ZYPREXA	5229382	APR 23, 2011	DS DP U149	I-417	NOV 22, 2009
020592 002	OLANZAPINE; ZYPREXA	5229382	APR 23, 2011	DS DP U149	I-417	NOV 22, 2009
020592 003	OLANZAPINE; ZYPREXA	5229382	APR 23, 2011	DS DP U149	I-417	NOV 22, 2009
020592 004	OLANZAPINE; ZYPREXA	5229382	APR 23, 2011	DS DP U149	I-417	NOV 22, 2009
020592 005	OLANZAPINE; ZYPREXA	5229382	APR 23, 2011	DS DP U149	I-417	NOV 22, 2009
020592 006	OLANZAPINE; ZYPREXA	5229382	APR 23, 2011	DS DP U149	I-417	NOV 22, 2009
021253 001	OLANZAPINE; ZYPREXA	5229382	APR 23, 2011	DS DP U149	I-417	NOV 22, 2009
021086 001	OLANZAPINE; ZYPREXA ZYDIS	5229382	APR 23, 2011	DS DP U149	I-417	NOV 22, 2009
021086 002	OLANZAPINE; ZYPREXA ZYDIS					
021086 003	OLANZAPINE; ZYPREXA ZYDIS					
021086 004	OLANZAPINE; ZYPREXA ZYDIS					

PREScription AND OTC DRUG PRODUCT  
PATENT AND EXCLUSIVITY DATA

A-11

See report footnotes for information regarding report content

APPL/PROD NUMBER	INGREDIENT NAME; TRADE NAME	PATENT NUMBER	PATENT/PED EXCL EXPIRES	PATENT CODE (S)	EXCLUS CODE	EXCLUS EXPIRES
>ADD>	021636 001	OMEPRAZOLE; ZEGERID	5840737 6645988 6489346 6699885 5763483 5866601 5952375 5763483*PED 5866601*PED 5952375*PED	JUL 16, 2016 JUL 16, 2016 JUL 16, 2016 JUL 16, 2016 DEC 27, 2016 FEB 02, 2016 FEB 02, 2016 JUN 27, 2017 AUG 02, 2016 AUG 02, 2016 FEB 02, 2016 FEB 02, 2016 DEC 27, 2016 JUN 27, 2017 AUG 02, 2016 AUG 02, 2016	DS DP DS DP DS DP DS DP U588 NCE PED OCT 27, 2004 APR 27, 2005	
>ADD>	021087 001	OSELTAMIVIR PHOSPHATE; TAMIFLU	5866601 5952375 5763483 5763483*PED 5866601*PED 5952375*PED	JUL 16, 2016 JUL 16, 2016 JUL 16, 2016 JUN 27, 2017 AUG 02, 2016 FEB 02, 2016 FEB 02, 2016 DEC 27, 2016 JUN 27, 2017 AUG 02, 2016 AUG 02, 2016	DS DP DS DP DS DP U588 NCE PED OCT 27, 2004 APR 27, 2005	
021246 001	OSELTAMIVIR PHOSPHATE; TAMIFLU	5763483 5763483*PED 5866601*PED 5952375*PED	JUN 27, 2017 AUG 02, 2016 AUG 02, 2016 AUG 02, 2016	U376		
021492 001	OXALIPLATIN; ELOXATIN 021492 002 013718 001	OXALIPLATIN; ELOXATIN OXANDROLONE; OXANDRIN	5872147 6670351 6576659 6090799 5872147 6670351 6576659 6090799 6743441	DEC 05, 2017 OCT 20, 2012 DEC 05, 2017 JUL 18, 2017 DEC 05, 2017 OCT 20, 2012 DEC 05, 2017 JUL 18, 2017 APR 26, 2020	U585 U585 U585 U585 U585 U585 U585 U585 DP U318	I-425 I-425 I-425 JAN 09, 2007 JAN 09, 2007
013718 002	OXANDROLONE; OXANDRIN					
021351 002	OXYBUTYNIN; OXYTROL 076168 001 020819 001	OXYCODONE HYDROCHLORIDE; OXYCODONE HCL PARICALCITOL; ZEMPLAR	5246925 5246925*PED 5587497 5587497*PED 6136799 6136799*PED 6361758 6361758*PED 5217974 5344932 5840763 5866581 5916893 6124304	APR 17, 2012 OCT 17, 2012 DEC 24, 2013 JUN 24, 2014 APR 08, 2018 OCT 08, 2019 APR 08, 2018 OCT 08, 2018 MAR 29, 2011 SEP 06, 2011 SEP 01, 2015 SEP 04, 2014 SEP 01, 2015 SEP 04, 2014	U314 U314 U314 DP PC M-31 M-31 M-31 M-31 U551 U501 U501 U501 U501	SEP 26, 2004 MAR 31, 2007 OCT 01, 2007 MAR 31, 2007 OCT 01, 2007
020819 002	PARICALCITOL; ZEMPLAR					
021462 001	PEMETREXED DISODIUM; ALIMTA					
>ADD>	020629 001	PENCICLOVIR SODIUM; DENAVIR				
>ADD>	021073 001	PIOGLITAZONE HYDROCHLORIDE; ACTOS 021073 002 021073 003 020639 001	4879288 4879288 4879288 4879288	SEP 26, 2011 SEP 26, 2011 SEP 26, 2011 SEP 26, 2011	DS DP U550 DS DP U550 DS DP U550 DS DP U550	FEB 04, 2009 FEB 04, 2011 FEB 04, 2011 FEB 04, 2011
020639 002	QUETIAPINE FUMARATE; SEROQUEL					
020639 003	QUETIAPINE FUMARATE; SEROQUEL					

PREScription AND OTC DRUG PRODUCT  
PATENT AND EXCLUSIVITY DATA

See report footnotes for information regarding report content

APPL/ PROD NUMBER	INGREDIENT NAME; TRADE NAME	PATENT NUMBER	PATENT/PED EXCL EXPIRES	PATENT CODE (S)	EXCLUS CODE	EXCLUS EXPIRES
020639 004	QUETIAPINE FUMARATE;SEROQUEL	4879288	SEP 26, 2011	DS DP U550	I-419	JAN 12, 2007
020639 005	QUETIAPINE FUMARATE;SEROQUEL	4879288	SEP 26, 2011	DS DP U550	I-418	JAN 12, 2007
020741 001	REPAGLINIDE; PRANDIN	6677358	JUN 12, 2018	DS DP U546	I-419	JAN 12, 2007
020741 002	REPAGLINIDE; PRANDIN	6677358	JUN 12, 2018	DS DP U546	I-418	JAN 12, 2007
020741 003	REPAGLINIDE; PRANDIN	6177074	NOV 01, 2016	DS DP U546	U454	
020903 002	RIBAVIRIN;REBETOL	6177074*PED	MAY 01, 2017	U454		
		6461605	NOV 01, 2016	U478		
		6461605*PED	MAY 01, 2017	U478		
		6472373	SEP 21, 2017	U479		
		6472377*PED	MAR 21, 2018	U479		
		6524570	NOV 01, 2016	U499		
		6524570*PED	MAY 01, 2017	U499		
076203 001	RIBAVIRIN;RIBASPERE	6465443	AUG 14, 2018	DP		
076192 001	RIBAVIRIN;RIBAVIRIN	6703403	JUN 26, 2016	U564		
021361 001	RIFAXIMIN;XIFAXAN	5474995	JUN 24, 2013	DS DP U266	NCE	
020835 003	RISENDRONATE SODIUM;ACTONEL	5691374	MAY 18, 2015	I-353	MAY 20, 2004	
020659 001	RITONAVIR;NORVIR	6063811	MAY 06, 2017	M-27	APR 11, 2005	
020945 001	RITONAVIR;NORVIR	6239173	JUN 24, 2013	U266	AUG 06, 2006	
021042 001	ROFECOXIB;VIOXX	5474995*PED	DEC 24, 2013	DS DP U266	PED	NOV 20, 2004
		5691374*PED	NOV 18, 2015	U266	PED	OCT 11, 2005
		6063811*PED	NOV 06, 2017	I-423	PED	FEB 06, 2007
		6239173*PED	DEC 24,	I-423	PED	MAR 26, 2007
021042 002	ROFECOXIB;VIOXX	5474995	JUN 24, 2013	DS DP U266	NCE	
		5691374	MAY 18, 2015	I-353	MAY 20, 2004	
		6063811	MAY 06, 2017	M-27	AUG 06, 2006	
		6239173	JUN 24, 2013	U266	PED	NOV 20, 2004
		5474995*PED	DEC 24,	I-423	PED	OCT 11, 2005
		5691374*PED	NOV 18, 2015	U266	PED	FEB 06, 2007
		6063811*PED	NOV 06, 2017	I-423	PED	MAR 26, 2007
021042 003	ROFECOXIB;VIOXX	6239173*PED	DEC 24,	I-423	PED	
		6239173	JUN 24,	I-423	PED	
		5474995	JUN 24,	I-423	PED	
		5691375	MAY 18,	I-423	PED	
		6063811	MAY 06,	I-423	PED	
		5474995*PED	DEC 24,	I-423	PED	
		5691374*PED	NOV 18,	I-423	PED	
		6063811*PED	NOV 06,	I-423	PED	
		6239173*PED	DEC 24,	I-423	PED	
021052 001	ROFECOXIB;VIOXX	5474995	JUN 24,	I-423	PED	
		5691374	MAY 18,	I-423	PED	
		6063811	MAY 06,	I-423	PED	
		6239173	JUN 24,	I-423	PED	
		5474995*PED	DEC 24,	I-423	PED	
		5691374*PED	NOV 18,	I-423	PED	
		6063811*PED	NOV 06,	I-423	PED	
		6239173*PED	DEC 24,	I-423	PED	

## PRESCRIPTION AND OTC DRUG PRODUCT

## PATENT AND EXCLUSIVITY DATA

See report footnotes for information regarding report content

APPL/PROD NUMBER	INGREDIENT NAME; TRADE NAME	PATENT NUMBER	PATENT/EXCL EXPIRES	PATENT CODE(S)	EXCLUS CODE	EXCLUS EXPIRES
021052 002	ROFECOXIB; VIOXX	5474995 5691374 6063811 6239173	JUN 24, 2013 MAY 18, 2015 MAY 06, 2017 JUN 24, 2013	U266	NCE I-353 M-27 PED	MAY 20, 2004 APR 11, 2005 AUG 06, 2006 NOV 20, 2004 FEB 06, 2007 OCT 11, 2005
021256 001	SECRETIN SYNTHETIC HUMAN; HUMAN SECRETIN	5474995*PED 5691374*PED 6063811*PED 6239173*PED	DEC 24, 2013			
020990 001	SERTRALINE HYDROCHLORIDE; ZOLLOFT	6727283	OCT 11, 2019	DP U580	ODE	APR 04, 2009
020926 001	SEVELAMER HYDROCHLORIDE; RENAGEL	6509013	AUG 11, 2013		NCE	APR 09, 2009
021179 001	SEVELAMER HYDROCHLORIDE; RENAGEL	6509013	AUG 11, 2013			
021110 003	SIROLIMUS; RAPAMUNE					
>ADD> >ADD>	SODIUM FERRIC GLUCONATE COMPLEX; FERRLECIT					
020280 004	SOMATROPIN RECOMBINANT; GENOTROPIN PRESERVAT	4968299	JUN 28, 2008			
020168 001	SOMATROPIN RECOMBINANT; NUTROPIN	5096885	MAR 17, 2009			
020168 002	SOMATROPIN RECOMBINANT; NUTROPIN	5096885	MAR 17, 2009			
020522 001	SOMATROPIN RECOMBINANT; NUTROPIN AQ	5763394	JUN 09, 2015			
020522 002	SOMATROPIN RECOMBINANT; NUTROPIN AQ PEN	5763394	JUN 09, 2015			
020080 001	SUMATRIPTAN SUCCINATE; IMITREX	4816470	DEC 28, 2006			
		5037845	AUG 06, 2008			
		4816470*PED	JUN 28, 2007			
		5037845*PED	FEB 06, 2009			
020132 001	SUMATRIPTAN SUCCINATE; IMITREX	4816470	DEC 28, 2006			
		5037845	AUG 06, 2008			
		6368627	MAR 02, 2012			
		5863559	JAN 26, 2016			
		6020001	MAR 02, 2012			
		6020001*PED	SEP 02, 2012			
		6368627*PED	SEP 02, 2012			
		4816470*PED	JUN 28, 2007			
		5037845*PED	FEB 06, 2009			
		5863559	JAN 26, 2016			
020132 002	SUMATRIPTAN SUCCINATE; IMITREX	4816470	DEC 28, 2006			
		5037845	AUG 06, 2008			
		6368627	MAR 02, 2012			
		5863559	JAN 26, 2016			
		6020001	MAR 02, 2012			
		6020001*PED	SEP 02, 2012			
		6368627*PED	SEP 02, 2012			
		4816470*PED	JUN 28, 2007			
		5037845*PED	FEB 06, 2009			
		5863559	JAN 26, 2016			
020132 003	SUMATRIPTAN SUCCINATE; IMITREX	4816470*PED	JUL 26, 2016			
		5037845	AUG 06, 2008			
		4816470	DEC 28, 2006			
		6368627	MAR 02, 2012			
		5863559	JAN 26, 2016			
		6020001	MAR 02, 2012			
		6020001*PED	SEP 02, 2012			
		6368627*PED	SEP 02, 2012			
		4816470*PED	JUN 28, 2007			
		5037845*PED	FEB 06, 2009			
		5863559	JAN 26, 2016			

PREScription AND OTC DRUG PRODUCT  
PATENT AND EXCLUSIVITY DATA

See report footnotes for information regarding report content

APPL/PROD NUMBER	INGREDIENT NAME; TRADE NAME	PATENT NUMBER	PATENT/PED EXCL EXPIRES	PATENT CODE (S)	EXCLUS CODE	EXCLUS EXPIRES
020626 001	SUMATRIPTAN; IMITREX	4816470 5037845 5307953 5554639 5705520 5554639*PED 5705520*PED	DEC 28, AUG 06, DEC 02, SEP 10, DEC 10, MAR 10, JUN 10,	2006 2008 2012 2013 2011 2014 2012	U72	
020626 002	SUMATRIPTAN; IMITREX	4816470*PED 5037845*PED 5307953*PED 4816470 5037845 5307953 5554639 5705520 5554639*PED 5705520*PED	JUN 28, FEB 06, JUN 02, DEC 28, AUG 06, DEC 02, SEP 10, DEC 10, MAR 10, JUN 10,	2007 2009 2013 2006 2008 2012 2013 2011 2014 2012	U232 U72	
020626 003	SUMATRIPTAN; IMITREX	4816470*PED 5037845*PED 5307953*PED 4816470 5037845 5307953 5554639 5705520 5554639*PED 5705520*PED	JUN 28, FEB 06, JUN 02, DEC 28, AUG 06, DEC 02, SEP 10, DEC 10, MAR 10, JUN 10,	2007 2009 2013 2006 2008 2012 2013 2011 2014 2012	U232 U72	
021368 001	TADALAFIL; CIALIS	4816470*PED 5037845*PED 5307953*PED 5859006 6140329 5859006 6140329	JUN 28, FEB 06, JUN 02, JAN 12, JUL 11, JAN 12, JUL 11,	2007 2009 2013 2016 2016 2016 2016	U232 U72	
021368 002	TADALAFIL; CIALIS	4816470*PED 5037845*PED 5307953*PED 5859006 6140329 5859006 6140329	JUN 28, FEB 06, JUN 02, JAN 12, JUL 11, JAN 12, JUL 11,	2007 2009 2013 2016 2016 2016 2016	U232 U72	
021368 003	TADALAFIL; CIALIS	4816470*PED 5037845*PED 5307953*PED 5859006 6140329 5859006 6140329	JUN 28, FEB 06, JUN 02, JAN 12, JUL 11, JAN 12, JUL 11,	2007 2009 2013 2016 2016 2016 2016	U232 U72	
>ADD>	020372 001 TALC; TALC TECHNETIUM TC-99M TETROFOSMIN KIT; MYOVIEW 021144 001 TELITHROMYCIN; KETEK	5045302 D459798 5635485 5681849 4755534 4680291 6121314 5681849 6121314 6121314 6005001 6005001 5856355 5856355	FEB 09, SEP 24, APR 21, OCT 28, DEC 30, JUL 14, MAY 18, OCT 28, APR 21, OCT 28, DEC 30, JUL 14, MAY 18, MAY 18, MAY 18, MAY 18, MAY 18, MAY 18,	2010 2015 2015 2014 2006 2004 2012 2014 2015 2014 2006 2012 2012 2012 2012 2012 2012	ODE NCE NCE	DEC 24, 2004 APR 01, 2009
020846 001	TERBINAFINE; LAMISIL					

PREScription AND OTC DRUG PRODUCT  
PATENT AND EXCLUSIVITY DATA

See report footnotes for information regarding report content

APPL/PROD NUMBER	INGREDIENT NAME ; TRADE NAME	PATENT NUMBER	PATENT/PED EXCL EXPIRES	PATENT CODE (S)	EXCLUS CODE	EXCLUS EXPIRES
>ADD> 020785 001	THALIDOMIDE; THALOMID	6755784	SEP 23, 2020	U371		
>ADD> 020785 002	THALIDOMIDE; THALOMID	6755784	SEP 23, 2020	U371		
>ADD> 020785 003	THALIDOMIDE; THALOMID	6755784	SEP 23, 2020	U371		
020898 001	THYROTROPIN ALFA; THYROGEN	6365127	NOV 24, 2015	DS DP U556	NCE	MAY 17, 2009
021618 001	TINIDAZOLE; TINDAMAX				NCE	MAY 17, 2009
021618 002	TINIDAZOLE; TINDAMAX				NCE	MAY 17, 2009
021395 001	TIOTROPIUM BROMIDE MONOHYDRATE; SPIRIVA	5610163	MAR 11, 2014	DS DP U566		
020771 002	TOLTERODINE TARTRATE; DETROL	5559269	NOV 05, 2013	U318		
>ADD> 020505 001	TOPIRAMATE; TOPAMAX	4513006	MAY 05, 2014			
>ADD> 020505 002	TOPIRAMATE; TOPAMAX	4513006	SEP 26, 2008	DS DP U83	D-88	DEC 16, 2006
>ADD> 020505 003	TOPIRAMATE; TOPAMAX	4513006	SEP 26, 2008	DS DP U83	D-88	DEC 16, 2006
>ADD> 020505 004	TOPIRAMATE; TOPAMAX	4513006	SEP 26, 2008	DS DP U83	D-88	DEC 16, 2006
>ADD> 020505 005	TOPIRAMATE; TOPAMAX	4513006	SEP 26, 2008	DS DP U83	D-88	DEC 16, 2006
>ADD> 020505 006	TOPIRAMATE; TOPAMAX	4513006	SEP 26, 2008	DS DP U83	D-88	DEC 16, 2006
>ADD> 020844 001	TOPIRAMATE; TOPAMAX SPRINKLE	4513006	SEP 26, 2008	DS DP U83	D-88	DEC 16, 2006
>ADD> 020844 002	TOPIRAMATE; TOPAMAX SPRINKLE	4513006	SEP 26, 2008	DS DP U83	D-88	DEC 16, 2006
>ADD> 020844 003	TOPIRAMATE; TOPAMAX SPRINKLE	4513006	SEP 26, 2008	DS DP U83	D-88	DEC 16, 2006
021257 001	TRAVOPROST; TRAVATAN	6011062	DEC 22, 2014	DP		
		5849792				
		5889052				
021595 001	TROSPIUM CHLORIDE; SANCTURA	5510383	AUG 03, 2013	DP U383	NCE	MAY 28, 2009
020675 001	URSODIOL; URSO 250	4859660	NOV 19, 2007			
021630 001	VORICONAZOLE; VPEND	5116844	AUG 11, 2009	DP U540	NCE	MAY 24, 2007
		5364938	NOV 15, 2011			NOV 14, 2006
		5567817	OCT 22, 2013	DS DP U540	I-409	
021450 004	ZOLMITRIPTAN; ZOMIG	5773443	JAN 25, 2011	DS DP U540		
		6750237	NOV 28, 2020	DP		
		6750237*PED	MAY 28, 2021			

Footnote:

- Patents are published upon receipt by the Orange Book Staff and may not reflect the official receipt date as described in 21 CFR 314.53(c) (3) (5).
- Patents submitted on FDA Form 3542 and listed after August 18, 2003 will have one to three patent codes indicating specific patent claims as submitted by the sponsor:
  - DS = Drug Substance claim
  - DP = Drug Product claim
  - U and number = Method of Use claim (may be multiple). Specific Method of use claims are listed at <http://www.fda.gov/cder/orange/patex.htm>
- Patents listed prior to August 18, 2003 are flagged with method of use claims only as applicable and submitted by the sponsor. They may not be flagged with respect to other claims which may apply.
- \*PED and PED represent pediatric exclusivity. Patents with pediatric exclusivity granted after August 18, 2003 will be indicated with \*PED as was done prior to August 18, 2003. Patents with \*PED added after August 18, 2003 will not contain any information relative to the patent itself other than the \*PED extension. Information related specifically to the patent will be conveyed on the original patent only.

## PATENT AND EXCLUSIVITY TERMS

DUE TO SPACE LIMITATIONS IN THE PATENT AND EXCLUSIVITY COLUMNS, ABBREVIATIONS AND REFERENCES HAVE BEEN DEVELOPED. PLEASE REFER BACK TO THE APPROVED DRUG PRODUCTS WITH THERAPEUTIC EQUIVALENCE EVALUATIONS, 24TH EDITION FOR A FULL LISTING OF PATENT AND EXCLUSIVITY TERMS (ABBREVIATIONS, NEW DOSING SCHEDULE, NEW INDICATIONS AND PATENT USE CODES). THE CUMULATIVE SUPPLEMENT WILL LIST NEW CODES ADDED SINCE THE LAST ANNUAL EDITION. THE MOST CURRENT COMPLETE LIST OF ALL PATENT AND EXCLUSIVITY TERMS IS AVAILABLE AT [HTTP://WWW.FDA.GOV/CDER/ORANGE/PATEX.HTM](http://WWW.FDA.GOV/CDER/ORANGE/PATEX.HTM).

### PATENT & EXCLUSIVITY ABBREVIATIONS

- W EXCLUSIVITY ON THIS APPLICATION EXPIRING ON THIS DATE HAS BEEN WAIVED BY SPONSOR - SEE SECTION 1.8 OF ORANGE BOOK PREFACE WAIVED EXCLUSIVITY

### EXCLUSIVITY DOSING SCHEDULE

- D-85 LOWER RECOMMENDED STARTING DOSE GUIDELINES FOR TREATMENT OF MODERATE TO SEVERE VASOMOTOR SYMPTOMS ASSOCIATED WITH THE MENOPAUSE
- D-86 FOR USE IN SELECT EXTERNAL INSULIN PUMPS
- D-87 ADDITION OF ONCE-WEEKLY DOSING FOR THE TREATMENT TO INCREASE BONE MASS IN MEN WITH OSTEOPOROSIS
- D-88 NEW DOSING RANGE OF 200-400MG PER DAY IN TWO DIVIDED DOSES FOR ADULTS WITH PARTIAL
- D-89 USE OF REYATAZ 300 MG/RITONAVIR 100 MG ONCE DAILY FOR TREATMENT IN HIV-INFECTED ANTIRETROVIRAL-EXPERIENCED PATIENTS

### EXCLUSIVITY INDICATION

- I-417 USE IN THE LONG TERM TREATMENT OF BIPOLAR I DISORDER
- I-418 ADJUNCTIVE THERAPY W/ MOOD STABILIZERS (LITHIUM OR DIVALPROEX) IN THE TREATMENT OF ACUTE MANIC EPISODES ASSOCIATED WITH BIPOLAR I DISORDERS
- I-419 MONOTHERAPY IN THE TREATMENT OF ACUTE MANIC EPISODES ASSOCIATED WITH BIPOLAR I DISORDER
- I-420 TOPICAL TREATMENT OF CLINICALLY TYPICAL, NONHYPERKERATOTIC, NONHYPERTROPHIC ACTINIC KERATOSES ON THE FACE OR SCALP IN IMMUNOCOMPETENT ADULTS
- I-421 TREATMENT OF COMPLICATED URINARY TRACT INFECTIONS AND PYELONEPHRITIS DUE TO E.COLI FOR PED PATIENTS (1-17) NOT AS FIRST CHOICE
- I-422 INDICATED FOR THE IN-HOSPITAL SHORT-TERM (UP TO 4 HOURS) REDUCTION IN BLOOD PRESSURE IN PEDIATRIC PATIENTS
- I-423 ACUTE TREATMENT OF MIGRAINE ATTACKS WITH OR WITHOUT AURA IN ADULTS
- I-424 MANAGEMENT OF SECONDARY HYPERPARATHYROIDISM IN PATIENTS WITH MODERATE TO SEVERE CHRONIC RENAL INSUFFICIENCY NOT YET ON DIALYSIS
- I-425 FLOXATIN IN COMBINATION WITH INFUSIONAL 5-FLUOROURACIL (5-FU) AND LEUCOVORIN (LV) FOR THE TREATMENT OF PATIENTS PREVIOUSLY UNTREATED FOR ADVANCED COLORECTAL CANCER
- I-426 TREATMENT OF ACUTE PULMONARY EMBOLISM WHEN ADMINISTERED IN CONJUNCTION WITH WARFARIN SODIUM
- I-427 TREATMENT OF ACUTE DEEP VEIN THROMBOSIS WITHOUT PULMONARY EMBOLISM WHEN ADMINISTERED IN CONJUNCTION WITH WARFARIN SODIUM
- I-428 FOR USE IN COMBINATION WITH PACLTAXEL FOR THE FIRST-LINE TREATMENT OF PATIENTS WITH METASTATIC BREAST CANCER AFTER FAILURE OF PRIOR ANTHRACYCLINE CONTAINING ADJUVANT CHEMOTHERAPY UNLESS ANTHRACYCLINES WERE CLINICALLY CONTRAINDICATED
- I-429 FOR USE IN COMBINATION WITH PREDNISONE FOR THE TREATMENT OF PATIENTS WITH ANDROGEN INDEPENDENT (HORMONE REFRACTORY) METASTATIC PROSTATE CANCER
- I-430 FOR USE IN THE RELIEF OF THE SIGNS AND SYMPTOMS OF RHEUMATOID ARTHRITIS IN ADULTS
- I-431 NOSOCOMIAL PNEUMONIA AND COMMUNITY-ACQUIRED PNEUMONIA CAUSED BY STREPTOCOCCUS PNEUMONIAE INDICATION EXPANDED TO INCLUDE MULTI-DRUG RESISTANT STRAINS

- I-432 TREATMENT OF COMMUNITY ACQUIRED PNEUMONIA CAUSED BY MULTI-DRUG RESISTANT STREPTOCOCCUS PNEUMONIAE
- I-433 TREATMENT OF BIOPSY-CONFIRMED, PRIMARY SUPERFICIAL BASAL CELL CARCINOMA IN IMMUNOCOMPETENT ADULTS, WITH A MAXIMUM TUMOR DIAMETER OF 2.0CM, LOCATED ON THE TRUNK (EXCLUDING ANOGENITAL SKIN), NECK, OR EXTREMITIES (EXCLUDING HANDS AND FEET)
- I-434 PREVENTION OF CARDIOVASCULAR DISEASE IN ADULT PATIENTS WITHOUT CLINICALLY EVIDENT HEART DISEASE, BUT WITH MULTIPLE RISK FACTORS FOR CORONARY HEART DISEASE TO REDUCE RISK OF MI AND RISK FOR REVASCULARIZATION PROCEDURES AND ANGINA

#### EXCLUSIVITY MISCELLANEOUS

- M-30 CHANGES TO CLINICAL PHARMACOLOGY, PRECAUTIONS, AND DOSAGE AND ADMINISTRATION SECTIONS OF LABELING CONCERNING USE OF LOTENSIN IN PEDIATRIC PATIENTS WITH HYPERTENSION
- M-31 INFORMATION FOR USE IN PEDIATRIC PATIENTS WITH CHRONIC KIDNEY DISEASE STAGE 5 (END-STAGE RENAL DISEASE)
- M-32 ADDITIONAL LANGUAGE TO CLINICAL PHARMACOLOGY AND CLINICAL STUDIES
- M-33 INFORMATION FOR USE OF ADVAIR DISKUS 100/50 IN CHILDREN 4 TO 11 YEARS OF AGE WITH ASTHMA
- M-34 EXPANDED INFORMATION TO PEDIATRIC USE SUBSECTION OF LABELING IN RESPONSE TO PEDIATRIC WRITTEN REQUEST
- M-35 ADDITIONAL INFORMATION REGARDING CLINICAL STUDIES DONE WITH ACTOS IN COMBINATION WITH METFORMIN, A SULFONYLUREA, OR INSULIN ADDED TO CLINICAL PHARMACOLOGY
- M-36 ADDITION OF INFORMATION TO CLINICAL STUDIES REGARDING PREVENTION OF CARDIOVASCULAR DISEASE

#### PATENT USE

- U-546 USE OF REPAGLINIDE IN COMBINATION WITH METFORMIN TO LOWER BLOOD GLUCOSE
- U-547 MAINTENANCE MONOTHERAPY FOR BIPOLAR DISORDER
- U-548 A METHOD OF REDUCING FLUSH IN AN INDIVIDUAL BEING TREATED FOR A LIPIDEMIC DISORDER AND EFFECTIVELY TREATING THE LIPIDEMIC DISORDER
- U-549 USE IN THE TREATMENT OF MEN WITH ADVANCED SYMPTOMATIC PROSTATE CANCER
- U-550 TREATMENT OF BIPOLAR MANIA AND SCHIZOPHRENIA
- U-551 METHOD FOR REDUCING TOXICITY OF ALIMTA TREATED PATIENTS BY ADMINISTERING FOLIC ACID
- U-552 TREATMENT OF HYPERTENSION AND HYPERLIPIDEMIA WITH A SINGLE COMPOSITION
- U-553 MANAGEMENT OF PAIN AND DISCOMFORT ASSOCIATED WITH PERIODONTAL SCALING AND ROOT PLANNING PROCEDURES BY APPLICATION OF AN EUTECTIC MIXTURE OF LOCAL ANESTHETICS TO PERIODONTAL POCKETS
- U-554 TREATING HIV INFECTION WITH INDINAVIR SULFATE IN COMBINATION WITH ANTIRETROVIRAL AGENTS
- U-555 TREATMENT OF COMPLICATED URINARY TRACT INFECTIONS AND ACUTE UNCOMPLICATED PYELONEPHRITIS
- U-556 USE AS ADJUNCT DIAGNOSTIC FOR SERUM THYROID GLLOBULIN (TG) TESTING
- U-557 NASAL TREATMENT OF SEASONAL AND PERENNIAL ALLERGIC RHINITIS SYMPTOMS
- U-558 INDICATED FOR THE RELIEF OF BRONCHOSPASM IN PATIENTS 2-12 YEARS OF AGE WITH ASTHMA (REVERSIBLE OBSTRUCTIVE AIRWAY DISEASE)
- U-559 METHOD OF DECREASING OR REDUCING PARATHYROID HORMONE LEVEL; METHOD OF MODULATING PARATHYROID HORMONE SECRETION; METHOD OF TREATING HYPERPARATHYROIDISM; METHOD OF REDUCING SERUM IONIZED CALCIUM LEVEL
- U-560 METHOD OF DECREASING PARATHYROID HORMONE LEVEL; METHOD OF TREATING HYPERPARATHYROIDISM
- U-561 COSOPT IS INDICATED FOR THE REDUCTION OF ELEVATED INTRAOCULAR PRESSURE IN PATIENTS WITH OPEN-ANGLE GLAUCOMA OR OCULAR HYPERTENSION WHO ARE INSUFFICIENTLY RESPONSIVE TO BETA BLOCKERS
- U-562 TOPICAL TREATMENT OF CUTANEOUS LESIONS IN PATIENTS WITH AIDS-RELATED KAPOSI'S SARCOMA
- U-563 MARINOL IS INDICATED FOR, INTER ALIA, ANOREXIA ASSOCIATED WITH WEIGHT LOSS IN PATIENTS WITH AIDS
- U-564 TREATMENT OF HIV IN CONCOMITANT THERAPY
- U-565 TREATMENT OF SEASONAL AND PERENNIAL ALLERGIC RHINITIS SYMPTOMS, AND CHRONIC URTICARIA
- U-566 FOR THE LONG-TERM, ONCE-DAILY, MAINTENANCE TREATMENT OF BRONCHOSPASM ASSOCIATED WITH CHRONIC OBSTRUCTIVE PULMONARY DISEASE (COPD), INCLUDING CHRONIC BRONCHITIS AND EMPHYSEMA
- U-567 METHOD OF TREATING INFERTILITY
- U-568 METHOD OF USING FSH ALONE (WITHOUT EXOGENOUS LH) IN IN VITRO FERTILIZATION
- U-569 METHOD OF USING FSH ALONE (WITHOUT EXOGENOUS LH) IN IN VITRO FERTILIZATION AND WHEREIN

- THEREAFTER AN OVULATORY INDUCING AMOUNT OF HCG IS ADMINISTERED
- U-570 METHOD OF USING FSH ALONE (WITHOUT EXOGENOUS LH) IN IN VITRO FERTILIZATION AND WHEREIN THE DAILY AMOUNT OF FSH IS ABOUT 5-10 IU/KG
- U-571 TREATMENT OF AGITATION ASSOCIATED WITH SCHIZOPHRENIA AND BIPOLAR I MANIA
- U-572 INTENSIVE CARE UNIT SEDATION
- U-573 TREATMENT OF ACUTE PROMYELOGENOUS LEUKEMIA (APL)
- U-574 PROPHYLAXIS AND TREATMENT OF THE NASAL SYMPTOMS OF SEASONAL ALLERGIC RHINITIS AND TREATMENT OF THE NASAL SYMPTOMS OF PERENNIAL ALLERGIC RHINITIS IN ADULTS AND PEDIATRIC PATIENTS 12 YEARS OF AGE AND OLDER
- U-575 LOTEMAX IS INDICATED FOR STEROID-RESPONSIVE INFLAMMATORY OCULAR CONDITIONS FOR WHICH A CORTICOSTEROID IS INDICATED AND WHERE SUPERFICIAL BACTERIAL OCULAR INFECTION OR A RISK OF BACTERIAL OCULAR INFECTION EXISTS
- U-576 ALREX IS INDICATED FOR STEROID-RESPONSIVE INFLAMMATORY OCULAR CONDITIONS FOR WHICH A CORTICOSTEROID IS INDICATED AND WHERE SUPERFICIAL BACTERIAL OCULAR INFECTION OR A RISK OF BACTERIAL OCULAR INFECTION EXISTS.
- U-577 TREATMENT OF BENIGN PROSTATIC HYPERPLASIA WITH FINASTERIDE IN COMBINATION WITH DOXAZOSIN
- U-578 TREATMENT OF COMMUNITY ACQUIRED PNEUMONIA, ACUTE EXACERBATION OF CHRONIC BRONCHITIS, AND ACUTE BACTERIAL SINUSITIS CAUSED BY SUSCEPTIBLE STRAINS OF DESIGNATED MICROORGANISMS IN PATIENTS 18 YEARS AND OLDER.
- U-579 TREATMENT OF EPILEPSY AND/OR MIGRAINE.
- U-580 TREATMENT OF DISORDERS OF THE SEROTONERGIC SYSTEM SUCH AS DEPRESSION AND ANXIETY-RELATED DISORDERS
- U-581 METHOD OF TREATING A CONDITION CAPABLE OF TREATMENT BY INHALATION, E.G. ASTHMA, COMPRISING ADMINISTRATION OF A FORMULATION CLAIMED IN US PATENT NO. 6743413
- U-582 METHOD FOR THE TREATMENT OF A RESPIRATORY DISORDER, E.G. ASTHMA, COMPRISING ADMINISTERING AN EFFECTIVE AMOUNT OF AN AEROSOL COMPOSITION TO A PATIENT FROM A METERED DOSE INHALER SYSTEM AS CLAIMED IN US PATENT NO. 6253762
- U-583 METHOD FOR THE TREATMENT OF A RESPIRATORY DISORDER, E.G. ASTHMA, COMPRISING ADMINISTERING TO A PATIENT BY INHALATION, A METERED AEROSOL DOSE OF A DRUG FORMULATION FROM THE METERED DOSE INHALER SYSTEM CLAIMED IN US 6546928
- U-584 SINGLE-DOSE ADMINISTRATION BY THE EPIDURAL ROUTE, AT THE LUMBAR LEVEL, FOR THE TREATMENT OF PAIN FOLLOWING MAJOR SURGERY
- U-585 TO PROMOTE WEIGHT GAIN AFTER WEIGHT LOSS IN CERTAIN TYPES OF PATIENTS
- U-586 AN INTERMEDIATE RELEASE NICOTINIC ACID FORMULATION SUITABLE FOR ORAL ADMINISTRATION ONCE-A-DAY AS A SINGLE DOSE FOR TREATING HYPERLIPIDEMIA WITHOUT CAUSING DRUG-INDUCED HEPATOTOXICITY OR ELEVATIONS IN URIC ACID OR GLUCOSE OR BOTH
- U-587 USE OF EPLERENONE IN COMBINATION WITH AN ANGIOTENSIN CONVERTING ENZYME (ACE) INHIBITOR (AND OPTIONALLY A DIURETIC) FOR TREATING CONGESTIVE HEART FAILURE AND HYPERTENSION
- U-588 SHORT-TERM TREATMENT OF ACTIVE DUODENAL ULCER; TREATMENT OF HEARTBURN AND OTHER SYMPTOMS ASSOCIATED WITH GERD; SHORT-TERM TREATMENT OF EROSIVE ESOPHAGITIS; MAINTENANCE OF HEALING OF EROSIVE ESOPHAGITIS
- U-589 METHOD FOR TREATMENT OF A RESPIRATORY DISORDER, E.G., BRONCHOSPASM, COMPRISING ADMINISTERING AN EFFECTIVE AMOUNT OF AN AEROSOL COMPOSITION TO A PATIENT FROM A METERED DOSE INHALER SYSTEM AS CLAIMED IN U.S. PATENT NO. 6131966
- U-590 METHOD FOR TREATMENT OF A RESPIRATORY DISORDER, E.G., BRONCHOSPASM, COMPRISING ADMINISTERING TO A PATIENT BY ORAL OR NASAL INHALATION A DRUG FORMULATION BY USING THE METERED DOSE INHALER SYSTEM AS CLAIMED IN US PATENT NO. 6532955
- U-591 TREATMENT OF ATTENTION DEFICIT HYPERACTIVITY DISORDER USING A DOSAGE FORM WHICH PROVIDES ONCE-DAILY ORAL ADMINISTRATION OF A PHENIDATE DRUG



Order Processing Code:  
**8414**

**Approved Drug Products, ADP**  
SUBSCRIPTION ORDER FORM

**Easy Secure Internet:  
[bookstore.gpo.gov](http://bookstore.gpo.gov)**

Toll Free: (866) 512-1800  
Phone: (202) 512-1800  
Fax: (202) 512-2250

Mail: Superintendent of Documents  
PO Box 371954  
Pittsburgh, PA 15250-7954

YES, enter my subscription(s) as follows:

subscription(s) of Approved Drug Products with Th  
Supplements, for \$110.00 per year. The total cost of my order  
subject to change. International customers please add 40%

**Personal name**

Comma name

卷之三

Daytime sphere including area code

---

#### Purchase Order Summary (optional)



### **Check method of payment:**

*Thank you for your order!*

Authorizing signature \_\_\_\_\_ Date \_\_\_\_\_

02/04

ST. LOUIS COLLEGE OF PHARMACY



3 2201 90044 0617

Approved drug products with  
therapeutic equivalence evaluations.  
Cumulative supplement.

RM 301.45 .A66 2004 v.24 suppl.7

Library Use Only

